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SUMMARY
When one examines the scientific literature pertaining to the NANSAID, 
piroxicam, it is clear that controversy of one type or another has not been far away. 
Perhaps the most serious threat to the drugs existence concerned its reputed potential to 
induce a range of gastrointestinal toxicity, including perforation and haemorrhage.
After intense investigation by the regulatory authorities, however, it was concluded that 
the data cited were flawed due to reliance on spontaneous Adverse Drug Reaction 
reports.
This controversy, together with the withdrawals of Opren® and Osmosin® 
during the 1980’s, focused attention on prophylactic remedies for the potentially 
serious gastrointestinal toxicity exhibited, not only with piroxicam, but with all the 
NANSAIDs. Initial therapy was confined to the coadministration of H2  receptor 
antagonists but now other treatments are available. Little interest, however, has been 
placed on the theoretical interaction between NANSAIDs and cimetidine, an H 2  
receptor antagonist known to reduce the clearance of drugs that are metabolised via 
cytochrome P450 hepatic enzymes. Of the two studies that have examined this 
phenomenon, both have been of such a poor design that definite conclusions have been 
impossible. Before addressing the question of an interaction, therefore, simulation 
work was performed to design a study which would ensure the right degree of statistical 
confidence. The technique known as the Jackknife was introduced, its theory explained 
and its application to study design optimisation described. A prospective power 
calculation was performed to determine the number of subjects required to detect a 20% 
difference in the steady state AUC of piroxicam. The 20% value was chosen because it 
was considered that any alteration in the AUC, as a result of H2  receptor antagonist 
coadministration, greater than this value would be clinically significant
The interaction study was a randomised crossover design comparing the
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coadministration of cimetidine and nizatidine in padents receiving chronic piroxicam 
therapy. No clinically significant interaction was found. There was no statistically 
significant alteration in the plasma AUCs of piroxicam and its metabolite 5- 
hydroxypiroxicam. However, the ratio of the two (5-hydroxypiroxicam :piroxicam) 
showed a statistically significant decrease in combination with either cimetidine or 
nizatidine. This indicated that a mild inhibition of piroxicam metabolism occurred. It 
is known that cimetidine binds to all isoenzymes of cytochrome P450 with low affinity, 
but to only a few with high affinity, resulting in a significant clearance alteration. 
Nizatidine has been shown to cause mild in vitro inhibition of cytochrome P450. The 
conclusion must therefore be that the H2  receptor antagonists bind to the isoenzyme 
responsible for piroxicam metabolism with low affinity, and as a consequence no 
clinically significant interaction will occur as a result of this combination.
Another controversy, but by no means as crucial to the drugs continued 
availability for prescribing, was the question of whether piroxicam entered the bile and 
underwent enterohepatic circulation. Only one previous study has attempted to 
examine this, but it was flawed in its design, which made investigation of this 
phenomenon compelling.
Piroxicam’s biliary excretion was examined in one patient with a naso-biliary 
drain which allowed complete collection of the biliary output. The patient received 
80mg of piroxicam over 3 days and samples of bile, urine and plasma were collected 
over a 24 hour period and quantitated for piroxicam, 5-hydroxypiroxicam, and 5- 
hydroxypiroxicam glucuronide (after development of a suitable assay technique). 
Neither piroxicam nor 5-hydroxypiroxicam entered the bile in sufficient quantities to 
undergo significant enterohepatic circulation. However, 5-hydroxypiroxicam 
glucuronide was present in the bile in large amounts, but this is likely to become 
important only if reverse metabolism to reform parent drug takes place.
It can be concluded that the "multiple peak" phenomenon in piroxicam plasma
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concentration/time curves was not a result of enterohepatic circulation. To investigate 
other possible mechanisms a volunteer study was performed in which careful 
consideration was made of the content and timing of food administration. A protocol 
rich in sampling points was employed to characterise these "multiple peaks" in greater 
detail. It was shown that the term "multiple peaks" was inaccurate as the perturbations 
formed were consistently the result of a rapid fall, followed by a more sustained rise in 
the plasma concentrations. Their appearance was not consistent with enterohepatic 
circulation. Investigation was therefore made of the possible physiological events that 
may accompany the consumption of food as the perturbations were coincident with 
particular meals. The proposed mechanisms included alteration in protein binding, and 
food induced alterations in clearance and volume distribution. Although likely 
displacement from albumin was demonstrated, the consequences of such a displacement 
would not give the results obtained. Piroxicam, in man, has a low clearance and any 
transient alterations as a result of an increase in unbound fraction, even up to 400% of 
the baseline value, would have little overall effect Piroxicam also has a small total 
volume of distribution and again any alteration in fraction unbound, even up to 400% 
of the normal value, would have little or no effect on the total volume of distribution. 
However, alteration in volume of distribution can occur by other mechanisms. For 
example, an increase in plasma compartment volume might occur, and this was 
investigated by means of simulation studies. It was shown that alteration in plasma 
volume could result in a "dilution" of the concentration of drug present in the plasma. 
This situation would eventually normalise with homeostatic control, explaining the 
apparent fall and rise in the plasma concentrations witnessed in each subject. Clearance 
alterations could not explain the subsequent rise, and also could not explain the 
complimentary fall in plasma metabolite concentration, leading to the eventual 
conclusion that the perturbations found in plasma piroxicam concentration/time curves 
were the result of food induced alterations in the plasma compartment volume.
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CHAPTER 1
REVIEW: THE EFFICACY, TOXICITY AND CLINICAL USE OF PIROXICAM
AND THE NANSAIDs
21
1.1 INTRODUCTION TO CHAPTER 1
This chapter will review the pharmacological and pharmacokinetic properties of 
the non-aspirin non steroidal anti-inflammatory drug (NANSAID) piroxicam in man.
In the later sections of this introductory chapter, examination will be made of the 
manifestations, epidemiology and prevention of adverse toxic reactions associated with 
piroxicam, and the other NANSAIDs. Particular emphasis will be placed on the 
incidence of NANSAID induced gastropathy, a well recognised and important side 
effect when the number of subjects likely to be exposed to these drugs is considered.
Where appropriate, distinction will always be made between the studies that 
examined NANSAIDs in isolation and those that simply examined NSAIDs (non 
steroidal anti-inflammatory drugs) i.e. whether aspirin derived data was excluded from 
the eventual study conclusions.
22
1.2 THE PLACE OF PIROXICAM IN RHEUMATOLOGY
Piroxicam was the first of the oxicam group of NANSAIDs to be introduced into 
the U.K., in 1980. By 1988 it had achieved eleventh place in terms of world sales with 
a gross return of the order of $350 million. Since the drug’s introduction, the choice of 
NANSAIDs available for prescribing has changed dramatically with the withdrawal of 
benoxaprofen, zomepirac, alclofenac, Osmosin®, fenclocfenac, methrazone, 
indoprofen, isoxicam, and suprofen, with phenylbutazone only being available for use 
by hospital specialists.
The oxicams (Figure 1.1) were discovered in the late 1960’s, and they are 
structurally unique, unrelated to the other groups (Figure 1.2, adapted from Calin 
1988). Piroxicam has a pKa of 6.5, the acidic moiety being the enol group in the 
benzothiazine ring which can undergo ionisation (Whitehouse 1986). The SC> 2  group is 
lipophilic and enhances absorption as does the heterocyclic side-chain. The SC>2 group 
also exerts a steric hindrance on hydroxylation, with the result that clearance values for 
this drug, in man, are very low (Blocka et al 1988).
The slow elimination of piroxicam has contributed to its undoubted commercial 
success. The convenience of a once a day dosage regimen (perhaps in patients who are 
receiving numerous other drugs) proved to be commercially attractive. In a recent 
study (Kay et al 1987) it was shown that piroxicam was much more commonly 
prescribed by General Practitioners compared to hospital based doctors (including 
Rheumatologists).
23
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13  ANIMAL AND HUMAN PHARMACOLOGY 
13.1 ANTI-INFLAMMATORY ACTIVITY
In a number of non specific animal models, piroxicam has been shown to possess 
anti-inflammatory activity. These include inhibition of carrageenan-induced paw 
oedema, adjuvant-induced arthritis and granuloma tissue formation in rats, urate 
crystal-induced synovitis in dogs, ultraviolet-induced erythema in guinea-pigs 
(Wiseman et al 1976) and leucocyte migration in inflammatory exudates (Schiantarelli 
et al 1981).
In the carrageenan-induced paw oedema test, piroxicam was found to be twice as 
potent as indomethacin (Schiantarelli et al 1981), 7 times more potent than naproxen, 
and 14 times more potent than phenylbutazone (Wiseman et al 1976). The anti­
inflammatory activity of this drug is similar in adrenalectomised and intact animals, 
indicating that its mode of action is not due to adrenal stimulation.
13.2 ANALGESIC ACTIVITY
At a dose of 10-32mg/kg piroxicam, administered orally, inhibited phenylquinone 
induced writhing in mice to an extent similar to aspirin, 320mg/kg (Wiseman et al 
1976). In this model, piroxicam 1.85mg/kg was less active than indomethacin 
(0.39mg/kg), but more active than fenoprofen (3.6mg/kg), ibuprofen (4.9mg/kg), 
naproxen (20.1mg/kg) and phenylbutazone (32mg/kg), in reducing writhing frequency 
by 50% (Milne & Twomey 1980).
Schiantarelli & Cadel (1981) chose as an index for investigation, a 70% reduction 
in writhing frequency. In this animal model piroxicam was 70 times more potent than 
phenylbutazone. Piroxicam was inactive in the "hot plate" and "tail flick" tests in mice 
and "flinch jump" and "tail pinch" procedures in rats, which indicated that the drug has 
no opiod-like analgesic effect (Milne & Twomey 1980).
24
1 3 3  EFFECT ON THE GASTROINTESTINAL MUCOSA AND PLATELET 
FUNCTION
The ulcerogenic effect of oral piroxicam in starved rats was 30-50% of that 
observed with indomethacin, and 4 times that of phenylbutazone when expressed in 
terms of the dose producing gastric ulcer in 50% of rats. Rectal administration halved 
the ulcerogenic effect of piroxicam administered orally, indicating that the drug may 
have a topical action on the gastrointestinal mucosa (Schiantarelli & Cadel 1981).
In man, the nature and time course of acute piroxicam-induced gastric mucosal 
injury was determined in 10 volunteers (Fellows et al 1989). Each received lOmg b.d. 
orally for 21 days and endoscopic assessments were made, together with luminal blood 
loss determinations via haemoglobin measurements in gastric washings. Acute mucosal 
injury consisted mainly of haemorrhagic lesions in the gastric body which developed to 
a maximum extent within 10 hours of the first dose of piroxicam, without any 
subsequent increase. On chronic administration intraluminal bleeding increased little 
for 10 days. However, by 21 days, there was a significant increase. These results 
suggest that the gastric mucosal injury was due to a topical action of the drug 
(maximum effect occurred at low plasma drug concentrations) and that the intraluminal 
bleeding may be a consequence of an inhibition of platelet aggregation (Weintraub et al 
1978).
13.4 EFFECT ON PROSTAGLANDIN SYNTHESIS
In 1971 Vane showed that prostaglandins contributed to inflammation, fever and 
pain which could be inhibited by aspirin and NANSAIDs (Vane 1987). Apart from 
erythrocytes, all cells are capable of producing prostaglandins via the arachidonic acid 
cascade. Aspirin and the NANSAIDs were unable to inhibit the synthesis of the 
leukotrienes, and therefore, two pathways were proposed. One, the cyclooxygenase 
pathway, led to the formation of prostaglandins, thromboxanes etc., and could be 
inhibited by aspirin and the NANSAIDs. The other, the lipoxygenase pathway, led to
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the formation of leukotrienes and could not be inhibited by these drugs (except by the 
dual pathway blockers e.g. benoxaprofen) (Figure 1.3). Unlike aspirin, NANSAIDs do 
not irreversibly acetylate the cyclooxygenase enzyme active site; they are selective, 
reversible inhibitors (Carty et al 1980). This action on prostaglandins provides an 
explanation for the analgesic effects of aspirin and the NANSAIDs, but it is likely that 
it only contributes partly to their anti-inflammatory effect in vivo.
13.5 EFFECT ON CELLULAR FUNCTION AND IMMUNE RESPONSE
Polymorphonuclear leucocytes (PMNL) are believed to play an important role in
both early and chronic stages of the inflammatory state. In rheumatoid arthritis and 
other inflammatory diseases, PMNL and macrophages are stimulated, resulting in the 
secretion of inflammatory mediators, including large amounts of superoxide ions (O^) 
and hydrogen peroxide (H2 O2 ). These cells produce superoxide via NADPH-oxidase 
(nicotinamide adenine dinucleotide phosphate, in its reduced form) an enzyme complex 
located in the plasma membrane and phagosome. In the non-phagocytosing cell the 
NADPH-oxidase is inactive, but when the cell is stimulated to phagocytose the enzyme 
is activated Little is known about the molecular basis for this activation. Treatment 
with piroxicam in vivo has shown a 25% reduction in superoxide secretion by isolated 
granulocytes in both osteoarthritis and rheumatoid arthritis (Biemond et al 1986). In 
vitro experiments showed that piroxicam inhibited superoxidc production of 
granulocytes by interference with the stimulation of NADPH-oxidase (Biemond et al 
1986). It was noted, however, that piroxicam had to be present during stimulation of 
the enzyme in order to diminish superoxide production. Once the enzyme was 
stimulated piroxicam had no effect (Biemond et al 1986).
13.6 EFFECT ON ARTICULAR CARTILAGE
The rate of proteoglycan synthesis and turnover is increased in osteoarthritis. As 
the disease progresses, the chondrocytes are unable to replace the depleted 
proteoglycans, hastening cartilage degeneration. The treatment of osteoarthritis relies
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principally on the analgesic properties of NANSAIDs, although most have the capacity 
to modify the natural course of cartilage destruction in experimental animal models. 
However, some may adversely affect normal cartilage metabolism. In an in vitro study 
on weight-bearing porcine articular cartilage, the effects of NANSAIDs on normal 
cartilage glycosaminoglycan, collagen and non-collagen protein synthesis was 
examined Indomethacin and sodium salicylate were shown to inhibit the synthesis of 
these substances whereas piroxicam had no effect (Hess & Herman 1986).
Realistically, any NANSAID induced damage to chondrocytes must be considered 
preferable to the likely joint destruction obtained if the disease is allowed to progress 
untreated.
13.7 MECHANISMS OF ACTION
All the NANSAIDs inhibit prostaglandin synthesis, and it has up until recently 
been thought that their mechanism of action in rheumatoid disorders was a consequence 
only of this suppression. However, piroxicam and the other NANSAIDs also inhibit 
the activation of neutrophils, which provoke inflammation by releasing products other 
than prostaglandins (Weissmann et al 1985). Neutrophils are activated by a "twin 
signal" which is part of the general response to inflammatory stimuli. This "twin 
signal" consists of the mobilisation of intracellular calcium resulting in the activation of 
protein kinase C. Piroxicam has been shown to inhibit early steps in neutrophil 
activation by inhibiting calcium movements and increasing intracellular cyclic AMP 
levels (Weissmann et al 1985). Binding studies have shown that the mechanism of this 
effect appears to be an interference with the ligand receptor site modulated by the G 
protein (Weissmann 1987).
The inhibition of neutrophil activation, therefore, constitutes one of a number of 
possible modes of action of this and the other NANSAIDs. The other proposed 
mechanisms include inhibition of plasma prostaglandin synthesis (resulting in reduced 
synovial prostaglandin levels), reduced superoxide ion production via alteration of
27
PMNL function, and a decreased formation of IgM rheumatoid factor.
13.8 THERAPEUTIC TRIALS
In human efficacy studies, (examining both pain relief and anti-inflammatory 
properties in rheumatoid arthritis) piroxicam has been shown to be superior to placebo 
and comparable to aspirin (4.8g/day). Compared with other NANSAIDs piroxicam 
20mg daily has been shown to be equivalent to indomethacin (75-200mg daily), 
ibuprofen (1.2-2.4g daily), naproxen (0.5-lg daily), diclofenac (75-150mg daily), 
ketoprofen (300mg daily), sulindac (400mg daily) and phenylbutazone (400mg daily).
When osteoarthritis is considered, favourable results were again obtained, with 
20mg piroxicam shown to be as effective as diclofenac (150mg conventional 
formulation, lOOmg sustained release, daily), fenbufen (600mg daily), indomethacin 
(75-125mg conventional formulation, 75mg sustained release, daily), and naproxen 
(0.5-0.75g daily).
Studies comparing piroxicam to indomethacin in the treatment of ankylosing 
spondylitis have shown piroxicam to be a suitable alternative. Results of open trials 
also suggest its usefulness in the treatment of gout, and placebo controlled trials have
shown its efficacy in acute musculoskeletal injuries, dysmenorrhoea, post-surgical and 
traumatic pain.
For a more complete description of these studies the review paper by Brogden et 
al (1984) should be consulted.
13.9 GASTROINTESTINAL TOXICITY
Initially when piroxicam was introduced in the U.K. its potential to cause serious 
gastrointestinal side-effects was considered low. Indeed, early data sheets did not have 
pre-existing peptic ulcer disease as a contra-indication (Emery & Grahame 1982). 
Problems arose, however, as a result of the initial dosage form. The tablet preparation 
resulted in a number of gastrointestinal side effects being reported, and the drug was 
subsequently reformulated as a capsule. As pre-existing peptic ulcer disease was not a
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contra-indication, a number of patients received piroxicam who were previously unable 
to tolerate an NANSAIDs. These patients were therefore most likely to be susceptible 
to the gastrointestinal side effects any NANSAID, with inevitable consequences.
Concern regarding the drug’s safety emerged in 1985 (Fok et al 1985) when the 
suggestion was made that the methods used to assess gastrointestinal side effects were 
faulty, especially in the trials that reported a low incidence. The authors suggested that 
the incidence was underestimated because many patients remained asymptomatic. 
Gastroscopic studies have confirmed that up to 46% of patients with rheumatoid 
arthritis receiving a variety of NANSAIDs (and aspirin) have gastric lesions which are 
completely asymptomatic, possibly due to the analgesic effect of the drug (Bianchi 
Porro et al 1987). However, one problem in determining whether these lesions are 
drug-induced is that lesions similar in appearance are common in arthritic patients not 
receiving any drug treatment (Festen 1988). Interestingly, 19% of patients who 
complained of upper gastrointestinal symptoms were found to have no lesions.
The concern at the reported low incidence of piroxicam gastrointestinal side 
effects was supported by both the Swedish Committee on Adverse Drug Effects and the 
Belgian Centre for Drug Postmarketing Surveillance (Beerman et al 1985, Meyer & 
Thijs 1985).
O ’Brien & Burnham (1985) also reported data from a study examining 
electrocoagulation treatment of bleeding peptic ulcers. Of the 204 bleeding ulcers, 
confirmed by gastroscopy, 53 (26%) had taken an NANSAID (or aspirin) prior to 
admission, although no data were given on the duration of therapy. Using a chi-square 
analysis they concluded that the observed frequency of bleeding episodes associated 
with piroxicam was statistically greater than would be expected, and of the 14 cases 
encountered with piroxicam, 12 were receiving no other medication. It must be 
stressed, however, that it is unknown whether the regional prescribing frequency was 
representative nationally.
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Similar conclusions regarding the relationship between NANSAIDs and bleeding 
peptic ulcers were made by Somerville et al (1986). This study was important as it 
included both matched hospital and community-derived controls. Although the authors 
could not make firm statements about particular drugs, they contended that piroxicam, 
indomethacin, and naproxen were associated with bleeding complications particularly 
with patients over the age of 60. This view was generally supported. Furthermore, 
there were calls for drugs that exhibited a "long elimination half-life", such as 
piroxicam, to be contra-indicated in the elderly due to possible alterations in 
pharmacokinetics (Collier & Pain 1986, Christophidis & Louis 1983). Somerville’s 
conclusion regarding the number of deaths associated with total NANSAID 
consumption was regarded by others to be an underestimate of the "true" incidence of 
approximately 3000 per annum (Armstrong & Blower 1986).
Pressure was placed on the regulatory bodies, both here and in the U.S.A., to 
limit, or ban the use of piroxicam in the over 60’s. The Health Research Group in 
America petitioned the Food and Drug Administration (FD A .) on the grounds that 
gastrointestinal toxicity was more common with piroxicam than with other 
NANSAIDs. They contended that elderly patients exhibited reduced clearance. 
Furthermore, gastrointestinal toxicity was dose related and any reduction in clearance 
(as postulated in the elderly) would make this group particularly liable to suffer serious 
side-effects.
This petition, in common with the many other studies which reported that the 
gastrointestinal toxicity associated with piroxicam was greater than the other 
NANSAIDs, was flawed because it relied on spontaneous Adverse Drug Reaction 
(A.D.R.) reports. In rejecting the H.R.G.’s assertions, the FD.A. stated that
spontaneous reports could only provide "a signal of a potential problem they are not
an appropriate basis for a fmal conclusion which must be based on epidemiological and 
other evidence" (F.D.A. Assessment of the Safety of Piroxicam 1986).
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In response, to this result the H.R.G. cited a report by three F.D.A. 
epidemiologists which showed, after data adjustment to correct reporting rates over 
time, a "highly statistically significant increase in A.D.R. reports of bleeding, 
perforation, and ulcer for piroxicam" (Wolfe 1986). It is interesting to note, however, 
that when this study was eventually published, it concluded that there were no clinically 
significant differences in the frequency of cases of upper gastrointestinal bleeding, 
perforation, and ulcer between piroxicam and the other NANSAIDs (Rossi et al 1987).
Paulus, a rheumatologist who liaised with the F.D.A., highlighted some of the 
drawbacks of spontaneous A.D.R. reports (Paulus 1985). For example, the number of 
actual reports received represent only a fraction of the events actually occurring, but 
this fraction was unknown and can vary with time. Furthermore, difficulty lay in 
determining the number of patients actually exposed to the drug as data were only 
available for the total number of prescriptions dispensed. When the data for piroxicam 
and diclofenac were corrected for the length of time since its introduction (reporting 
rates during the second year of introduction can be up to five times greater than the 
level seen during the first) the results resembled the established agents far more closely. 
When the Committee on the Safety of Medicines (C.S.M.) examined "yellow card" 
reports, piroxicam was found to be no worse than any other NANSAID (apart from 
ibuprofen at low doses) available at that time (C.S.M. Update 1986). Confounding 
factors such as indications for use, marketing claims, media events, and reporting rates 
during the particular period of study were considered. It was concluded that the most 
toxic agents had already been withdrawn, and that the remainder were equally toxic.
Langman (1986) in the A.D.R. Bulletin stated that even although mucosal 
damage was evident from these agents, prolonged exposure did not mean that ulcers 
would develop as a result. This questioned the validity of endoscopic studies which 
had visualised the mucosa after short term exposure to an NANSAID. He emphasised 
that piroxicam’s short marketing life-span may have influenced reporting rates. This
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was supported by examining the Norwegian data gathered with sulindac (Giercksky 
1986). It, like piroxicam when introduced, was claimed to be less gastrotoxic than the 
other NANSAIDs. Similar results, in terms of the number of A.D.R. reports sent to the 
regulatory bodies, were obtained with sulindac as were obtained after piroxicam’s 
launch in the U.K..
The methods used to assess piroxicam toxicity have subsequently received much 
criticism, especially the papers that predicted likely gastrointestinal problems.
Professor Inman at Southampton felt that the Swedish data relied too heavily on 
anecdotal reports (Inman & Rawson 1985). The post marketing surveillance scheme, 
which he set up with the co-operation of the C.S.M., indicated that the frequency of 
upper gastrointestinal bleeding or perforation in patients receiving benoxaprofen, 
fenbufen, zomepirac, indomethacin, or piroxicam ranged from 3-6 per 1000 patient 
years. Interestingly this range was the same whether the patient was receiving an 
NANSAID or not He concluded that piroxicam could not be considered to be any 
more toxic than the other NANSAIDs examined in this study (benoxaprofen, fenbufen, 
zomepirac, and indomethacin).
Concerns, however, about the safety of this drug reappeared in 1987. Armstrong 
& Blower (1987a) gave details of a prospective study started in 1984. They concluded 
that there was a significantly higher frequency of ulcer complications observed in 
patients taking piroxicam compared to other NANSAIDs. Another paper indicated that 
A.D.R.’s were more commonly associated with NANSAIDs that exhibited a long 
elimination half-life in man (Adams 1987). Once again these studies were criticised 
due to the methodology employed, and their conclusions were questioned (Bortnichak 
et al 1987, Calin 1987, Stevens 1988).
The pharmaceutical company that manufactures piroxicam, Pfizer, obtained a 
great deal of information regarding the long term safety and tolerance of piroxicam 
from patient studies also performed in Norway (Husby 1986, Meisel 1986, Zizic et al
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1986, Sachs & Bortnichak 1986, Bortnichak & Sachs 1986). However, assessment of 
side effects relied on Visual Analogue Scale (V.A.S.) data which may not be valid as 
many patients with mucosal damage may remain asymptomatic. Perhaps it was not 
surprising, therefore, that piroxicam was found to be no worse than any of the other 
NANSAIDs in terms of safety and efficacy.
In conclusion, it would appear that piroxicam has a side effect profile similar to 
the other NANSAIDs (Gerber 1987). Care must be taken to examine the source and 
methods employed in studies examining risks, with a particularly cautious emphasis 
placed on spontaneous A.D.R.’s as an index of toxicity (Langman 1989).
13.10 OTHER ADVERSE SIDE-EFFECTS
Side effects other than those affecting the gastrointestinal tract have been 
infrequently reported. As with other NANSAIDs, A.D.R. reports have implicated ankle 
oedema, dermatological side effects including rashes, pruritus, and photosensitivity, 
reversible elevations of blood urea, decrease in haemoglobin and haematocrit 
unassociated with gastrointestinal bleeding, increased serum transaminase, and 
bronchoconstriction in some aspirin hypersensitive asthmatic patients (Data Sheet 
Compendium 1990).
13.11 DOSAGE AND ADMINISTRATION
The initial adult dose in rheumatoid arthritis, osteoarthritis and ankylosing 
spondylitis is 20mg once daily. In most subjects this is adequate for long term 
maintenance, but a few require 30mg daily. Administration of higher doses has been 
associated with increased side effects with no increased benefits. In acute gout an 
initial 40mg is given followed by 40mg daily for one week. In the treatment of acute 
musculoskeletal disorders, 40mg daily for two days is followed by 20mg daily.
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1.4 PHARMACOKINETIC PROPERTIES
1.4.1 ABSORPTION
Although piroxicam is most often prescribed orally, it can also be administered 
intramuscularly, topically, and rcctally (with efficacy equal 10  that of oral 
administration, Chantraine 1984). Two oral preparations are currently available, a 
capsule and a dispersible tablet. In the future, a pro-drug, piroxicam pivalic ester, may 
be available (Ligniere et al 1987).
Table 1.1 shows the absorption characteristics of piroxicam. Following oral 
administration of the capsule, peak plasma concentrations occur between 2 and 4 hours. 
Administration of piroxicam to the elderly yielded absorption characteristics similar to 
those obtained in younger subjects. One study (Ishizaki et al 1979) has published 
values for ka, the absorption rate constant. The mean value obtained from 8 subjects 
was 7.60 ±5.32 h '1.
The absolute bioavailability (F) has not been determined because no intravenous 
formulation exists. However, relative bioavailability, as determined by comparison of 
the area under the curve (AUC) following oral and rectal administration, is similar in 
extent, but different in the rate of absorption (Schiantarelli e: al 1981). In the study by 
Kozjek et al (1987), however, 10 male volunteers received 20mg piroxicam orally and 
rectally in a crossover study and no significant differences were found in the AUC’s 
obtained
Concurrent administration of food appears to affect the rate of absorption of 
piroxicam but not its extent. Ishizaki et al (1979) studied 2" healthy subjects who were 
given either 30 or 60mg of piroxicam with or without food Although food intake 
caused a significant decrease in maximum plasma concentration (Cmax) and increase in 
the time to maximum plasma concentration (Tmax), AUC *as unaffected. In the study 
by Tilstone et al (1981) neither food nor a single ferrous sulphate tablet (iron is known 
to chelate certain drugs, therefore decreasing absorption) had any effect on AUC,
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clearance, volume of distribution, or elimination half-life.
Topical preparations of piroxicam show limited absorption into the systemic 
circulation (Norris et al 1985). After administering 3g of 0.5% gel for 8 hours in eight 
volunteers, the plasma levels obtained were less than 10% of those from either 20 mg 
orally or rectally.
An intramuscular preparation was studied by Fourtillan (1985) in 18 healthy 
males. Comparison was made between the 20mg orally and 20mg intramuscularly in a 
repeated dose crossover study. The two preparations had similar bioavailabilities, but 
the intramuscular administration resulted in higher plasma concentrations.
1.4.2 DISTRIBUTION: PROTEIN BINDING
Piroxicam is extensively bound to plasma albumin (>99%) (Richardson et al 
1985: Blocka et al 1988). Consequently it is primarily confined to the extracellular 
fluid as reflected by a small apparent volume of distribution in both patients and 
volunteers (Table 1.2 and 1.3).
Piroxicam has been shown to have two binding sites on the albumin molecule. 
Matsuyama et al (1987) showed the association constants, after 6 hours equilibrium 
dialysis at 37°c against 0.1M phosphate buffer, to be 1.6 xlO^ ±0.5 xlO^ 1/mol for the 
high affinity site and 3.04 xlO^ ±0.5 xlO^ 1/mol for the low affinity site. Piroxicam 
binding was shown to be altered by both warfarin and fatty acids, but not by diazepam.
1.4.3 DISTRIBUTION: SYNOVIAL FLUID
In the synovial fluid, which is the proposed primary site of action for NANSAIDs 
in rheumatoid arthritis, piroxicam has been shown to be present in approximately half 
its plasma concentration (Tmavska et al 1984). Again there are two binding sites which 
have similar association constants to those in plasma after 20 hours equilibrium dialysis 
at 20°c against 0.1M phosphate buffer. For synovial fluid Kj = 2.38 x 10^ ±0.86 xlO^ 
1/mol and K2 = 2.29 xlO^ ±0.75 xlO^ 1/mol (for plasma K j= 1.93 xlO^ ±0.40 xlO^
1/mol and K2 = 2.08 xlO^ ±0.70 xlO^ 1/mol). Bontoux et al (1984) examined the extent
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to which synovial fluid concentration depended on the plasma concentration. Ten 
patients, mean age 58, received a single 20mg dose of piroxicam and in another study,
11 patients, mean age 53, received repeated doses of 20mg. In the single dose study the 
ratio of synovial fluid to plasma concentration was 0.48 +0.27 and in the multiple dose 
study this ratio was 0.41 +0.17 (the number of repeated doses ranged from 3-8 with one 
patient taking the drug for 25 days). Positive correlations were obtained between 
plasma and synovial fluid concentrations, independent of the duration of administration 
(R^= 0.64, p<0.0001), and between synovial fluid protein concentration and the ratio of 
synovial fluid to plasma piroxicam concentrations (R = 0.53, p<0.03).
1.4.4 DISTRIBUTION: OTHER TISSUES
Piroxicam was detected in breast milk at about 1-3% of the maternal plasma 
concentrations (Ostensen et al 1988). In this study four women received 20mg of 
piroxicam daily. Steady state levels were achieved with a milkiplasma ratio of between 
0.01-0.03. The relative dose ingested daily by a breast fed baby would therefore be 
3.5-6.3 % of the maternal dose, which would approximate to 0.7-1. lmg for a 20mg 
daily dose.
1.4.5 ELIMINATION
Piroxicam is virtually completely metabolised. Only 2-5% is excreted in the 
urine as parent drug (Wisemen & Hobbs 1982). Clearance (Cl) and the elimination 
half-life (t j ^ )  of piroxicam has been estimated in healthy volunteers (Darragh et al
1985), in patients (Hobbs & Twomey 1979), in young and old (Richardson et al 1985), 
and in single and multiple dose studies (Tables 1.2 and 1.3). Reported clearance values 
have ranged from 1.56 xlO'^ ±0.12 xlO'^ to 3.12 xlO'^ ±0.16 xlO'^ in these groups. 
The long elimination half-life (range 30-90 hours) has permitted a once daily dosage 
regimen, although it may take up to 18 days to achieve steady state concentrations 
(Fourtillan & Doubourg 1984). A loading dose of 40mg for two days will result in 
steady state levels being obtained much more quickly.
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The early pharmacokinetic studies relied on a non specific degradative 
fluorometric assay which has subsequently been superseded by more sensitive 
chromatographic techniques, and this may have contributed to some of the differences 
between the pharmacokinetic parameters obtained in the early studies compared to 
recent studies (Verbeeck et al 1986).
1.4.6 METABOLISM
Piroxicam is extensively metabolised by hepatic cytochrome P450 enzymes, 
principally to the hydroxyl metabolite. Hydroxylation occurs at the five position in the 
pyridine ring and the hydroxylated metabolite undergoes subsequent glucuronidation. 
Figure 1.4 shows the major routes of metabolism in man (Hobbs 1986). Less than 5% 
of the parent drug is excreted in the urine, and, under steady state conditions, 75% of a 
dose is excreted as either 5-hydroxypiroxicam or 5-hydroxypiroxicam glucuronide in 
the urine and faeces (Verbeeck et al 1986). Richardson examined the proportions of 
these metabolites (Richardson et al 1987). On average 25% of a dose was recovered in 
the urine as 5-hydroxypiroxicam with two-thirds (17%) of this total obtained from 
hydrolysing the glucuronide metabolite. If 60-75% of a total dose is excreted as 5- 
hydroxypiroxicam or 5-hydroxypiroxicam glucuronide in the urine and faeces, the 
faecal content must therefore amount to 35-50% of this total.
1.4.7 BILIARY EXCRETION
Bile as a medium for the elimination of piroxicam has received much speculation 
but little experimental attention. Early studies witnessed a "multiple peak" 
phenomenon in the plasma concentration time curve and it was thought that drug 
entering the bile underwent enterohepatic circulation (Rogers et al 1981, Hobbs et al 
1983, Richardson et al 1985, Edwards et al 1985, Fenner 1985) which contributed to 
the drug’s long elimination half-life in man (Brune et al 1985). Figure 1.5 illustrates 
some typical plasma concentration/time curves which were considered to indicate the 
existence of piroxicam enterohepatic circulation. Only one published study has
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attempted to quantify the biliary secretion of this drug (Verbeeck et al 1986). Fifteen 
hours after administration of a single 20mg dose of piroxicam to a healthy volunteer, 
bile was aspirated into a collecting tube following cholecystokinin infusion. No 
detectable levels of piroxicam or 5-hydroxypiroxicam were obtained, but no attempt 
was made to quantify possible glucuronides.
Indirect evidence of biliary secretion was provided by two studies which 
examined the effect of coadministration of cholestyramine (an anionic exchange resin) 
which binds bile salts (in addition to some drugs) to form an Insoluble complex in the 
gastrointestinal lumen. This is likely to interrupt the enterohepatic circulation of bile 
and thus the disposition of any drug secreted in the bile. In these studies a single 20mg 
piroxicam capsule was administered with either cholestyramine or placebo in a 
crossover manner to healthy volunteers. Guentert examined the effect of 4g 
cholestyramine t.i.d. and Benveniste examined the effect of 8g td.d. (Guentert et al 
1988: Benveniste et al 1990). The administration of cholestyramine was 3.5-4 hours 
after the piroxicam dose to avoid interference with the absorption of piroxicam. In both 
cases the clearance of piroxicam was increased with a reduction in the elimination half- 
life (46.8 to 28.1 hours, Guentert et al; 50.3 to 28.1 hours, Benveniste et al). 
Interestingly, in the Guentert study, the "multiple peaks" were not removed by the 
coadministration of cholestyramine. This casts doubt on the idea that the enterohepatic 
circulation was involved in the generation of these "perturbations". These results 
should, therefore, be examined closely as they cannot be used as direct evidence for 
enterohepatic circulation, as contended by Benveniste. The fact that the clearance is 
increased due to cholestyramine coadministration may indicate that piroxicam enters 
the bile and is cleared by that route in the faeces. It does not allow unequivocal 
statements to be made as to whether the drug (or drug metabolite) subsequently leaves 
the bile (undergoes reverse metabolism to form parent compound) and then re-enters 
the systemic circulation.
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Boylan et al (1987) have shown, with cholestyramine, that drugs can be removed 
from the systemic circulation and excreted in the faeces via mechanisms other than 
those involving biliary excretion. Cholestyramine (and activated charcoal, Berlinger et 
al 1983) creates a "sink condition" whereby there is an artificially increased flux of 
drug from the blood into the intestinal lumen with a net increase in excretion via the 
faeces. This would result in increased drug clearance, irrespective of whether it entered 
the bile or not. This may be the case with piroxicam, because as stated before there 
little evidence that it is present in the bile. Speculation about "multiple peaks" in the 
plasma concentration time profiles resulting from enterohepatic circulation therefore 
may be erroneous.
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1.5 IMPLICATIONS OF PHARMACOKINETIC PROPERTIES FOR 
THERAPEUTIC USE
1.5.1 DOSE AND THERAPEUTIC RANGE/SIDE EFFECTS
The usual dose for piroxicam in inflammatory joint conditions is 20mg once a 
day, but evidence is scarce for a "therapeutic range" for plasma piroxicam 
concentrations with respect to anti-inflammatory effects in humans. Wiseman noted 
that in patients with chronic polyarthritis, correlations were evident between plasma 
concentrations and duration of morning stiffness and pain (Wiseman & Hobbs 1982). 
In both indices, improvement was noted as steady state levels were attained, and as 
concentrations declined exacerbation of the clinical symptoms were seen. Pavelka in a 
study of 24 rheumatoid arthritic patients noted "therapeutic results" were significantly 
better in the patients who attained plasma levels greater than 5.4mg/l in comparison to 
those who were below this level (Pavelka et al 1988). In the large multi-centre 
crossover study by Rugstad et al (1986), 640 patients with osteoarthritis (192 males, 
448 females), mean age 67, had a single blood sample taken within 3-12 hours of their 
20mg dose at monthly intervals. Adverse events were assessed by direct questioning 
and visual analogue scales during the first 4 and 12 weeks of therapy. No correlations 
were apparent between drug concentrations and adverse events in this study, and no 
differences were seen between the 4 week and 12 week data.
Using 8 different measures of disease activity, Blocka et al (1988) examined 23 
patients with rheumatoid arthritis (9 males, 14 females) aged between 27-79 in a six 
week study using the standard dose of 20mg piroxicam daily. The degree to which the 
patients responded did not correlate with either piroxicam plasma concentrations, 
bound or unbound, or with synovial fluid levels. However, synovial fluid 
concentrations were only determined in 6 patients. Of the patients who experienced 
mild side effects (9 out of 23) the average steady state plasma levels were in fact 
slightly lower than the group as a whole (7.04 ±2.78mg/L versus 9.20 ±4.43mg/L).
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1.5.2 DISEASE AND PIROXICAM PHARMACOKINETICS
Tables 1.2 and 1.3 show the pharmacokinetic parameters obtained in patient and 
volunteer studies. These parameters are similar irrespective of which group is studied. 
However, Woolf ct al (1983) found in 19 patients with rheumatoid or osteoarthritis that 
the volume of distribution values were twice those previously reported. This was 
considered to be the result of low plasma albumin concentrations, but it is not clear 
whether the low albumin was due to the disease itself (causing hypoalbuminaemia), or 
due to the study being performed during an acute "flare-up" resulting in a disruption of 
piroxicam protein binding.
The influence of renal impairment on piroxicam pharmacokinetics was studied by 
Darragh et al (1985). In 18 patients with mild to moderate impairment no differences 
in pharmacokinetic parameters were found between patients with and without renal 
impairment. Woolf et al (1983) examined the relationships between half-life, steady 
state plasma concentrations, plasma albumin levels, and creatinine clearance, in 19 
patients. No significant correlations were obtained. This is not surprising because of 
the drug’s extensive hepatic metabolism.
Limited data are available on the effects of liver disease on piroxicam 
pharmacokinetics. Preliminary reports indicate that "plasma concentrations are 
increased" in severe liver insufficiency (cirrhosis) but not in mild liver disease (fatty 
infiltration) (De Schepper & Heynen 1984).
1.5.3 INFLUENCE OF AGE AND SEX
There is no conclusive evidence that the pharmacokinetics of piroxicam are either 
sex or age related, although studies are contradictory (Tables 1.2 and 1.3). Edwards et 
al (1985) examined single dose pharmacokinetics in 24 volunteers, 12 young (<40) and 
12 elderly (>65). There were no differences in the pharmacokinetic parameters 
between the groups. Richardson et al (1985) also studied single dose pharmacokinetics. 
Significant differences in volume of distribution disappeared once volumes were
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corrected for body weight. However, significant differences existed for both clearance 
and elimination half-life between young and elderly women. These results may, 
however, be spurious: multiple comparisons were performed in 4 small groups.
Woolf et al (1983) also examined multiple dose pharmacokinetics (14 days) in 19 
patients between 27 and 94 years of age. In this study, there were no correlations 
between clearance or steady state plasma concentration and age. The study by Darragh 
et al (1985) in which 21 healthy volunteers and 23 patients with osteoarthritis received 
20mg daily for 36 days had similar conclusions. Plasma concentrations, elimination 
half-life, AUC, and volume of distribution were unaffected by age. The large 
retrospective study by Hobbs & Gordon (1984) also did not show any age related 
effects on the steady state plasma concentrations in 279 patients ranging from 21 to 83 
years.
However, two studies disagreed with these findings. Rugstad et al (1986) showed 
an increase in plasma piroxicam concentrations with increasing age, with females 
showing higher piroxicam concentrations than males. After regression analysis, 
however, only 15% of the total intersubject variability was accounted for by age or sex.
In the study by Blocka et al (1988) 23 rheumatoid arthritis patients (9 male, 14 female) 
aged between 27 and 79 received 20mg piroxicam for 6 weeks. Marginally significant 
correlations were obtained between steady state concentrations and age (r= 0.43, p= 
0.043); half-life and age (r= 0.41, p= 0.050) and plasma clearance and age (r= 0.52, p= 
0 .011 ).
The difficulty lies in interpreting the importance of the latter results as 
methodological differences exist between the studies. For this reason, conclusive 
statements cannot be made. It would appear, however, that if age or sex exerts any 
effect on the clearance of piroxicam, the well documented intersubject variability would 
overwhelm any marginal age or sex relationships.
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1.6 PHARMACOKINETIC DRUG INTERACTIONS
1.6.1 ASPIRIN
Hobbs & Twomey (1979) examined the influence of aspirin coadministration on 
the plasma piroxicam AUC in healthy volunteers. Two groups of eight healthy male 
volunteers received an initial 40mg dose of piroxicam followed by 20m g daily for 2-5 
days. One group also received aspirin 972mg q.i.d. on day 4 or 5. No significant 
effects were obtained as a result of coadministration.
1.6.2 ANTACIDS
In another study in 20 males, Hobbs & Twomey (1979) examined, in a cross over
manner, the effect of two proprietary antacid preparations, Amphogel (aluminium
(R)hydroxide and magnesium hydroxide) and Mylanta II (aluminium hydroxide, 
magnesium hydroxide and activated dimethicone). Again no significant effects on 
piroxicam pharmacokinetics were obtained. However, as in the previous study, the 
authors point out that, due to the large intersubject variability, and the small numbers 
involved, these studies could only detect large effects (>45%) with any statistical 
certainty.
1.6.3 RIFAMPICIN
Rifampicin is a well documented inducer of liver enzymes, and 6 healthy 
volunteers entered a trial in order to determine if single dose piroxicam 
pharmacokinetics were altered as a result of coadministration (Patel et al 1988). 
Rifampicin 600mg was given for 7 days prior to administration of a single 40mg dose 
of piroxicam, and the results were compared to another single piroxicam dose given 
after a washout period. No significant differences were noted in the pharmacokinetic 
parameters elimination half-life, Cmax, Tmax, and AUC.
1.6.4 RANITIDINE
In a double-blind two way crossover study, piroxicam 20mg plus ranitidine 
150mg b.d. for 10 days was compared to piroxicam plus placebo given in random order
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28 days apart to 18 healthy male subjects (Dixon et al 1989). Mean results showed no 
significant differences between treatments.
1.6.5 CIMETIDINE
Two studies have been performed examining the coadministration of cimetidine 
in man. Cimetidine has been shown to inhibit the clearance of drugs that undergo 
cytochrome P450 metabolism. In the study by Mailhot et al (1986), 10 male volunteers 
(23-35 years) received 20mg piroxicam after one week’s treatment with cimetidine 
300mg q.i.d. and the results were compared to those obtained from piroxicam 20mg 
without any pretreatment with cimetidine. Statistically significant differences were 
obtained for AUC^3, clearance, volume of distribution and Cmax. However, Tmax, 
t j / 2  and ke were not statistically different. The authors contended that the differences 
in AUC could be due to an increase in bioavailability, a decrease in the volume of 
distribution, or a decrease in ke. However, no change in ke was noted in this study, and 
the increase in AUC is more likely to be due to a decreased clearance or increased 
bioavailability. As kc is unaltered, both the clearance and volume of distribution must 
have altered to the same degree since ke= Cl/V.
In the study by Said and Foda (1989) 12 males (21-36 years) were divided into 
two groups of six. One group received 20mg piroxicam while the other received 
200mg cimetidine t.i.d., with this group receiving their piroxicam dose two hours after 
the cimetidine dose. Six blood samples were taken within the 24 hour period and 
analysed by the degradative fluorometric assay technique. A U C ^, X^ f2 ^  ^e were 
calculated from semilogarithmic plots. A statistical difference in AUC was detected 
between the two groups, with the cimetidine group having an increased AUC. No 
statistically significant differences existed between ke and t ^ .  The paucity of data 
points, however, is likely to have contributed to this result Extrapolations from 6-24 
hours is likely to have defined the slope, and hence kg, and as this entailed only 3 points 
the margin for error was great if one (or more) of these points was inaccurate.
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Furthermore, given the well known pharmacokinetic variability of piroxicam and the 
study design employed (two parallel groups with no crossover) retrospective power 
analysis indicates that 33 subjects per group would be required to detect the differences 
observed with an 80% power. The results can therefore at best be regarded as 
inconclusive.
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1.7 NANSAID INDUCED GASTROPATHY: MAMFESTATIONS
Endoscopic reports suggest that lesions and ulcers associated with NANSAIDs 
show consistent differences from the peptic ulcers in the general population (Roth
1986). For this reason, the term "NANSAID gastropathy" has been introduced to 
differentiate between the NANSAID induced lesion and classical peptic ulcer disease.
In many instances, significant damage only occurs when other agents such as bile or 
ethanol are present.
In the absence of such agents, NANSAIDs cause mucosal reddening, 
vasoconstriction and shedding of surface epithelial cells, but few breaks in the mucosa. 
This implies that NANSAIDs may act by impairing the prostaglandin-mediated defence 
mechanisms (Somerville & Hawkey 1986).
Indomethacin and piroxicam appear to have a topical irritancy (like aspirin), 
which can be reduced by formulation alterations. However, some novel formulations 
have been disastrous, e.g. Osmosin®, which merely moved the problem further down 
the gastrointestinal tract
As these drugs inhibit the cyclooxygenase pathway, there may be diversion of 
arachidonic acid production down the lipoxygenase pathway (Figure 1.3). This would 
result in an increased production of hydroperoxyeicosatetraenoic acid (HPETE), 
hydroxyeicosatetraenoic acid (HETE), and leukotrienes, which could lead to cellular 
damage. Rainsford (1984) proposed that since most of these drugs are weak acids, 
intracellular accumulation would occur, resulting in the release of oxygen free radicals 
and lysosomal enzymes, which, in combination with the drug’s prostaglandin synthesis 
inhibition, would cause local ischaemia, microhaemorrhage with further production of 
oxygen free-radicals potentiating their effects. Another mechanism includes an 
impairment of the mucosal metabolism of ATP (adenosine triphosphate) which disrupts 
cell function, regeneration and synthesis of mucus.
Lange et al (1986) concluded that drug induced gastric injury was directly related
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to inhibition of local prostaglandin synthesis. Their study in volunteers showed that the 
endoscopically derived gastric injury scores were higher for aspirin and indomethacin 
compared to placebo, but that no significant difference was found between placebo and 
piroxicam. Inhibition of gastric mucosal prostaglandin synthesis exhibited a similar 
pattern of results. A significant correlation was shown between the gastric mucosal 
injury and decreased mucosal prostaglandin synthesis. However, no such relationships 
were seen in the duodenum indicating that the duodenal mucosa was not affected by the 
NANSAIDs to the same extent as the gastric mucosa. Goldin et al (1988), in a patient 
study, refuted these findings. Endoscopic assessment of gastroduodenal mucosal 
damage in addition to gastric PGE2  and 6-ketoPGFja  (stable metabolite of PGI2 , 
prostacyclin) levels were obtained before and after treatment with indomethacin at a 
daily dose of 150mg. After one week, the concentrations of both prostaglandins were 
significantly lower, irrespective of the presence or absence of mucosal damage. 
Cimetidine 400mg twice daily or ranitidine 150mg twice daily reduced the mucosal 
damage but had no effect on the prostaglandin concentration.
Indomethacin enterohepatic circulation has been studied as a possible factor in 
both gastric and duodenal toxicity (Brune et al 1987). A correlation was obtained 
between biliary excretion of several NANSAIDs, including indomethacin, ibuprofen, 
diflunisal, diclofenac, and naproxen with ileal perforation in rats. Reducing the extent 
of enterohepatic circulation caused a reduction in the degree of small intestinal 
erosions. However, studies need to be carried out in humans, as data on the degree of 
biliary excretion of these drugs and the incidence of intestinal side-effects are 
unavailable.
Intestinal permeability tests have been carried out by Bjamason et al (1986) in 
patients receiving aspirin or NANSAIDs. There are at least three permeability 
pathways across the small intestine with the most important one, with regard to 
macromolecular transport, being defective intercellular tight junctions between adjacent
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enterocytes. ^Chromium labelled ethylenediamine-tetra-acetate Cr EDTA) and 
lactulose, with molecular weights of 340 and 342 respectively, test specifically for the 
integrity of these junctions. Intestinal permeability may be important in rheumatoid 
arthritis because antigens may gain access to the body if intestinal permeability is 
increased. This may initiate disease either directly or indirectly with the production of 
circulating immune complexes.
Twelve patients with rheumatoid arthritis untreated by aspirin or an NANSAID 
had normal test results, whereas 12 aspirin or NANSAID treated patients had increased 
intestinal permeability to ^ C r  EDTA. An increase in permeability was also found in 
volunteers taking these drugs. Furthermore, indomethacin suppositories also increased 
intestinal permeability, indicating that it was a systemically mediated effect. As no 
change was detected in untreated rheumatoid arthritis patients, the suggestion was made 
that aspirin and the NANSAIDs cause increased permeability and enhanced 
macromolecular absorption (assuming the same pathway is used by these 
macromolecules as ^  CrEDTA).
The use of * * * Indium labelled leucocyte scintiscans and faecal collections 
showed that aspirin and NANSAIDs produced small intestinal inflammation on long 
term treatment (Bjamason et al 1987). The study in 90 rheumatoid arthritis and 7 
osteoarthritic patients showed that inflammation of the small intestine occurred in two 
thirds of the patients examined and could persist for up to sixteen months after 
discontinuation of therapy.
The data reviewed here refer to the upper gastrointestinal tract. Evidence is also 
available which implicates NANSAIDs in the development of lower gastrointestinal 
disorders (Rampton 1987, Langman et al 1985). This implies that these drugs may 
have toxic effects throughout the whole of the alimentary tract, based on a toxicity 
mechanism similar to that observed in the stomach. The small intestine is likely to 
bear the main brunt of NANSAID induced side-effects, probably due to high local
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concentrations of NANSAID at the site of absorption, and continuous re-exposure by 
enterohepatic circulation (if it exists), but many colonic side-effects may go unreported 
or unrecognised.
In conclusion, it can be seen that the surface mucosal-bicarbonate barrier (which 
maintains a pH gradient in order to neutralise any hydrogen ions back-diffusing from 
the lumen) has a limited capacity to resist injury by luminal contents once a primary 
insult has "breached" the barrier. Disruption of this barrier appears to be equivalent to 
destroying the superficial epithelium, and if the noxious stimulus continues, the defence 
and repair mechanisms are overwhelmed, and damage occurs to the proliferative zone 
(the area where epithelial cell migration commences and which normally replaces 
desquamed superficial epithelial cells within three days). Factors that maintain a high 
intracellular pH play a role in preventing deeper damage. It appears that aspirin and 
NANSAIDs have the ability to disrupt this barrier by a variety of mechanisms including 
both topical and systemic actions.
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1.8 NANSAID INDUCED GASTROPATHY: EPIDEMIOLOGY
NANSAID induced gastropathy has been described for many years, and more 
recent endoscopically derived evidence has tended to implicate these drugs further in 
the generation of gastrointestinal toxicity. Reports of gastrointestinal complications 
have increased to both the C.S.M. and the F.D.A. (Roth 1986) with bleeding reported 
twice as often as ulcers. This is a source of concern as it is known that approximately 
22 million prescriptions were written for these drugs in the U.K. in 1983 (Walt et al 
1986).
In this section the attributable risk (AR) and relative risk (RR) are reported. The 
AR provides an estimate of the number of patients with the endpoint of interest e.g. 
haematemesis and/or melaena directly caused by NANSAID consumption. This differs 
from relative risk which would be the risk of patients developing, for example, 
haematemesis and/or melaena whilst receiving NANSAIDs compared to patients not 
receiving NANSAIDs.
Caruso and Bianchi-Porro (1980) examined endoscopically patients on a variety 
of NANSAIDs. When the group was considered as a whole, lesions occurred in 23% 
of patients taking a single drug but in 51% when two or more were taken. A further 
endoscopic study by Lanza et al (1983a) showed that the combination of NANSAIDs 
and aspirin or alcohol resulted in an additive toxic effect on the gastric mucosa.
Acute superficial erosions caused by a drug do not necessarily mean that chronic 
administration with the same drug will cause frank ulceration. Large studies would be 
required to prove causal links, such as that mounted for aspirin by the Boston 
Collaborative Drug Surveillance Programme (B.C.D.S.P.) which examined data from 
over 16,000 admissions. In order to get round the expensive and time consuming 
nature of such trials, Clinch et al (1983) limited themselves to the question of whether 
anti-inflammatory drugs, as a whole, were associated with adverse gastrointestinal 
effects. They used a pre-existing "active" endoscopy service, i.e. endoscopies at
54
regular intervals in elderly patients, regardless of the presence or absence of dyspepsia, 
and carried out a retrospective study in over 200 patients with a mean age of 75 years. 
When aspirin was excluded there was a highly significant association between "lesions" 
and NANSAID use, with a significantly higher proportion of females in the "lesion 
group". The "lesion group" in this study included patients with endoscopic evidence of 
oesophagitis, benign gastric ulceration, gastritis, duodenal ulceration, or duodenitis. 
There were no differences in terms of age, smoking or drinking habits between the 
control and "lesion groups". However, in the "lesion group" there was an increased 
incidence of patients with either rheumatoid arthritis or osteoarthritis, all of whom 
received NANSAIDs.
As an alternative to examining patients receiving NANSAIDs and looking for 
associations between drug use and gastric lesions, Langman’s group in Nottingham 
examined the consumption of anti-inflammatory drugs in patients who had been 
admitted with small or large bowel perforation or haemorrhage (Langman et al 1985). 
These patients were matched for age and sex with a group of patients who had 
uncomplicated lower bowel disease. It was shown that patients with perforation or 
haemorrhage were more than twice as likely to have been taking anti-inflammatory 
drugs.
Bartle et al (1986) found 42.1% of patients with upper gastrointestinal bleeding 
admitted to hospital were taking NANSAIDs compared to 18.3% of the controls. 
Furthermore the patients whose bleeding was associated with NANSAID use were 
significantly older. The relative risk of developing an acute nonvariceal upper 
gastrointestinal tract bleeding episode was estimated in this study as 3.5 for any 
NANSAID.
O ’Brien & Burnham (1985) looked at their gastroscopic data for patients 
admitted with a presumptive diagnosis of upper alimentary bleeding. Of the 204 
patients examined, 24% had taken NANSAIDs before admission.
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Duggan et al (1986) showed that associations previously described for aspirin 
also existed for NANSAIDs i.e. an association between chronic use and gastric 
ulceration but not duodenal ulceration. This was a case control study involving 180 
matched pairs (85 duodenal,95 gastric ulcers) with the cases obtained from surgical 
wards and the controls from dermatological wards. There was a RR of 5.0 between the 
regular use of anti-inflammatory drugs and gastric ulcer shown in this study. No 
relationships were obtained between NANSAID intake and duodenal ulcer.
Another important study from Langman’s group (Somerville et al 1986) matched 
patients admitted with bleeding peptic ulcer not only to hospital in-patient controls but 
also community-derived controls. This was the first study to do this and it also 
specifically examined patients who were over the age of 60. It was discovered that 
38% of the patients admitted with bleeding peptic ulcers used NANSAIDs. Indeed, 
NANSAIDs were taken over twice as often by the patients as by the community derived 
controls (RR 2.7) and nearly four times as often as the hospital controls (RR 3.8). An 
interesting finding was that these relative risks not only applied to gastric ulcer, as seen 
in the earlier studies, but also to duodenal ulcer.
The AR was also derived. When comparison was made to community controls 
the AR was 0.22, and compared to hospital controls, it was 0.24. Using the number of 
patients studied (290 over 2 years) and an AR 0.22, about 60 patients would have been 
admitted with bleeding due to their medication, a serious and worrying number if the 
population as a whole is considered. The view that NANSAIDs predispose patients to 
perforation was supported by Collier & Pain (1985). Although the incidence was not 
as common as gastrointestinal haemorrhage derived from other studies, their case 
control study found that 47% of a consecutive series of patients over 65 years admitted 
to hospital with peptic ulcer perforation took NANSAIDs, compared to 7% in the 
surgical control group. The methodology has been criticised in the respect that there 
might have been greater identification of NANSAID intake in the perforation group,
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but this is unlikely to account completely for the differences observed.
Carson et al (1987) carried out a retrospective study using a computerised data 
base to evaluate the risk of developing upper gastrointestinal bleeding 30 days after 
"exposure" to an NANSAID. Over 47,000 "exposed patients" were compared to over 
44,000 "unexposed patients". The relative risk, once adjusted for confounding factors, 
was only 1.5, which is small compared to the previous studies. Patients were 
followed-up for six months after a prescription for a single NANSAID had been 
dispensed. However, they did not take into account the length of exposure to the drug 
prior to the study period, and they only excluded those patients with a previous 
diagnosis of upper gastrointestinal bleeding.
A further note of caution was made by Montgomery (1987). He accepted 
Somerville’s and Collier & Pain’s data showing an association between NANSAIDs 
and haemorrhage and perforation in elderly patients with gastric ulcer, but he 
considered that the case that these drugs caused ulcers was not proven. Although an 
agent could cause ulcer bleeding or perforation, Montgomery contended that it could 
not be assumed that it would also cause ulcers.
The data for Adverse Drug Reactions associated with NANSAIDs reveal that 
gastrointestinal diseases constitute a large percentage of all "yellow cards" submitted to 
the C.S.M. (C.S.M. update 1986). It is only when national figures like these are 
considered that the scale of the problem can be appreciated, as it is likely that only a 
faint impression of the problem would be apparent to an individual General Practitioner 
(Cockel 1987). However, more recent reports from the B.C.D.S.P. suggest that the 
risks associated with NANSAID consumption may be overestimated. Beard et al 
(1987) examined hospitalisation due to bleeding from the stomach or the oesophagus in 
patients over 64 who had received a prescription for an NANSAID within the previous 
90 days, and this included long term as well as short term users. The observed 
difference in rates (NANSAID users= 1.3 x non users) appeared to indicate that
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NANSAID use in this group would be unlikely to lead to any major increase in 
hospitalisation. However, it should be noted that these data were generated from only 
29 patients taking NANSAIDs and 28 matched controls. In another study from the 
same group, Jick et al (1987) found that the frequency of hospital admission for 
perforated ulcer was not affected by concomitant NANSAID use. They examined 
patients over 10 years of age whose diagnosis on discharge was perforated ulcer and 
who had presented a prescription for any NANSAID within 90 days prior to admission.
Later, Jick’s standpoint was supported by Henry et al (1987). This was a case 
control study which found that NANSAIDs were taken by 399c of patients who had 
died of ulcer complications. Similar rates were also found for aspirin use. The authors 
were keen to note that relative risks could not have been determined in this study as 
they did not include a control group without ulcers. However, they concluded that the 
data indicated that neither aspirin nor NANSAIDs could be associated with an increase 
in mortality due to ulcer complications.
This study, together with that of Jick et al, appears to be at variance with the large 
body of evidence which concludes that NANSAIDs are causal for not only ulcer 
complications but also for the development of peptic ulcer in susceptible patients.
Henry et al contradicted the evidence that aspirin intake was associated with frank 
ulceration and perforation. This view is hard to justify as no data were presented on 
the amount and duration of aspirin intake in either cases or controls. This omission of 
data is important as a body of evidence had been built up which states that aspirin is a 
problem in chronic heavy use, and only under these conditions are serious adverse 
effects likely to be seen. Not only does the paper contradict other workers’ studies, it 
also contradicts earlier work by their own group. In 1986 Duggan et al showed that an 
association existed (RR 5.0) between the regular use of NANSAIDs and the 
development and complications of gastric ulcer. Associations between regular aspirin 
consumption, either used singly or in combination with NANSAIDs, and gastric
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ulceration were also described, in keeping with previous studies. Obviously, this more 
recent paper helped to confuse rather than clarify the issue.
A prospective longitudinal study - American Rheumatism Association Medical 
Information System (Fries et al 1989) was performed in 22,000 patients in 17 centres 
throughout the USA and Canada. It is the most recently published epidemiological 
study. They noted that patients receiving any NANSAIDs (or aspirin) had a hazard 
ratio for any gastrointestinal symptoms severe enough to require hospitalisation that 
was 6.45 times that of patients not taking these drugs. Characteristically, older patients, 
or those who had previous symptoms requiring either discontinuation of therapy or 
coadministration of H2  receptor antagonists or antacids, were at greatest risk. The 
authors estimated that anti-inflammatory drug induced gastropathy accounted for 2,600 
deaths and 20,000 hospitalisations each year in patients with rheumatoid arthritis alone.
Some interesting work has been published by surgeons dealing with the 
consequences of haemorrhagic and perforated peptic ulcers (Armstrong & Blower 
1987b). They strongly disagreed with the studies that considered aspirin and 
NANSAID gastrointestinal toxicity as rare, and more controversially, benign. They 
showed that 60% of patients with life threatening complications of peptic ulcers took 
these drugs. Furthermore, 78.2% of the patients who died were shown to have received 
anti-inflammatory drugs. The mortality rate associated with complications of peptic 
ulcer disease in patients taking NSAEDs was more than twice that expected in patients 
not receiving NSAIDs. If this mortality rate was extrapolated to the national level it 
would indicate that 4,000 people died each year due to NSAID induced upper 
gastrointestinal complications. It must be noted, however, that the cases and controls in 
this study were not matched, casting some doubt on the value of the results. 
Furthermore, questioning of the two groups took place at different times and by 
different people.
Dewer (1985), another surgeon, showed similar data. In this study 50% of the
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over 60s (who have the worst prognosis for emergency surgery) took aspirin or an 
NANSAIDs compared to 20% of the under 60s. The incidence in females was twice 
that in males, although fewer females were studied. This was also in agreement with 
Armstrong & Blower’s results. The association was greater with bleeding than with 
perforation, except in the over 60s where perforation rates were higher than in the under 
60s.
Table 1.4 summarises all the above studies. Studies have been excluded if their 
methodology did not allow relative risks to be calculated. If relative risks were not
stated, but could be calculated, the following formula was employed:-
RR = JL + JL 
a+b c+d
where:
a = number of patients receiving drug with lesions 
b = number of patients receiving drug without lesions 
c = number of patients not receiving drug with lesions
d = number of patients not receiving drug w’ithout lesions
Differences therefore exist as to the perceived risk of gastrointestinal 
complications associated with NANSAID use. This may be accounted for largely by 
the differences in size of studies, patient populations, statistical methods, study design 
and study outcomes. This makes any attempt to formalise a meta-analysis impossible. 
If individual risk is low, it is necessary to consider whether risk is concentrated in any 
specific group e.g. the elderly. Langman noted that, by case control studies, it was 
possible to show an increased risk of ulcer complications in individuals aged over 60 
(Langman 1989). Collier & Pain (1985) demonstrated a highly statistically significant 
correlation between annual number of elderly patients with perforated peptic ulcer who 
were taking an NSAID and the annual number of prescriptions issued for these drugs.
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Jick et al (1987) also showed that perforation rates increased sharply with age.
Another problem with the data is the significant occurrence of "silent ulceration". 
Many ulcers in patients receiving NSAIDs are asymptomatic (Roth 1986). In the 
absence of routine endoscopy, clinical estimates of ulcer frequency are probably too 
low. Many ulcers first present with a catastrophic bleed or perforation. Almost 60% of 
the cases of complicated ulceration reported by Armstrong & Blower had no 
gastrointestinal symptoms. It may be argued that silent ulcers are more dangerous than 
symptomatic ulcers because of the absence of warning symptoms. Even when 
symptoms are present, they are not necessarily indicative of ulceration, confounding 
further the difficulty in recognising the presence of potentially life threatening 
ulceration.
Maintenance treatment with H 2  receptor antagonists appears to some extent to 
decrease the frequency of asymptomatic ulcers (Pounder 1989). Curiously, it also 
appears to prevent asymptomatic ulcers becoming symptomatic. Another confounding 
factor is that ulcers can heal despite continued drug intake (Dewer 1985). Dewer
noticed that patients who had symptoms of peptic ulcer for less than three months were 
more likely to be taking NSAIDs than not. However, if they had experienced the 
symptoms for more than 1 year they were less likely to be taking NSAIDs (Dewer 
1985). This could indicate refractoriness, or adaptation to the drugs’ gastrointestinal 
toxicity.
In conclusion, the development of NANSAID induced gastropathy is a well 
recognised phenomenon. There is, however, disagreement as to the extent of the 
problem. Chronic use appears to be associated with the development of duodenal, and 
especially, gastric lesions which can progress into more serious conditions. The 
heterogeneous nature of the individual studies described in this section has made formal 
meta-analysis almost impossible.
Examination of Table 1.4 shows that the prospective studies consistently found
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higher relative risks compared to the retrospective studies which may be due to the 
removal of some confounding factors and bias exhibited in retrospective studies. The 
attributable risk may not be as high as previously thought. In general, there would be a 
reduction of mortality and morbidity by the decreased prescribing of these agents, 
especially in conditions where their clinical benefit is doubtful such as low back pain. 
Their use, however, remains disturbingly great.
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1.9 NANSAID INDUCED GASTROPATHY: TREATMENT AND PREVENTION
Whether or not peptic ulcer is drug related, its therapy tends to be similar. 
However, if ulcers in patients receiving NANSAIDs have a different aetiology, does it 
follow that they will have a similar response rate if traditional anti-ulcer treatment is 
employed?. In this section examination will be made of the treatments available, the 
studies carried out in both normal subjects and patients, and the effects of continuing or 
discontinuing the NANSAID during therapy. When consideration of the results of 
studies are made, it should be borne in mind that the body’s own intrinsic healing 
capabilities also play a role. The extent of this has been shown in "classical" peptic 
ulcer disease where placebo groups in some studies have been shown to have healing 
rates between 30 and 60% (Clearfield & Borowsky 1986). Furthermore, healing rates 
can differ between populations, with Europeans showing faster healing rates than North 
Americans.
1.9.1 H2 RECEPTOR ANTAGONISTS
Since the back diffusion of acid into the gastric mucosa has been shown to cause 
acute injury, initial therapy was aimed at decreasing acid secretion or neutralising intra­
luminal acid. Of the H2 receptor antagonists available, both cimetidine and ranitidine 
have been marketed for a number of years with an enviable safety record. Recently two 
newer agents, nizatidine and famotidine, have been introduced, and although they differ 
structurally, they do not appear to offer any specific advantages over existing agents.
Lanza et al (1983b) carried out a double blind endoscopic study in two groups of 
15 volunteers. One group received aspirin 650mg q.i.d., the other, flurbiprofen, 50mg 
q.i.d.. After a one week endoscopy, four subjects from each group exhibited significant 
gastric and/or duodenal damage. Those eight continued their particular drug for another 
month but with the addition of cimetidine 300mg q.i.d.. On re-endoscopy significant 
improvement was seen only in the subjects with duodenal damage.
When consideration is made of the coadministration of H2 receptor antagonists in
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order to prevent or heal NANSAID induced gastropathy, studies involving healthy 
volunteers may not be able to predict this situation in patients. For example, patients 
with rheumatoid arthritis have a higher incidence of peptic ulceration even when they 
are not receiving any medication (O’Brien 1983). Therefore, the disease can influence 
the response and direct comparisons may not be valid.
Golan & Keren (1982) showed a reduction in upper gastrointestinal symptoms 
with cimetidine as a single night time dose in arthritic patients receiving indomethacin 
or diclofenac. Loiudice et al (1981) showed cimetidine coadministration healed 
NANSAID induced gastric ulcers. Croker et al (1980) also looked at arthritic patients 
with anti-inflammatory drug induced ulcers and found similar healing and recurrence 
rates to non arthritic ulcer patients. In duodenal ulcer, expected healing rates with H 2  
receptor antagonists are 75% within 4 weeks and up to 90% at 8 weeks; gastric ulcer 
healing rates tend to be slower (Howden & Hunt 1990). However, most ulcers recur 
when treatment stops indicating that these drugs do not alter the natural history of the 
condition.
These studies all showed a reduction in severity of gastrointestinal damage once
the anti-inflammatory drug had been discontinued. It would be more appropriate to 
examine the situation when NANSAIDs are continued. Rachmilewitz et al (1986a) 
showed cimetidine decreased the mucosal damage caused by indomethacin despite its 
continued use. Another study (Rachmilewitz 1988) showed that cimetidine could 
prevent damage due to short term courses of aspirin 650mg q.i.d., naproxen 500mg 
b.d., or indomethacin 50mg t.i.d.. Roth (1982) showed cimetidine to be significantly 
better than placebo in decreasing the frequency of endoscopically determined peptic 
ulceration in arthritic patients who had been receiving a number of different 
NANSAIDs (and aspirin) on a long term basis. An improvement was also seen in 
rheumatoid arthritis patients on long term salicylate therapy with cimetidine despite 
continued aspirin therapy.
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In the large double blind multicentre study from Norway comparing piroxicam 
and naproxen, 63 out of 2000 osteoarthritis patients experienced serious gastrointestinal 
side effects (16 diffuse gastritis, 17 gastric ulcers, and 30 duodenal ulcers). Cimetidine 
400mg every eight hours was given in order that they could continue their medication. 
Of the 47 who had either gastric and duodenal ulcers, 43 healed within eight weeks. 
None of these patients, or the remaining sixteen with diffuse bleeding gastritis 
experienced further symptoms (Giencksky et al 1988).
Cimetidine 800mg given as a single night time dose to treat anti-inflammatory 
drug induced erosions was examined by Bijlsma (1988a) in 187 patients who continued 
their medication. Patients with ulcers had a healing rate of 497c at four weeks w'hich 
increased to 817c by eight weeks. Erosions had a four week and eight week healing 
rate of 82% and 97% respectively. Maintenance treatment with 400mg daily was 
continued in 113 patients with endoscopically-healed lesions. During six months of 
observation with endoscopy at one monthly intervals, the cumulative probability of 
recurrence of lesions was 12%, with a mean time to recurrence of 116 days. This 
figure is similar to the relapse rates obtained in non drug induced peptic ulcer disease.
Similar results were found by the author in 127 patients receiving NANSAIDs, 
and aspirin, who experienced gastrointestinal symptoms which were significant enough 
to warrant endoscopy but which subsequently proved negative (Bijlsma 1988b). In 
this double blind placebo controlled study, the four week healing rates were 72% on 
cimetidine and 49% on placebo. Relief from heartburn was 877c in the cimetidine 
group and 607c on placebo. In the maintenance phase, 117c in the cimetidine group 
relapsed (mean time 120 days) and 10% in the placebo group (mean time 35 days). 
Cimetidine was therefore considered useful in the treatment of both endoscopically 
positive, and negative, drug induced gastrointestinal symptoms despite continued use.
Few of these studies address the differing effects of cimetidine on gastric ulcers 
and duodenal ulcers associated with NANSAIDs. It cannot be assumed that their
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healing rates are the same. For example, Stalnikowicz et al (1988) showed that 
although cimetidine reduced the amounts of endoscopically scored mucosal lesions in 
patients receiving indomethacin (50mg three times a day), it only achieved statistical 
significance in the duodenum. This difference between healing rates for gastric and 
duodenal lesions has been an area of exploitation for the manufacturers of synthetic 
prostaglandin analogues (see section 1.9.2).
Overall, although cimetidine has been demonstrated to be beneficial in the 
situations outlined above, care must be taken when examining individual studies. 
Reliance on endoscopic scoring systems may be problematical (Graham 1989). Many 
authors provide separate scores for each type of lesion e.g. erythema, petechiae, 
erosions and acute ulcers. Lesion scores may be given for different areas e.g. 
oesophagus, gastric body/antrum, and duodenum and the totals for each lesion type in 
each area may be added to give a total that is statistically compared. There are 
therefore so many comparisons made that finding a statistical significance by chance is 
highly likely.
When ranitidine was considered, similar results to cimetidine were obtained. 
Bianchi P o ito  et al (1987) showed impressive trends in favour of ranitidine healing 
gastric mucosal lesions in arthritic patients, either continuing or discontinuing their 
NANSAID treatment. However, the power of this study may have been so low that 
conclusive statements would be difficult to make as only 48 rheumatoid patients were 
investigated and they, in turn, were subdivided into four equal groups. Furthermore, 
ranitidine did not prevent gastric damage. Musi et al (1984) performed endoscopy on 
patients with obvious gastrointestinal symptoms from a rheumatology clinic. 
NANSAIDs and aspirin (if appropriate) were continued and patients were given either 
ranitidine or aluminium hydroxide. Patients treated with ranitidine achieved improved 
endoscopic lesion scores, but, this was only significant when severe lesions were 
present.
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These findings have been confirmed by studies from Scandinavia (Manniche et al 
1987, Malchow-Moller et al 1985, Malchow-Moiler 1987). These authors examined 
the effects of different ulcer treatments in rheumatoid patients with peptic ulcers who 
had either continued or discontinued their medication. There was no statistical 
difference in the healing times for ranitidine or sucralfate (section 1.9.3) either in the 
presence or absence of anti-inflammatory drug therapy. This indicated that ulcer 
healing could be brought about despite continued intake, and furthermore, the healing 
rates found corresponded to those obtained in non-rheumatoid patients.
Rachmilewitz et al (1986b) showed that ranitidine increased the synthesis of 
PGE2  and 6-ketoPGFla  in both antral and fundal gastric mucosa. This effect occurred 
at non-antisecretory doses indicating that ranitidine may also have an effect on 
prostaglandin synthesis.
As far as the newer agents are concerned there are insufficient data on their use in 
NANSAID induced gastropathy at present.
In conclusion, only full doses of H2  receptor antagonists have been shown to heal 
ulcers and prevent recurrences. They do reduce severe acute injury and also reduce 
non-ulcer gastrointestinal disturbances. However, there appears to be differences 
between their effectiveness in the treatment of NANSAID induced gastric ulcer when 
compared to duodenal ulcer, (McCarthy 1989) and as their efficacy in prophylaxis has 
not been established, their routine use in all cases would appear to be unjustified.
1.9.2 PROSTAGLANDINS
The cyclooxygenase enzyme may exist as different isoforms in various body 
tissues (Whittle et al 1980). The possibility therefore existed for the development of 
prostaglandin analogues to reverse the NANSAID induced cyclooxygenase inhibition 
in selective tissues e.g. the gastric mucosa. In this section, therefore, discussion will be 
made of the role of exogenous prostaglandins in the treatment of NANSAID 
gastropathy. These agents have been called "cytoprotective", a term which implies that
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they will protect against mucosal injury by mechanisms other than reduction of acid 
secretion. This has been criticised as a misleading term because the individual cells are 
not "strengthened" or "cytoprotected" (cell protected) (Guth 1987). Nevertheless, the 
term has come into widespread use. The problem with it is that, by definition, 
cytoprotection is a preventative effect of an agent given prior to the administration of a 
necrotising substance, resulting in a reduction in damage caused by that substance.
This action cannot be extrapolated to a completely separate action that heals an already 
established lesion. It may be logical to assume that if an agent has one of the above 
actions it will have the other. What cannot be assumed is that the same mechanisms are 
involved in each case.
It has been show that prostaglandins have two main actions. At lower doses they 
are considered to be cytoprotective whereas at higher doses they suppress acid 
secretion. Prostaglandins are thought to protect against all ulcerogenic agents as they 
prevent the appearance of lesions after exposure to necrotising agents in animal studies 
(Holt & Hollander 1986). Restitution of the mucosa appears to be more rapid after 
prostaglandin pretreatment than when there is no pretreatment (Hawkey & Walt 1986). 
This may be a consequence of preserving the cells that initiate mucosal repair, rather by 
than direct stimulation of the repair processes. These findings have, by and large, not 
been reproduced in human studies (Charlet et al 1985). The ability to state 
unequivocally that certain actions occur at non-antisecretory doses has also proved 
difficult. This is due to a lack of standardised methods and the use of techniques which 
were not sensitive enough to differentiate between the two proposed activities with 
regard to the dose. Animal studies have indicated that prostaglandins may be involved 
in the "adaptation" seen after chronic therapy with aspirin and the NANSAEDs; 
nevertheless this remains controversial (Hawkey & Rampton 1985).
If prostaglandins are important in the integrity of the mucosal barrier, does a 
deficiency predispose to peptic ulceration?. Wright et al (1982) noted that patients
70
with chronic gastric ulcers had reduced mucosal PGE levels compared to controls.
Other studies indicate that there may also be abnormalities in duodenal ulceration 
(Hawkey & Rampton 1985, Hawkey & Walt 1986).
The synthetic prostaglandins are based on either PGE j (e.g. misoprostol) or 
PGE2  (e.g. enprostil). Diarrhoea is a common side effect although it varies between 
drugs. Abdominal pain and possible abortifacient effects further mitigate against their 
use. The accumulating evidence suggests that misoprostol and enprostil are of similar 
potency to H2  receptor antagonists in healing both "classical" gastric and duodenal 
ulcers. Furthermore, there is little evidence to suggest that their healing rates are any 
higher than those expected from their antisecretory activity. For this reason it appears 
that "cytoprotection" may not be a major factor in ulcer healing by prostaglandins 
(Hawkey & Walt 1986).
Hawkey et al (1986) examined some strategies to reduce anti-inflammatory drug 
induced gastropathy. This study involved looking at healthy volunteers who had been 
taking either aspirin or an NAN SAID for over two days. Mucosal damage was 
quantified by determining blood content in the gastric washings. Experimental agents
used in this study included enprostil, ranitidine, milk, and a linoleic acid and gamma
(R)linolenic acid preparation (Efamol ). These were given for 20 - 60 minutes before the
(R)dose or alternatively, Laboprin , a lysine containing aspirin preparation, was given 
instead of regular aspirin. Only enprostil and ranitidine reduced mucosal bleeding and 
increased the pH of the washings. This suggested that acid inhibition was the 
mechanism by which mucosal damage was reduced.
Rachmilewitz et al (1986b) examined PGE2  and 6-ketoPGFja  levels in fundal 
and antral mucosa obtained from patients with active duodenal ulcer, healthy controls, 
and patients on long-term anti-inflammatory therapy. Levels were significantly reduced 
in both the patient groups. There was a greater reduction in the group receiving 
medication in comparison to the duodenal ulcer group. The decreased prostaglandin
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content in the duodenal ulcer group was not affected by one month’s treatment with 
misoprostol, arbaraprostil, sucralfate, pirenzepine or placebo. However, ranitidine 
significantly increased the levels, especially of PGE2 . Unfortunately, these drugs were 
not given to the anti-inflammatory drug treated group.
The ability of prostaglandins to protect against NAN SAID induced damage was 
examined in two studies. In the first Lanza et al (1988) compared misoprostol (200|ig 
q.i.d.) and cimetidine (300mg q.i.d.) to placebo in protecting tolmentin induced (400mg 
q.i.d.) gastric and duodenal injury in normal volunteers. After six days treatment 
endoscopic assessment showed a success rate for preventing overall damage to be 
26.7% in the placebo group, 63.3% in the cimetidine group and 93.1% in the 
misoprostol group (p < 0.001). When the different sites were compared independently, 
the success rates for cimetidine and misoprostol did not differ in the duodenum, but 
there was a statistically higher success rate in the gastric mucosa with misoprostol.
This finding was confirmed in a long term study using piroxicam, ibuprofen, or 
naproxen in 420 patients with osteoarthritis (Graham et al 1988). Endoscopy was 
performed at entry and after one, two, and three months of continuous treatment with 
either 100 or 200jig misoprostol q.i.d. or placebo. Treatment failure was defined as the 
development of gastric ulcer. 5.6% of the lOOpg group and 1.4% of the 200pg group 
developed gastric ulcers compared to 21.7% in the placebo group (p < 0.001). In these 
two studies diarrhoea was very common (two to three times more common in the 
treatment group compared to placebo).
Another feature of the Graham study was the low occurrence of duodenal ulcer.
In patients taking misoprostol, this only occurred in 2.5% compared to 3.6% in the 
placebo group. This placebo rate is lower than most other studies and may reflect 
exclusion of patients with prior ulceration. Even if it is true, at a rate of 3.6% it will be 
very hard to show that any drug could better it.
In a study by Dammamm et al (1989), the high prevalence o f diaiThoea in the
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misoprostol group was associated with a 20-60% reduction in the steady state 
indomethacin concentration when compared to volunteers receiving ranitidine or 
placebo. It was the authors contention that this reduced absorption could have played a 
role in the lower gastroduodenal lesion scores found in their study in the misoprostol 
group. This area, therefore, requires further investigation.
In conclusion, the role of prostaglandins in the treatment of NANS AID induced 
gastropathy is still controversial. They do not heal ulcers with any greater efficiency 
than would be predicted from their inhibition of acid secretion. The ability to prevent 
damage by necrotising agents seen in animal studies, the so-called cytoprotective effect, 
has not been well demonstrated in humans. Their side effects and healing rates indicate 
that they possess no therapeutic advantage over the H2  receptor antagonists in ulcer 
healing, although they have demonstrated efficacy in preventing gastric ulcers in 
patients receiving anti-inflammatory drugs, but this needs further investigation. At 
present, positive indications for these drugs are few.
1.9.3 SUCRALFATE
This is a molecule of sucrose with multiple substitutions for aluminium salts. It 
has been shown to be effective in the treatment of both gastric and duodenal ulcers 
(Holt & Hollander 1986). At low pH values some aluminium hydroxide ions 
dissociate and the residual compound becomes negatively charged. This then 
polymerises to form a viscous paste-like substance which is the "active" form of 
sucralfate. This substance adheres to the mucosa. However, when the mucosa is 
damaged, sucralfate binds with six times its normal affinity as the negatively charged 
sucralfate binds to the positively charged denatured proteins for at least 6 hours. 
Sucralfate therefore protects the mucosa by insulating it from the luminal acid, by 
adsorbing bile salts, and by reducing peptic activity. It is not an antacid; however the 
aluminium hydroxide may provide local buffering against gastric acid. Sucralfate also 
appears to stimulate local prostaglandin production (Tamawski et al 1987).
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Caldwell (1985) examined the use of sucralfate in reducing gastrointestinal 
symptoms associated with NSAID intake. Sucralfate was given for two weeks, while 
NSAIDs were continued. Sucralfate administration resulted in a disappearance of 
heartburn, epigastric pain and distress, despite continued anti-inflammatory drug intake. 
This result was in agreement with the Scandinavian studies described earlier (Manniche 
et al 1987, Malchow-Moller et al 1985, Malchow-Moller 1987) which showed that 
sucralfate healed ulcers at the same rate irrespective of whether an NANSAID was 
continued or not.
One factor that mitigates against the drug’s success is that on long term treatment 
aluminium absorption may be a problem (Allain et al 1990) and for this reason it is 
only licensed in the U.K. for up to 12 weeks continuous treatment.
1.9.4 BISMUTH CHELATE
(R)The proprietary preparation of De Nol (Tripotassium dicitrato bismuthate = 
colloidal bismuth subcitrate = bismuth chelate) has recently come back into favour for 
the treatment of peptic ulceration due to its actions on Helicobacter pylori, and its 
ability to reduce ulcer relapse rates. It selectively chelates the proteinaceous material of
an ulcer base forming a protective coat which adheres for about 6 hours. In addition, it 
directly inactivates pepsin, via chelation, and may also increase luminal PGE2  levels 
(Konturek et al 1987). It was also shown that this increased luminal release of PGE2  
was completely abolished by aspirin in man, and by indomethacin in dogs (Konturek et 
al 1987). The role therefore for this agent in NANSAID gastropathy will only become 
clear once the appropriate studies are performed.
Bismuth cannot be used for maintenance therapy as absorption may lead to 
encephalopathy (Gavey et al 1989). It darkens the teeth, tongue and stools, the liquid 
formulation smells of ammonia, and needs to be taken q.i.d.. For these reasons a more 
palatable tablet formulation with a convenient b.d. dosage regimen has been introduced. 
The maximum length of the course is 56 days with at least 1 month between courses.
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1.10 CONCLUSIONS
All NANSAIDs decrease prostaglandin synthesis, with the result that mucosal 
prostaglandin levels fall. NANSAID induced gastropathy is a well recognised 
phenomenon, although the heterogeneous nature of the studies thus far performed make 
it is impossible to say whether or not a causal relationship exists.
Prophylactic treatments e.g. H2  receptor antagonists, prostaglandins can heal and 
delay the recurrence of gastropathy, however, it is unclear whether they can prevent the 
condition. The "cytoprotective" effect of prostaglandins has not been well recognised 
in humans, and although the current prostaglandins appear to heal NANSAID induced 
gastric ulcers more effectively than H2  receptor antagonists their side effect profile will 
restrict their use.
Piroxicam is no better or no worse, in terms of toxicity, than the other 
NANSAIDs currently available despite assertions to the contrary. Its long elimination 
half-life has ensured its commercial success, as General Practitioners (and patients) 
prefer the simplicity of a once a day dosage regimen, and this popularity has been 
reflected in terms of sales, making it one of the most profitable branded NANSAIDs 
ever developed.
There are, however, a number of unresolved questions regarding the 
pharmacokinetics of piroxicam e.g. the outcome when it is combined with known 
hepatic enzyme inhibitors ( e.g. H2  receptor antagonists), the implications of any 
clearance alterations, the extent of it’s biliary excretion, and the nature of the "multiple 
peaks" present in plasma concentration time curves. These questions, warrant further 
investigation and consideration.
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CHAPTER 2 
MATERIALS AND METHODS
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2.1 INTRODUCTION TO CHAPTER 2
In this chapter, examination is made of the existing methods available to 
determine piroxicam and 5-hydroxypiroxicam in plasma and urine. Their drawbacks 
are outlined, and the need for a specific assay to quantify trace amounts of drug and 
metabolite not only in plasma and urine, but also in bile, is described The methods 
developed, with the materials used, are listed, in addition to a description of the assay’s 
reliability in terms of extraction recovery, accuracy and precision (both inter- and intra­
assay). Finally, discussion is made of the advantages of these methods and some of the 
problems that had to be overcome in the assay development.
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22  RATIONALE FOR ASSAY DEVELOPMENT
Early studies on the pharmacokinetics of piroxicam employed a degradative 
fluorometric "wet" chemical analytical technique. This involved strong acid hydrolysis 
of piroxicam to generate 2-aminopyridine followed by fluorometric assessment of this 
product after purification. External standards were used to determine the concentration 
of drug present in the sample. This technique was not ideal as it lacked sensitivity and 
selectivity. By using chromatographic techniques improved assay systems were 
developed. Chromatography could be performed on biological samples containing 
piroxicam without chemical modification of the drug. Furthermore, they were simpler 
analytically, more rapid, and as they incorporated internal standards, they were also 
more accurate. Table 2.1 lists the published chromatographic methods for the analysis 
of this drug (and in some instances 5-hydroxypiroxicam). It was considered essential 
that the assay system employed in this work would be flexible enough to cope with a 
variety of biological samples (plasma, urine and bile) with sufficient accuracy and 
precision to be able to detect quantities of both piroxicam and 5-hydroxypiroxicam at 
concentrations as low as 50ng/ml in each of these body fluids. Table 2.1 shows that no 
published assay system has yet fulfilled these criteria.
An HPLC (High Performance Liquid Chromatography) system was envisaged for 
the reasons outlined above. From the point of view of simplicity, use of a single 
column to enable analysis of piroxicam and 5-hydroxypiroxicam in all biological 
samples, without sacrificing accuracy, was desired. None of the published assays met 
these conditions for both plasma and urine and no published reports were available for 
the analysis of this drug and/or metabolite in bile. Method development therefore 
proceeded with the objective of establishing an assay technique which would fulfil all 
the above mentioned criteria.
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23  MATERIALS
23.1 CHEMICALS
The following chemicals were used in all analyses: acetic acid (Pronalys AR,
May and Baker); acetonitrile (HPLC Far UV, Fisons); citric acid (AnalaR, FSA); 
diethlyethcr (Pronalys AR, May and Baker); disodium phosphate (AnalaR, BDH); (5- 
glucuronidase enzyme (Bovine Type BI, Sigma); hydrochloric acid (Pronalys AR, May 
and Baker); orthophosphoric acid (Pronalys AR, May and Baker); sodium acetate 
(AnalaR FSA); sodium dihydrogen phosphate (Pronalys AR, May and Baker); sodium 
hydroxide (AnalaR BDH).
2.3.2 CONSUMABLES
The following items were uniformly used in all analyses: Waters 4ml sample 
vials (cat. no. 72710); Waters compression spring (cat. no. 72708); Waters H-style caps 
(cat. no. 72711); Waters PTFE septa (cat no. 73005); Microsert limited volume inserts
(Jones Chromatography, cat. no. 150710); Pyrex disposable culture tubes 13 xlOOmm
(K)(Coming); Centrifree micropartition system (Amicon); Gilson Pipetteman with
Gilson polypropylene tips; Techsil 10 CN column packing (HPLC Technology).
23.3 DRUGS
Piroxicam was a gift from Pfizer (Sandwich U.K.) and 5-hydroxypiroxicam was a 
gift from Pfizer (Groton, Conn. U.S.A.). Isoxicam was a gift from Wamer- 
Lambert/Parke-Davis (Gwent, U.K.).
2.3.4 EQUIPMENT
The following apparatus were used: Waters autosampler WISP 7 10B; Waters 
pump M45; Shimadzu UV detector SPD6A; Shimadzu Chromatopack Integrator 
CR3A; Gallenkamp orbital shaker; MSE Mistral 21 centrifuge; Techne Dri-block DB3; 
SMI Multitube Vortexer 2601; Dawe Sonicleaner; Grant Waterbath.
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2.4 SOLUTIONS
2.4.1 0.1M ACETIC ACID
0.58ml glacial acetic acid was made up to volume (100ml) in a volumetric flask 
with freshly distilled and filtered water.
2.4.2 0.1M SODIUM ACETATE
0.8203g sodium acetate was dissolved in a 100ml volumetric flask with freshly 
distilled and filtered water.
2.4.3 0.1M ACETATE BUFFER pH 5.0
To 14.8ml acetic acid 0.1M was added 35.2ml sodium acetate 0 .1M and made up 
to 100ml in a volumetric flask with freshly distilled and filtered water.
2.4.4 0.1M CITRIC ACID
2.1g citric acid was dissolved in a 100ml volumetric flask with freshly distilled 
and filtered water and made up to volume.
2.4.5 0.2M DISODIUM PHOSPHATE
3.56g disodium phosphate was dissolved in a 100ml volumetric flask with freshly 
distilled and filtered water and made up to volume.
2.4.6 CITRIC ACID-PHOSPHATE BUFFER pH 4.9
To 50.5ml citric acid 0.1M was added 49.5ml disodium phosphate 0.2M in a 
100ml volumetric flask.
2.4.7 HYDROCHLORIC ACID 1.0M
8.6ml glacial hydrochloric acid was added to 70ml freshly distilled and filtered 
water in a 100ml volumetric flask before making up to final volume.
2.4.8 SODIUM HYDROXIDE 0.01M
0.4g sodium hydroxide was made up to volume (1000ml) in a volumetric flask 
with freshly distilled and filtered water.
2.4.9 MOBILE PHASES
In order to analyse piroxicam and 5-hydroxypiroxicam in plasma, urine and bile,
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on the same chromatography column, specific mobile phases were employed to optimise 
the separation of the various chromatographic peaks. For the analysis of plasma and 
urine samples, a mobile phase containing 22% acetonitrile gave optimal results. For the 
preparation of this solution, 440ml acetonitrile was made up to 2 Litres with freshly 
distilled and filtered water. 3.423g sodium dihydrogen phosphate was added, and after 
mixing for 5 minutes, the final pH was adjusted to 3.5 with orthophosphoric acid.
Helium was then bubbled through for 20 minutes to degas the solution. If patients were 
also receiving sulphasalazine, the final pH was adjusted to 2.5 and not 3.5 (see section 
2.5).
For the analysis of bile samples, a mobile phase consisting of 10% acetonitrile 
was employed. For its preparation, 200ml acetonitrile and 1.560g sodium dihydrogen 
phosphate was used. Otherwise the method was identical to that described above.
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2.5 METHODS
2.5.1 HPLC ANALYSIS OF PIROXICAM AND 5-HYDROXYPIROXICAM IN 
PLASMA, URINE AND BILE
2.5.1.1 EXTRACTION PROCEDURE IN PLASMA
To 0.5ml of plasma, in a 12ml heavy duty glass centrifuge tube (manufactured by 
Glass Blowing Department, Glasgow University) was added: 1ml of 0.01M sodium 
hydroxide (containing piroxicam and 5-hydroxypiroxicam if spiking samples in order 
to obtain calibration line), 0.1ml internal standard solution (O.lmg/ml isoxicam in
0.01M sodium hydroxide), 0.25ml of 1M hydrochloric acid, and 5ml diethylether. The 
tubes were stoppered and shaken for 6 minutes at 240 revs/min using a Gallenkamp 
Orbital Shaker and centrifuged at 2000 revs/min for 10 minutes at 4°C (MSE Mistral 
2L). The ether phase was transferred to a pyrex tube (Coming) and evaporated to 
dryness (37°C) under nitrogen (Techne Dri-block DB3). The residue was reconstituted 
in 250pl of acetonitrile/water (50:50) and vortexed for 60 seconds (SMI multitube 
vortexer 2601) immediately prior to injection (50p.l) on to the column.
2.5.1.2 EXTRACTION PROCEDURE IN URINE AND BILE
The extraction procedure for unconjugated piroxicam and 5-hydroxypiroxicam in 
the urine and bile was identical to that used in plasma, with the addition of one extra 
stage. After collection of the ether phase, a back-extraction was performed to purify 
the sample. 2ml citric acid-phosphate buffer (pH 4.9) was added to the ether in a clean 
centrifuge tube. This was again shaken and centrifuged before collecting the ether 
phase. The ether was then evaporated and reconstituted in the above manner.
For the measurement of 5-hydroxypiroxicam glucuronide, 5ml urine or bile was 
adjusted to pH 5.0 with an equal volume of 0.1 M acetate buffer. This was incubated 
for 24 hours in a water bath at 37°C, in the presence of 500 I.U. Bovine Liver (3- 
glucuronidase. 1ml of this mixture was then acidified by 0.25ml 1.0M hydrochloric 
acid after addition of internal standard (0.1ml O.lmg/ml isoxicam in 0.01M sodium
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hydroxide). Extraction was performed as per the unconjugated 5-hydroxypiroxicam.
In all instances, residues were reconstituted in 250p.l acetonitrile/water (50:50) 
and vortexed for 50 seconds (SMI multitube vortexer 2601) prior to injection (50|il) on 
to the column.
2.5.13 REVERSED-PHASE CHROMATOGRAPHY
Instrumentation included a Waters autosampler WISP 710B, a Waters M45 
pump, a fixed wave length UV detector (Shimadzu SPD6A) and an integrator 
(Shimadzu CR3A chromatopack). For simultaneous quantitation of piroxicam and 5- 
hydroxypiroxicam in plasma, urine and bile a Techsil CN column (20cm x3.9mm,
10pm particle size, HPLC Technology) was used. For the analysis of plasma and urine 
the mobile phase consisted of 50 mM sodium dihydrogen phosphate in 
acetonitrile/water (22:78) with a final pH of 3.5. For the analysis of bile the mobile 
phase was similar except that the acetonitrile concentration was 10%.
The flow rate in all instances was 2.5ml/minute and the eluate was monitored at 
365nm. A guard column using Techsil CN was employed in all instances and replaced 
after each run.
In each run, spiked samples were included over the concentration range 0.05 to 
30mg/l. This was used to construct a calibration line for that particular run. In 
addition, 0.5mg/l standard samples were dispersed throughout the patient samples in 
order to evaluate assay performance throughout the analysis.
Figure 2.1 shows an example of a typical plasma (both bound and unbound) 
chromatogram. Figures 2.2 and 2.3 show an example of a chromatogram obtained both 
pre- and post-glucuronidase incubation in urine and bile respectively.
23.2 HPLC ANALYSIS OF UNBOUND PLASMA CONCENTRATION OF 
PIROXICAM AND 5-HYDROXYPIROXICAM.
23.2.1 INTRODUCTION
As was outlined in Chapter 1, piroxicam is greater than 99% bound to plasma
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FIGURE 2.1 EXAMPLE OF PLASMA CHROMATOGRAPHS
[ 1 ]
A
11 min
A = PIROXICAM 
B = 5-HYDROXYPIROXICAM
C = ISOXICAM ( INTERNAL
S T A N D A R D '
[ 2 ]
11 min
1. TYPICAL CHROMAGRAPH OBTAINED 
IN PLASMA ( BOUND AND UNBOUND )
2. TYPICAL CHROMAGRAPH OBTAINED 
IN PLASMA ( UNBOUND )
FIGURE 2.2 EXAMPLE OF BILE CHROMATOGRAPHS
A = PIROXICAM
B = 5-HYDROXYPIROXICAM
C = ISOXICAM ( INTERNAL
STANDARD )c
20 min
TYPICAL CHROMAGRAPH OBTAINED IN BILE PRE-GLUCURONIDASE
INCUBATION.
< *
20 min
TYPICAL CHROMAGRAPH OBTAINED IN BILE POST-GLUCURONIDASE 
INCUBATION.
FIGURE 2.3 EX AMPLE O F  URINE C H R O M A T O G R A P H S
A = PIROXICAM 
B = 5-HYDROXYPIROXICAM
C =  ISOXICAM (INTERNAL
S T A N D A R D )
11 min11 min
TYPICAL CHROMAGRAPH OBTAINED IN URINE PRE - GLUCURONIDASE 
INCUBATION
TYPICAL CHROMAGRAPH OBTAINED IN URINE POST- GLUCURONIDASE 
INCUBATION
albumin, and as a consequence the circulating unbound concentration of this drug is low. 
Determination of unbound drug by ultrafiltration methods confers advantages over 
other techniques such as equilibrium dialysis (Lin et al 1987). It is very rapid, therefore 
eliminating the disadvantages of long equilibrium times which may degrade unsuitable 
ligands or proteins. Furthermore, long dialysis times may result in adsorption to the 
membrane and dilution of plasma compartment by buffer which would result in a false 
equilibrium being set up. Ultrafiltration methods do not show these drawbacks.
Unbound drug concentration determined in the ultrafiltrate is independent of the 
fractional volume of the sample filtered (Lin et al 1987). For these reasons 
ultrafiltration methods were employed in the analysis of unbound concentrations of 
piroxicam and 5-hydroxypiroxicam.
2.5.2.2 ULTRAFILTRATION METHODS
1.0ml of plasma (either patient unknowns or spiked volunteer samples) was 
pipetted in to a Centrifree® micropartition system (Amicon) at room temperature. This 
was centrifuged at 2000 revs/min for 2 hours at 25°C until 0.25ml of ultrafiltrate was 
obtained.
2^.2.3 EXTRACTION PROCEDURE
To 0.25ml of ultrafiltrate, in a 12ml heavy glass centrifuge tube (manufactured by 
Glass Blowing Department, Glasgow University) was added: 0.5ml of 0.1 M sodium 
hydroxide, 0.05ml of internal standard solution (O.lmg/ml isoxicam in 0.01M sodium 
hydroxide), 0.125ml 1.0M hydrochloric acid and 5ml diethylether. The extraction 
procedure was then identical to that listed for plasma in section 2.5.1.1 with the 
exception that lOOpl of the reconstituted residue was injected on to the column. Figure
2.1 shows a typical chromatogram.
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2.6 ASSAY VALIDATION
2.6.1 EXTRACTION RECOVERIES
Table 2.2 lists the extraction recoveries consistently obtained in each biological 
sample. The addition of a purification step to both urine and bile samples improved the 
recovery of low concentration samples as the influence of interfering peaks was 
lessened. The results obtained are in agreement with the previously published values 
shown in Table 2.1. The extraction recoveries obtained for isoxicam, the internal 
standard, were 88%, 94%, and 90% in plasma, urine and bile samples respectively.
2.6.2 LLNEARITY
The assay linearity for drug and metabolite was determined by performing linear 
regression analysis on the plot of the peak-height ratios of either piroxicam or 5- 
hydroxypiroxicam over the internal standard, versus concentration in the range 0.05 to 
30mg/l. No measured concentrations were ever greater than 19mg/l. Table 2.3 lists the 
correlation coefficients obtained in the assay of both piroxicam and 5- 
hydroxypiroxicam using known standards in the range 0.05 to 20mg/1. Correlation 
coefficients obtained were typically 0.9999.
2.6.3 ASSAY PRECISION
Bulk control standards were prepared by adding know-n amounts of piroxicam 
and 5-hydroxypiroxicam to blank plasma and urine. Pre-dose bile was collected from 
the individual and this was used as the control. Table 2.4 summarises both the intra- 
and the inter-assay coefficients of variation obtained over the range 0.05mg/l to 30mg/l. 
Only at the extreme end of the concentration range does the inter-assay variability 
approach 20%. For concentrations greater than 0.1 mg/1 inter-assay variability is for 
most instances less than 10%.
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2.7 DISCUSSION OF ASSAY DEVELOPMENT
As has been previously outlined, the development of an HPLC assay system 
conferred advantages over other analytical techniques. However, problems were 
encountered in the development of this assay. Initially disposable plastic test tubes (not 
glass) were employed for economic reasons. It was discovered that adsorption of the 
drug and internal standard occurred into the plastic if left in contact with the plastic 
container walls. For this reason, disposable and heavy duty re-usable glassware was 
essential in this assay system.
Another problem was encountered with patients receiving the second line 
antirheumatic agent, sulphasalazine. It is used in high doses (2 to 4g daily) and, in 
man, is excreted in the urine after azo-reduction to sulphapyridine and 5-aminosalicylic 
acid, as their hydroxylated metabolites. The UV max of sulphapyridine is 359nm and 
piroxicam is 360nm, as determined by scanning UV measurements. Therefore as 
sulphasalazine is taken in such large amounts, interference and partial obliteration of 
both the piroxicam and 5-hydroxypiroxicam chromatographic peaks was obtained in 
both plasma and urine samples. By adjusting the pH of the mobile phase to pH 2.5, the 
polarity of the interfering material was increased and as a consequence the peak was 
eluted after both the piroxicam and 5-hydroxypiroxicam peak but before the internal 
standard allowing detection and quantitation to occur as before. Figure 2.4 shows the 
effect of altering the mobile phase pH.
Ratios of drug to internal standard peaks were quantified in terms of heights and 
not areas as it was found that height was less variable. It also conferred the advantage 
that manual assessment of individual chromatograms could be performed at all stages 
which proved to be of particular benefit in the analysis of bile.
Initially bile analysis was performed in a 22% acetonitrile mobile phase as 
discussed earlier. However, after glucuronidase incubation, interfering peaks were 
obtained which made detection of small quantities of piroxicam and 5-
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FIGURE 2.4 EXAMPLE OF PLASMA CHROMATOGRAPHS IN 
PATIENTS RECIEV1NG SULPHASALAZINE
A = PIROXICAM
B =  5 * HYDROXYP1ROXICAM
C = ISOXICAM ( INTERNAL
S T A N D A R D ) 
D = SULPHASALAZINE 
METABOLITE
[ 1
11 min
*
13 min
1 TYPICAL CHROMAGRAPH OBTAINED IN MOBILE PHASE pH 3.5
2. TYPICAL CHROMAGRAPH OBTAINED IN MOBILE PHASE pH 2.5
hydroxypiroxicam difficult. By decreasing the acetonitrile concentration to 10%, the 
retention times of these drugs relative to each other was increased and good separation 
was obtained. However, instead of tall, narrow peaks, short, broad peaks were obtained 
which the integrator had difficulty in quantitating satisfactorily. For this reason, peak 
heights were always reported.
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CHAPTER 3
AN INVESTIGATION OF TH E PERTURBATIONS IN PLASMA PIROXICAM  
CONCENTRATIONS EXHIBITED IN MAN
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3.1 INTRODUCTION TO CHAPTER 3
As discussed in Chapter 1, the extent of enterohepatic circulation of piroxicam 
has been the subject of much speculation, but it has not been investigated to any great 
extent. In the work described in this chapter, the nature and extent of the perturbations 
exhibited in plasma piroxicam concentration/time curves were examined by carefully 
designed experimental and simulation studies. The effect of food consumption on the 
disposition of piroxicam was also examined in healthy volunteers with particular 
emphasis on possible alterations of protein binding, and both clearance and volume of 
distribution. Furthermore, the appearance of piroxicam and 5-hydroxypiroxicam in a 
variety of biological fluids, including bile, was investigated in order that unequivocal 
statements could be made about the role of enterohepatic circulation in the disposition 
of this drug in man.
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3 2  THE INFLUENCE O F FOOD CONSUMPTION ON PLASMA PIROXICAM  
CONCENTRATIONS
32.1. INTRODUCTION
Several studies in man have reported "multiple peaks" in plasma piroxicam 
concentration/time curves, as described in Chapter 1. It has been suggested that these 
"multiple peaks" indicate that the drug undergoes enterohepatic circulation, and that 
biliary recycling contributes to the drug’s long elimination half life. In this study, we 
wished to examine this contention in greater detail. The nature and extent of these 
"multiple peaks" was unclear. If they were the result of enterohepatic circulation, food 
consumption might well result in stimulated release of bile, reflected by a post-prandial 
increase in the plasma concentration of the recycled material. This study, therefore, 
standardised the timing of food administration and employed a blood sampling 
schedule which attempted to characterise these "multiple peaks" in greater detail.
The content of food was standardised as various nutrients have been shown to 
have differential effects on physiological functions. In the study by Moneta et al (1989) 
superior mesenteric artery blood flow, as determined by Duplex ultrasound, was 
increased to varying degrees after a protein, fat, carbohydrate or mixed constituent 
meal. When Indocyanine Green (ICG) clearance was employed as an indicator of 
hepatic blood flow, a post-prandial increase was shown by Svensson et al (1983) after a 
high protein meal. The maximum increase (69%) was obtained 40 minutes after 
consumption and was still 36% above control values after 100 minutes. This had 
important implications for drugs whose hepatic elimination is flow dependent.
Alteration in haemodynamics due to food consumption is not exclusively 
confined to the gastrointestinal tract and surrounding tissues. In the studies by Fagan et 
al (1986a,b) both volunteers and patients exhibited post-prandial increases in 
supine/standing heart rate and cardiac output, together with a decrease in 
supine/standing diastolic blood pressure and total systemic resistance. Consumption of
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a high carbohydrate meal also reduced supine systolic blood pressure.
It is was therefore important to know the constituents of the meals provided and 
to standardise the constituents on each study day.
32.2. SUBJECTS
Table 3.1 lists the demographic details of the six healthy volunteers who 
participated in this study. The six had a mean age of 26 years and were all within 20% 
ideal body weight Renal and hepatic function tests and a full haematological screen 
including, serum ferritin were performed. Subjects were excluded if they had any 
current, or previous history of peptic ulceration, any allergy, or adverse reaction to 
aspirin or NAN SAID s.
3.2.3 METHODS
After an overnight fast, the volunteers received 1 piroxicam 20mg capsule 
(Feldene® Pfizer U.K.). Blood samples (5ml) were obtained for six days according to 
the sampling schedule shown in Figure 3.1. The content (Table 3.2) and timing of food 
administration was standardised with volunteers requested not to eat or drink outwith 
the allotted times and to fast after 10 p.m. each night.
Plasma piroxicam concentrations were measured by the HPLC method detailed in 
Chapter 2.
3.2.4. RESULTS
Figures 3.2 and 3.3 show the individual plasma piroxicam concentrations 
obtained during the interval 0-14 hours with Figure 3.4 showing the mean of all six. 
Figures 3.5 and 3.6 show the individual results obtained during the interval 14-120 
hours with Figure 3.7 showing the mean results. The time of food administration has 
been annotated. It appears that perturbations do occur, and that they correspond to food 
consumption. In most instances a greater effect is observed following lunch rather than 
the evening meal which may be a consequence of the different meals have different 
nutritional constituents (Table 3.2).
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TABLE 3*1
VOLUNTEER DEMOGRAPHI C DETAI LS
Y Q L U N T E E E  MZE
( y e a r s )
WE I GHT
(kg)
a l b u m i n
(g/i)
M 2 9 7 2 . 1 4 5
M 2 3 7 6 . 2 4 6
M 20 7 3 . 9 49
M 3 5 7 7 . 1 43
M 2 5 7 2 . 6 52
M 2 6 7 9 . 8 5 1
MEAN 2 6 7 5 . 3
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FOOD CONSTITUENTS
W_ATLR P ROTEIN £ A I  C A R B O H Y D R A T E  F I B R E  C A L O R I E S
(g) (g) (g) (g) (g) ( K c a i )
L u n c h  6 6 6  1 8 3 6  7 4  7 6 7 8
Di n n e r  4 6 7  6 . 5  4 2 0  1 1 4 5
S u p p e r  1 1 5  3 1 1 2  1 8 5
98
PL
A
SM
A
 
PI
R
O
X
IC
A
M
 
C
O
N
C
E
N
T
R
A
T
IO
N
 
(m
g/
L
)
FIGURE 3.2 : PLASMA PIROXICAM CONCENTRATIONS (SUBJECTS 1 - 3) 0 -14  HOURS
N o. 1
2
1 -
N o. 2
NO. 3
1 -
T"
10
~T~
12
~T"
13
—I 
14
TIME (HOURS)
L = LUNCH
D = DINNER
PL
A
SM
A
 
PI
R
O
X
IC
A
M
 
C
O
N
C
E
N
T
R
A
T
IO
N
 
(m
g/
L
)
FIGURE 3.3 : PLASMA PIROXICAM CONCENTRATIONS (SUBJECTS 4 - 6) 0 -1 4  HOURS
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FIGURE 3.4: MEAN ± S.D. OF PLASMA PIROXICAM CONCENTRATIONS
IN ALL SUBJECTS FROM 0 -14 HOURS
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FIGURE 3.5 : PLASMA PIROXICAM CONCENTRATIONS (SUBJECTS 1 - 3) 14 -1 2 0  HOURS
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FIGURE 3.6 : PLASMA PIROXICAM CONCENTRATIONS (SUBJECTS 4 - 6) 14 -1 2 0  HOURS
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3.2.5 DISCUSSION
The results of this study are consistent with previous observations which 
highlighted perturbations within the first 24 hours of piroxicam administration. 
Extensive sampling was continued beyond this interval and showed the presence of 
perturbations throughout the whole elimination phase of this drug. The perturbations, 
however, showed a sharp decrease followed by a slower return and the term "multiple 
peaks" is, therefore, inappropriate. The timing and content of food was controlled, and 
this, together with an extensive sampling schedule, made this study design unique in 
relation to all previous published work with this drug. The lack of secondary peaks 
after food consumption, therefore, adds little support to the view that this drug enters 
the bile and undergoes enterohepatic circulation to a significant degree, although 
unequivocal statements cannot be made until direct quantitation of biliary piroxicam 
concentrations are made. It is more likely that some physiological event brought about 
by the consumption of food (or some constituent of food) causes an alteration in the 
disposition of  piroxicam.
Although this work has characterised the appearance of these perturbations, no 
information is available regarding the underlying mechanism of this phenomenon, 
except that the perturbations accompany certain meals. Without prior information as to 
the nature of the basic mechanism(s) it would be impossible to "model" these events. 
Consideration must therefore be made of likely events (which accompany food 
consumption) that could mimic the results obtained. These events may include biliary 
recycling, protein binding alterations, modified clearance, or volume of distribution 
alterations. These will be explored further in the following sections.
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3 3  TH E DISPOSITION OF PIROXICAM  AND ITS METABOLITES IN THE 
PLASMA, URINE, AND BILE IN MAN
3.3.1 INTRODUCTION
As was shown in Chapter 1, there is little direct experimental evidence of the 
extent, if any, of piroxicam’s (or its metabolite’s) clearance via the biliary route in man. 
The only reported study (in a single healthy volunteer) failed to detect either piroxicam 
or 5-hydroxypiroxicam in aspirated bile 15 hours after ingestion of a single 20mg dose 
of piroxicam (Verbeeck et al 1986). This lack of information (which extends to the 
biliary excretion of all drugs in man) is partly due to the relative inaccessibility of the 
biliary tract and the limitations of the methods used to collect bile samples. 
Furthermore, the development of suitable assay techniques with which to quantitate 
drug concentrations is hampered by the relatively high concentration (up to 1000 times 
plasma concentration) achieved in the bile by compounds such as bile salts and 
bilirubin. This may have prevented Verbeeck from attempting to quantify piroxicam 
glucuronides as enzymic degradation of all glucuronides present in the bile will result 
in massive interfering peaks unless a suitable assay technique is employed (see Chapter 
2).
The need, therefore, existed for a study to be performed, to determine the extent 
of the biliary excretion of piroxicam, 5-hydroxypiroxicam, and 5-hydroxypiroxicam 
glucuronide in man, after development of a suitable assay, with careful consideration 
given to the methods employed in collecting the samples.
Initially, T-tube sampling was not considered a suitable method for bile collection 
as the subject would probably have disturbed hepatic function, and altered piroxicam 
metabolism. Moreover, complete bile collection is impossible with a T-tube (Rollins & 
Klaassen 1979). For these reasons, it was intended to study subjects who had a naso- 
biliary drain inserted after endoscopic retrograde cholangeopancreotography (ERCP) 
for the relief of biliary obstruction. Such patients ( medical, not surgical) would not
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suffer post-operative trauma. Furthermore, liver function would quickly improve after 
insertion of the drain to relieve the obstruction. Also the technique would allow total 
collection of biliary output during the study period. Initially, recruitment of four 
subjects was considered feasible (during the time available) but logistical problems 
reduced this number to only one. We therefore reverted to subjects with T-tubes 
inserted after surgery, with the clear understanding that the quality of information 
obtained from such subjects would not be as conclusive. Unfortunately even these 
subjects proved to be extremely elusive. Insertion of T-tubes only occurred if 
investigation of the biliary tree was performed during the operation. Only two T-tubes 
were inserted during an 8 month period and both patients were unsuitable for inclusion 
in this study. It can therefore be concluded that studies investigating biliary excretion 
are not only hampered by the inherent inaccessibility and collection problems posed in 
man, but perhaps more significantly, the lack of suitable subjects in which these 
investigations can be readily performed. This is true of all drugs, not only piroxicam, 
and until such studies are performed much of the data regarding the biliary excretion of 
drugs in man will remain largely speculative (Rollins & Klaassen 1979).
33.2 SUBJECTS
As outlined above, the initial plan was to study four male or female patients with 
obstructive jaundice who required naso-biliary drains to be inserted at ERCP. Patients 
were excluded if:
a) they had a current or past medical history of peptic ulceration, confirmed by
endoscopic examination during insertion of the drain
b) there was a history of allergy or adverse reaction to aspirin or NANSAIDs
c) blood coagulation was abnormal
d) they were of child-bearing age and pregnant
e) any other significant past medical history was present.
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ENZYME VALUE NORMAL RANGE
Aik. Phos. 154 40-115IU/I
Gamma-G.T. 54 0-40 IU/I
Bilirubin 20 5-20 ^imol/L
AST 30 13-42 IU/I
ALT 59 11-55 IU/I
L.D. 219 1-300 IU/I
The patient eventually studied was a 72 year old female with common bile duct 
stones, a history of obstructive jaundice and pyrexia on admission. The study was 
performed 5 days after insertion of the drain at a time when her liver function tests were 
practically normal (see opposite).
33.3  M ETHODS
As a single dose of piroxicam, 20mg would produce levels of 5- 
hydroxypiroxicam in plasma approaching the assay detection limits, the patient 
received 30mg piroxicam daily for 2 days prior to the study so that detectable levels of 
metabolites might be obtained. After an overnight fast, 20mg piroxicam was given at 
time zero (Figure 3.8). Blood samples (5ml) were obtained at 0 ,1 ,2 , 3 ,4 , 5, 6 ,7 , 8 ,9 ,
10,12 and 24 hours. Total urine output was collected for the 24 hour period in addition 
to total bile output which was collected in aliquots from -2 to 0 ,0  to 2, 2 to 4, 4 to 6, 6 
to 8, 8 to 10,10 to 12, and 12 to 24 hours.
Plasma samples were assayed for both piroxicam and 5-hydroxypiroxicam. Urine 
and bile were assayed for piroxicam, 5-hydroxypiroxicam, and 5-hydroxypiroxicam 
glucuronide.
33.4 DATA ANALYSIS
Linear and logarithmic trapezoidal AUCs were calculated for both piroxicam and 
5-hydroxypiroxicam in the plasma, and for piroxicam and 5-hydroxypiroxicam (before 
and after glucuronidase incubation) in bile and urine.
33.5 RESULTS
Table 3.3 shows the concentrations achieved and the amount of piroxicam and 5- 
hydroxypiroxicam excreted in the bile for each time interval. Figure 3.9 illustrates this 
diagrammatically. It can be seen that very little piroxicam enters the bile (0.036mg) 
and biliary excretion therefore cannot be considered an important route of elimination 
for piroxicam in this patient. However, 5-hydroxypiroxicam is present in twice the 
piroxicam concentration (0.073mg), in marked contrast to the situation in plasma,
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FIGURE 3.9 : BILIARY CONCENTRATIONS OF
PIROXICAM AND 5-HYDROXYPIROXICAM
■  PIROXICAM
□  5-HYDROXYPIROXICAM
□  TOTAL 5-HYDROXYPIROXICAM
2-,
2-4- 2-0 0-2 4-6 6-8 8-10 10-12 12-24
TIME (HOURS)
where piroxicam concentrations are approximately 10 times the 5-hydroxypiroxicam 
concentrations. Furthermore, it would appear from this subject that 5- 
hydroxypiroxicam (as the glucuronide) was excreted into the bile in significant amounts 
(0.607mg). Piroxicam, in the form of glucuronides, was not detected in the bile.
Table 3.4 lists the AUCs obtained for piroxicam, 5-hydroxypiroxicam and the 
total 5-hydroxypiroxicam (after glucuronidase incubation) in the plasma, urine and bile 
in this subject. The extensive metabolism of piroxicam is shown by the very small 
levels of the parent drug in either the urine or the bile. When 5-hydroxypiroxicam is 
considered, it is present in both the urine and plasma to a similar extent, with bile only 
contributing 15% of the total AUC value. However, when glucuronidated metabolite is 
considered, it can be seen that, similar to the situation found in the urine, the majority 
of 5-hydroxypiroxicam is glucuronidated. In the urine, approximately 20% of the total 
metabolite is unconjugated. In the bile this only accounts for 11%, indicating that the 
bile must be considered as a significant route of elimination for the metabolite in its 
conjugated form.
33.6 DISCUSSION
The Verbeeck study discussed earlier (Verbeeck et al 1986) failed to detect 
either parent or metabolite in the bile, possibly because only 20mg of piroxicam were 
given to the subject. Glucuronides were not measured in the bile.
In the patient described above, piroxicam, as parent drug, did not enter the bile to 
any significant extent, confirming that this drug undergoes extensive metabolism 
(Chapter 1). However, the glucuronidated metabolite was present in large quantities, 
and it is known that glucuronidated drugs present in the bile are likely to be subjected 
to enterohepatic circulation (Rollins & Klaassen 1979). The potential, therefore, exists 
for the metabolite, and not the parent drug, to undergo enterohepatic circulation. This 
will, however, have little consequence because the metabolite has only a fraction of the 
parent drugs anti-inflammatory activity (Lombardino 1981). Only if reverse
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TABLE 3.4
PIROXICAM
P l a s m a
Ur i n e
Bi l e
TOTAL
AND. 5-HYPROXYPIROXICAM AUC's IN PLASMA. URINE AND BILE
A U C 0 t (mg/L/h)
PI ROXI CAM 5- HYDROXY 5 - HY DR OX Y
El.RgXl.QAM PI ROXI CAM
(J.Q1AL)
1 1 3 . 7 6  1 2 . 9 7
1 . 3 9  1 6 . 5 6  8 1 . 3 6
2 .5 2  4 .7 7  4 2 .2 8
1 1 7 . 6 7  3 4 . 3 0  1 2 3 . 6 4
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metabolism of the metabolite occurs (to reform parent drug) could this become important 
It must be stressed that this study has shown the extent to which parent drug and 
metabolite enter the bile. However, as a result of collecting the total biliary output 
during the study period, any enterohepatic circulation was interrupted and no comment 
can be made about the eventual fate of the metabolite. It does appear, however, that the 
perturbations found in piroxicam plasma concentration/time curves are not a 
consequence of enterohepatic circulation. Other mechanisms, therefore must be sought.
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3.4 FOOD CONSUMPTION AND PLASMA PROTEIN BINDING 
ALTERATION
3.4.1 INTRODUCTION
As discussed in Chapter 1, more that 99% of piroxicam in the plasma is bound to 
albumin. Any alteration in the unbound fraction, therefore, may have important 
implications for the disposition of this drug. It is the unbound fraction that is free to 
distribute into the extracellular space, which contains 60% of total body albumin 
(Rowland & Tozer 1989) and it is the unbound fraction of piroxicam that is available 
for hepatic metabolism. Any alteration in the plasma protein binding of this drug (as a 
result of food consumption) should therefore be investigated, bearing in mind that there 
may be a number of confounding factors. For example, the binding characteristics of 
albumin may change with age. Plasma albumin concentration decreases with 
increasing age (Veering et al 1990) and patients with rheumatoid arthritis tend to have 
decreased plasma albumin concentrations (Wanwimolruk et al 1983). Examination of 
food related events must therefore include patients, across a wide age range.
3.4.2 SUBJECTS
Two healthy volunteers who took part in the original single dose study were 
available to return for this investigation (no.’s 4 and 6). Also, two rheumatoid arthritis 
patients who took part in the steady state interaction study to be described in Chapter 5 
(no.’s 13 and 14) agreed to participate in this study. Table 3.5 lists their demographic 
details. In the steady state study, the consumption of a standard lunch resulted in a 
similar perturbation of plasma piroxicam (and 5-hydroxypiroxicam) concentrations to 
that observed in the single dose volunteer study.
3.4.3. M ETHODS
The methods used differed between patients and volunteers. As the volunteers 
only received single doses of piroxicam, detection of unbound plasma concentrations 
was impossible as a result of the levels obtained being below the assay’s limit of
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IABUL_-2*5
PROTEIN. BINDING STUDY SUBJECT DEMOGRAPHIC DETAILS
SUBJECT M F  AGE
( Y e a r s )
V o l u n t e e r  N O . 4 M 3 5
V o l u n t e e r  N O . 6 M 2 6
Pat i e n t  N O . 1 3  F 7 1
Pa t i e n t  N O . 1 4  F 5 7
A L B U M I N
(g'i)
4 3
51
3 8
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detection. If the subject was at steady state, however, detection of unbound 
concentration is possible. In order to avoid the volunteers taking large amounts of 
piroxicam to achieve steady state concentrations each was given the standard lunch, as 
before, and the samples obtained were subsequently spiked prior to analysis. The 
volunteers therefore did not receive any piroxicam.
Venous blood samples (5ml) were obtained in each volunteer at the following 
times after consumption of the standard lunch (Table 3.2) -1 /2 ,0 ,1 /4 ,1 /2 , 3 /4 ,1 ,1  1/4, 
1 1/2,1 3 /4 ,2 ,2  1/2, 3, 3 1/2, and 4 hours and frozen until analysis. On the day of 
analysis, 0.9ml plasma was spiked with 0.1ml piroxicam standard solution (O.lmg/ml) 
which was equivalent to a final plasma concentration in each aliquot of 11.11 mg/1. The 
spiked samples were mixed thoroughly and centrifuged before determination of 
unbound concentration by ultrafiltration, as described in Chapter 2.
In the patients, who were already at steady state, spiking was unnecessary. 
Furthermore any alterations in the binding of the metabolite, 5-hydroxypiroxicam, 
could be investigated in these subjects. As before, patients were fasted before receiving 
the standard lunch. Venous blood samples (5ml) were obtained at -1 ,0 ,1 /4 ,1 /2 , 3/4,1, 
1 1/2, 2 ,2  1/2, 3 and 4 hours with 1ml plasma samples being subjected to ultrafiltration 
as described earlier.
Plasma piroxicam and 5-hydroxypiroxicam concentrations were determined by 
HPLC as described in Chapter 2.
3.4.4 DATA ANALYSIS
In the patients, the unbound concentration was divided by the total concentration 
to obtain the percentage unbound concentration of piroxicam and 5-hydroxypiroxicam 
for the interval studied. In the volunteers, only the unbound piroxicam concentration 
was reported.
3.4.5 RESULTS
Figure 3.10 shows the post-prandial increase in unbound piroxicam concentration
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obtained in the volunteers. Table 3.6 lists the results. There are some missing values as 
a result of inadequate collection of ultrafiltrate (less that 0.25ml). In both volunteers 
there was an increased unbound piroxicam concentration to approximately 260% 
within 1 to 2 hours which then declined to baseline value by about 4 hours. Figure 3.11 
shows the results obtained in the patients and Tables 3.7 and 3.8 list the data. It can be 
seen that the changes in the unbound concentration of piroxicam were similar in extent 
to those obtained in the volunteers, however, they did not appear to return to baseline 
values within the timescale studied. It is also evident that there is an increased unbound 
concentration of 5-hydroxypiroxicam which also does not return to baseline values 
within the 4 hour interval studied. This may reflect an age difference in the binding 
characteristics of NANSAIDs to albumin (or a result of the different methodologies 
employed in the derivation of the unbound concentrations).
When the patients are considered, it can be seen that not only do the unbound 
concentrations of both piroxicam and 5-hydroxypiroxicam rise, but their total plasma 
concentration falls. Therefore, when the percentage unbound is calculated, there is a 
relatively greater increase (between 300 and 400%) obtained in comparison to the 
unbound concentration alone. This was not a unique result. Figure 3.12 shows the 
results obtained in the interaction study (Chapter 5) where subjects received the 
standard lunch on three separate occasions. Although the concentrations shown are 
total plasma values, it can be seen that they are in very close agreement with the results 
presented here.
3.4.6 DISCUSSION
The consumption of the standard lunch in all subjects caused an alteration of 
unbound piroxicam in this study, indicating that a displacement of drug from its 
binding sites occurs. This drug is bound only to albumin, and the differences in plasma 
albumin concentrations (patients 38, 39g/l; volunteers 43, 51g/l) may have a role in 
both the extent and the duration of the displacement shown. In both the single dose
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TABLE 3.6
VOLUNTEER PIROXICAM UNBOUND CONCENTRATIONS
Unbound Pi roxi cam Conc ent rat i ons  fmq/L)
TIME NQ. 4 NQu-6
( h)
-1 / 2 0 . 0 6 7  0 . 0 6 8
0 0 . 0 6 8  0 . 0 6 7
1 / 4  0 . 0 8 2  0 . 0 8 0
1 / 2  0 . 0 8 5
3 / 4  0 . 0 8 2  0 . 0 9 5
1 0 . 0 9 2  0 . 1 0 6
1 1 / 4 0 . 1 0 3
1 3 /4 0 . 1 0 8  0 . 0 9 2
2 - 0 . 0 8 4
2 1 / 2  0 . 1 0 1  0 . 0 9 0
3 0 . 0 9 4  0 . 0 8 2
4 - 0 . 0 6 6
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TABLE 3.7
PATIENT N 0 . 1 3  BOUND AND UNBOUND PIROXICAM AND  
5 - HYDROXY PIROXICAM C ON CE NT RAT I ONS
TIME PIROXICAM ( m o ' U  5 - HYDROXYPI ROXI CAM
( h )  ( T o t a l )  ( F r e e )
0 1 4 . 8 5  0 . 1  1
1 / 2 1 6 . 5 4  0 . 1  1
1 1 / 2 1 2 . 1 4  0 . 1 3
2 1 2 . 0 8  0 . 2 2
2 1 / 2 1 2 . 1 6  0 . 2 0
3 1 2 . 9 3  0 . 1  8
4 1 2 . 8 3  0 . 2 0
( % )  ( T o t a l )  ( F r e e )
0 . 7 4  1 . 6 1  0 . 1 6
0 . 6 6  1 . 8 4  0 . 1 9
1 . 0 7  1 . 6 0  0 . 1 9
1 . 8 2  1 . 5 8  0 . 1 9
1 . 6 4  1 . 4 8  0 . 1 9
1 . 3 9  1 . 4 8  0 . 2 3
1 . 5 6  1 . 4 8  0 . 2 3
Im a l)
( % )
9 . 9 3  
1 0 . 3 3  
1 1 . 8 8  
1 2 . 0 2  
1 2 . 8 4
1 5 . 5 4
1 5 . 5 4
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TABLE 3.8
PATIENT NQ, 14 BOUND AND UNBOUND PIROXICAM 
ANJ2 5.-.HYDRPXYPIRQXICAM CONCENTRATIONS
T I M E  P I R OX I C A M ( m a ' L )  5 - H Y D R O X Y P I R O X I C A M
( h )  ( T o t a l )  ( F r e e )
- 1 9 . 1  8 0 . 0 4 3
0 8 . 9 5  0 . 0 4 9
1 / 4  8 . 9 9  0 . 0 5 2
1 / 2 8 . 8 5  0 . 0 6 6
I 7 . 1 9  0 . 0 8 6
I I /  2  7 . 3 1  0 . 1 0 5
3 7 . 6 6  0 . 1 3 4
4 7 . 4 6  0 . 1 5 3
( % )  ( T o t a l )  ( F r e e )
0 . 4 7  1 . 2 3  0 . 0 4 4
0 . 5 5  1 . 2 6  0 . 0 4 7
0 . 5 8  1 . 3 5  0 . 0 3 5
0 . 7 5  1 . 3 5  0 . 0 4 1
1 . 1 9  1 . 1  3 0 . 0 2 6
1 . 4 4  1 . 1 5  0 . 0 5 4
1 . 7 5  1 . 1 2  0 . 0 7 8
2 . 0 5  1 . 1 9  0 . 1  0 8  .
Lmfl'L)
( % )
3 . 5 8  
3 . 7 3
2 . 5 9  
3 . 0 4  
2 . 3 0  
4 . 6 9  
6 . 9 6  
9 . 0 8
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3.12 TOTAL PIROXICAM AND 5-HYDROXYPIROXICAM IN 
PATIENTS ON FOUR OCCASIONS
o
□
PIROXICAM/
ONLY
PIROXICAM/
CIMETIDINE
PIROXICAM/
NIZATIDINE
PIROXICAM 
TOTAL/FREE STUDY
No. 13
No. 14
PIROXICAM
5 - HYDROXY PIROXICAM
No. 13
°  No.  14
T---------1---------1---------1---------1---------1-------- 1-------- 1
3 4 5 6 7 8 9  10
TIME (HOURS)
volunteer study and the steady state interaction study, the perturbations were associated 
with the consumption of the standard lunch, but not the standard evening meal. The 
phenomenon may therefore depend critically on the constituents of a meal. The fat 
content may be important Fats are hydrolysed to fatty acids (2-monoglycerides and 
glycerol) which are absorbed only from the small intestine once micelles are formed 
with bile. These micelles are then carried across the epithelial cells by pinocytosis, the 
bile salts are reabsorbed via another active transport mechanism. The long chain fatty 
acids and the 2- monoglycerides are resynthesised to triglycerides and glycerol 
phosphatides in the epithelial cells of the intestine. Minute globules of fat incorporating 
cholesterol and phospholipids are coated with protein forming chylomicrons of 0.5pm 
diameter. These are then transferred into lymph from where they enter the systemic 
circulation via the thoracic duct. Their half-life is approximately 15 minutes, and they 
remain in the blood for a few hours after consumption of a fat containing meal. Once 
in the blood, they can either be stored by tissues or used immediately, after hydrolysis 
to triglycerides by the enzyme lipoprotein lipase which is produced in the endothelial 
cells of capillaries. This is a rapid process. If less than 30g total fat is ingested, no 
alteration in plasma lipids and related substances will be observed. In the above study, 
only the standard lunch had a fat content above 30g, and after consumption of such an 
amount, it would be expected that total serum fatty acid levels would reach a maximum 
2-4 hours after the meal. Shorter chain fatty acids, however, are not absorbed in this 
manner. They are more hydrophilic than the longer chain molecules, and absorption is 
possible from the stomach. They would appear in the portal circulation much more 
quickly than the fat that is absorbed by the above mechanisms, and the possibility that 
these short chain fatty acids could result in displacement of drugs from plasma albumin 
has to be considered.
It has been shown that fatty acids bind to plasma albumin via 2 high affinity 
binding sites located in the I s* domain, one for carbon chains of less than 10 and
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another for carbon chains greater than 10 (Kragh-Hansen 1981). The NANSAIDs 
binding sites however, are located in the 6 ^  domain, making direct competition for 
binding sites unlikely. However, increased fatty acid binding can result in 
conformational changes in the binding sites of other domains together with a physical 
masking of other binding sites due to the fatty acids’ long carbon chain preventing 
receptor-ligand complexes forming (Kragh-Hansen 1981).
The possibility that fatty acids could disrupt piroxicam binding to albumin was 
examined by Matsuyuma et al (1987). In this in vitro study, human serum albumin 
binding to various ligands was investigated using equilibrium dialysis and significant 
alterations of piroxicam binding was shown as a result of increased fatty acid content of 
human serum albumin. It appears likely that the differential effects of the meals could 
be due to the different nutritional composition of the meals, with displacement brought 
about as a result of the higher fat content of the standard lunch.
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3.5 FOOD CONSUM PTION AND ALTERATIONS IN PIROXICAM  
CLEARANCE AND VOLUME O F DISTRIBUTION
3.5.1 CLEARANCE ALTERATIONS : INTRODUCTION
Piroxicam is a low extraction drug, i.e., only unbound drug is available for 
metabolism. In the protein binding study, there was up to a 400% increase shown in 
the percentage of unbound drug in the plasma. This implies that more drug is available 
to be cleared and the consequences of this should be considered further. It is clear, 
however, that any alterations in clearance as a result of food induced displacement will 
be transient. The prediction of the overall effects on the clearance of piroxicam was 
estimated by means of a simulation study.
3.5.2 CLEARANCE ALTERATIONS: SIMULATION STUDY METHODS
Piroxicam exhibits first order absorption and elimination characteristics in man, 
and one compartment models have been adequately fitted to plasma concentration/time 
data (Chapter 1, Chapter 4). A simulation programme was written (A.W.Kelman, a 
copy of which appears in the Appendix) that allowed a step-up in clearance to be 
introduced at any time during the elimination of a drug with the above pharmacokinetic 
characteristics. The new clearance value then declined exponentially to its original 
value at a pre-selected rate. The programme required values for the following 
parameters: clearance, a value by which clearance is altered (AC1), a rate constant for 
the recovery of clearance values, a volume of distribution, an absorption rate constant, 
an initial plasma concentration, a dose, and the time after the dose when the clearance 
was altered. These parameters were calculated or estimated for the four subjects who 
took part in the protein binding study, and Table 3.9 lists the individual parameters for 
each subject. For the volunteers, parameter values were obtained after fitting a one 
compartment, first order absorption, first order elimination model to the individual 
subject’s plasma concentration/time data (Chapter 4). Mean values of ka and V 
(corrected for weight) were used to estimate the patient parameters. This was
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considered justified as little or no differences in piroxicam pharmacokinetic parameters 
have been shown between patients and volunteers in numerous pharmacokinetic studies 
(Chapter 1). Patient clearance values (Cl/F) were estimated from individual trapezoidal 
AUC assessments i.e. D /A U C ^ (Chapter 5).
Clearance values in each subject were altered four hours after the dose had been 
introduced. In each subject, clearance was increased by 100, 200, 300, and 400% to try 
to match the results obtained in the protein binding study. Rates at which initial 
clearance values were resumed were set at 0.1,0.5, 1.0, and 2.0 h'* to cover the range 
of values obtained from each individual.
3.5.3 CLEARANCE ALTERATIONS: SIMULATION STUDY RESULTS
Figures 3.13 to 3.19 show the results obtained in this study. In order to allow a 
comparison between actual and simulated results, the actual decline in plasma 
piroxicam concentrations (solid line) is superimposed on the upper graph. The dotted 
line represents the simulated fall in plasma piroxicam concentration assuming there is 
no alteration in clearance. Also shown on this upper graph is the effect on plasma 
piroxicam concentrations of increasing the initial clearance value by 100-400%, and 
then allowing recovery at the various rates detailed in the Figure title. The lower graph 
illustrates the extent of the clearance alteration and its return to initial values.
When patient no.13 is considered (Figures 3.13 to 3.16) at high recovery rates (1, 
2h’ l) there is a negligible change in the simulated plasma concentrations as a result of 
small alterations in clearance. It is also evident that the profile is flat, a consequence of 
relatively low clearance values. From the actual profile, it can be seen that there is a 
rapid decline in plasma concentrations, followed by a slower increase. This rapid 
decline does not appear to be a result of a change in clearance as the simulated profiles 
show greatest effect at later time points. Even with the slow rates of recovery, the 
massive (400%) clearance changes can only account for a decrease in plasma 
concentration of about lmg/1 whereas the actual levels had decreased by more than
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FIGURE 3.13 EFFECT OF CHANGING CLEARANCE BY 100 - 400 %
AT A RATE OF RECOVERY OF 2.0h 1IN PATIENT NO.13
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FIGURE 3.14 EFFECT OF CHANGING CLEARANCE BY 100 - 400 %
AT A RATE OF RECOVERY OF 1.0h 1IN PATIENT NO.13
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FIGURE 3.15 EFFECT OF CHANGING CLEARANCE BY 100 - 400 %
AT A RATE OF RECOVERY OF 0.5h 1IN PATIENT NO.13
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FIGURE 3.16 EFFECT OF CHANGING CLEARANCE BY 100 - 400 %
AT A RATE OF RECOVERY OF 0.1 h 11N PATIENT NO.13
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FIGURE 3.17 EFFECT OF CHANGING CLEARANCE BY 100 - 400 %
AT A RATE OF RECOVERY OF 0.1 h 11N PATIENT NO.14
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FIGURE 3.18 EFFECT OF CHANGING CLEARANCE BY 100 - 400 %
AT A RATE OF RECOVERY OF 0.1 h 11N VOLUNTEER
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FIGURE 3.19
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twice this amount by four hours. When patient no. 14 was considered, similar patterns 
were found (Figure 3.17) with the initial decline unlikely to be accounted for by an 
alteration in clearance, although it may contribute to the later changes.
Figures 3.18 and 3.19 show the results in each volunteer at the slowest recovery 
rate. It appears that increasing the clearance in these subjects has a greater effect on the 
plasma piroxicam profile than it did in patients. Once again, however, alterations in 
clearance appear to be poor predictors of the initial rapid decline in actual plasma 
concentrations. However, unlike the patients, the decline and rise in actual 
concentrations was virtually symmetrical implying that clearance alterations were likely 
to have even less of an impact than that seen in patients. The patients certainly had 
lower initial clearance values compared to the volunteers, and they also had lower 
plasma albumin concentrations, as already discussed. These factors may have 
contributed to the slower "rise" in actual plasma concentrations.
From the simulations performed, it would appear that in all instances, even a 
massive increase in clearance (400%) and a slow rate or recovery (O.lh"*) would be 
inadequate to explain the actual results in both patients and volunteers. Consideration 
should therefore be made of alterations in volume of distribution as a result of food 
consumption.
3.5.4 VOLUM E O F DISTRIBUTION ALTERATIONS:INTRODUCTION
Piroxicam has a small volume of distribution (approximately 0.2L/kg) and 
binding to albumin can occur both in the plasma (40% total body albumin) and in the 
extracellular space (60% total body albumin). As a consequence, any alteration in 
binding to plasma proteins, as shown earlier, will be reflected throughout the whole of 
the extracellular space and not only in the intravascular site.
A model is therefore required to predict the consequences of changes in plasma 
protein binding on both the apparent volume of distribution and the overall 
pharmacokinetics of piroxicam.
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3 3 3  VOLUME OF DISTRIBUTION ALTERATIONS: MODEL 
CHARACTERISTICS
Figure 3.20 shows the model. A more complete description of its application can 
be found in Rowland & Tozer (1989), Chapter 25. The amount of drug in plasma is the 
product of the plasma volume and the plasma drug concentration. Using this model it 
is possible to predict the alteration in total volume of distribution as a result of 
increasing the fraction unbound (Figure 3.21). It can be seen that by increasing the 
fraction unbound even up to 400% of its original value, little or no changes occur in the 
total volume of distribution of a drug with a normal unbound fraction of 0.01. Patient 
no. 13 had a normal unbound fraction of 0.007, patient no. 14,0.005, and volunteers 4 
and 6 both had an unbound fraction of 0.006. It can therefore be anticipated from this 
model that despite an increase in unbound fraction of up to 400%, no change in total 
volume of distribution would occur. This is in agreement with Lin et al (1987).
With the model, the volumes of the intravascular, extravascular, and intracellular 
spaces were fixed at 3,12, and 27 litres respectively, a reasonable approximation as all 
subjects were about 70kg in weight. However, the model did not account for 
alterations in these volumes as a result of food consumption.
The volumes of these compartments are brought about by an equilibrium between 
opposing forces. Pressure in the capillaries forces fluid and its dissolved substances 
through the capillary pores into the extravascular space. Osmotic pressure exerted by 
plasma proteins results in fluid movement from the extravascular space into the 
intravascular space which will prevent the continued loss of fluid volume from the 
blood into the extravascular space. This simplified situation is complicated by the 
influence of the lymphatic system which returns to the intravascular space the small 
amounts of fluid and protein that continually leak into the extravascular space.
The consumption of liquid causes an increase in the intravascular volume as it is 
rapidly absorbed from the stomach. This results in the intravascular space becoming
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hypotonic relative to the extravascular space. Osmosis begins immediately at all 
membranes with large amounts of water moving from one space to another with the 
result that, within minutes, the extra volume is distributed evenly between the intra- and 
extravascular spaces. It would therefore appear that the fluid content of the meals 
would only result in an transient alteration in plasma volume.
Utilisable carbohydrates in the diet are hydrolysed to mono- or disaccharides.
The monosaccharides are absorbed by active transport mechanisms whereas the 
disaccharides are absorbed passively into the portal circulation. The rapid reformation 
of isotonic conditions described in the situation of fluid consumption would also 
quickly reverse the hypertonicity induced by the increase in carbohydrate concentration 
after absorption from the gastrointestinal tract. As a consequence, the influence of 
carbohydrate on the overall plasma volume would, like the other food constituents that 
disrupt isotonicity, only result in a transient alteration of plasma volume.
Proteins are enzymatically hydrolysed to amino acids and absorbed (98% total 
intake) by active transport if they are the L-enantiomer, and passive transport if they are 
the D-enantiomer. Proteins are the only dissolved substances of the plasma and the 
extravascular fluid which do not readily diffuse through the capillary membrane. 
Furthermore, when small quantities of protein do diffuse through the membrane into the 
extravascular fluid they are soon transferred to the lymph. The net effect is that the 
total protein concentration of plasma averages about three times that of the 
extravascular fluid (73g/l versus 20-30g/l). This inequality in concentration gives rise 
to the osmotic pressure described earlier. The magnitude of this effect is not linear with 
protein concentration, as an additional force exists, the so called Donnan effect. This is 
a result of proteins possessing a negative charge which requires small cations (Na+) to 
flux from the extravascular space in order to surround the protein molecule. This 
increases the number of osmotically active substances with the result that the osmotic 
effect is increased by another 50%. As already stated, the consequences of this would
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only be felt in the intravascular space as these charged molecules do not readily pass 
through the capillary membrane.
It was therefore considered appropriate to perform a simulation study where 
alterations were made to the total volume of distribution after food consumption. 
Theoretically it is possible that protein absorption from a meal could cause an increase 
in the total intra- and extravascular volume, with the increased osmotic effect of 
proteins (or amino acids) in the intravascular space causing a flux of fluid from the 
extravascular space which in turn would cause a flux from the lymphatic system.
3.5.6 VOLUME OF DISTRIBUTION ALTERATIONS: SIMULATION STUDY 
METHODS
As with the previous simulation study it was assumed that piroxicam exhibited 
First order absorption and elimination characteristics. The effect of altering the volume 
from its baseline value by pre-set amounts (5,15, or 25%) was investigated. Unlike the 
situation with the simulated clearance alterations both the rate of change and the rate of 
recovery of the individual’s initial volume of distribution were varied The programme 
(a copy of which appears in the Appendix) therefore required values for the following 
parameters: clearance, initial volume of distribution, a value by which volume of 
distribution was altered (AV), a rate constant by which this alteration occurred, a rate 
constant for the recovery of the original volume of distribution, an absorption rate 
constant, initial plasma concentration, dose, and the time after the dose when the 
volume was altered. Table 3.9 lists the pharmacokinetic parameters used in this 
simulation study.
Volume of distribution values were altered in each subject by 5,15, and 25% four 
hours after the dose had been introduced. Rates of alteration varied between 0.1 to 2h"* 
and rates of recovery ranged from 0.05 to lh '*  in order to include all the actual values 
obtained from each subject.
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3.5.7 VOLUME OF DISTRIBUTION ALTERATIONS: SIMULATION STUDY 
RESULTS
Figures 3.22, 3.23, 3.24 show the results obtained in patient no. 13 at various rates 
and extent of volume changes. As with the Figures illustrating clearance alterations, 
the actual plasma profiles (solid line) and the unchanged situation (dotted line) have 
been superimposed on all graphs. If one examines the upper graph of Figure 3.22 it can 
be seen that the rate of change of volume of distribution has been allowed to alter by
0.1h“* (triangles), 0.5h'* (dots), and 2.0h'* (squares) but the rate of recovery has been 
fixed in all instances at 0.05h"*. The extent of the volume change varied from 5, 15, to 
25%. The legend on the right hand side allows identification of the individual profile 
corresponding to a particular combination of rate of change and extent of change. The 
subsequent Figures, whilst using the same nomenclature and symbols, have different 
recovery rates. In the lower graphs the combination of recovery rate and extent of 
change on the initial volume of distribution value is illustrated. Once again the same 
nomenclature and symbols have been employed for consistency.
Unlike the situation found with the simulated clearance alterations, volume of 
distribution alterations, of the magnitude examined in this study, could explain the 
actual changes exhibited in the individual i.e. a rapid initial decline in plasma 
concentrations followed by a more sustained rise. However, large alterations in volume 
would be required i.e. 15, 25% and slow recovery rates (£0.25). Similar results were 
found with patient no. 14 (Figure 3.25) and it would therefore appear that in these two 
subjects volume changes alone could describe the plasma concentration alterations 
exhibited, providing that the volume of the intra- and extravascular spaces increased by 
greater than 15%.
Figures 3.26 and 3.27 show the results in each volunteer at the slowest recovery 
rate. Once again the initial rapid decline found in each subject was adequately
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FIGURE 3.22 EFFECT OF CHANGING TOTAL VOLUME OF
DISTRIBUTION BY 5 - 25 % AT A RATE OF 0.1 - 2h 1
WITH RECOVERY RATE OF 0.05h 11N PATIENT NO. 13
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FIGURE 3.23 EFFECT OF CHANGING TOTAL VOLUME OF
DISTRIBUTION BY 5 - 25 % AT A RATE OF 0.5 - 2h 1
WITH RECOVERY RATE OF 0.25h 1IN PATIENT NO. 13
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FIGURE 3.24 EFFECT OF CHANGING TOTAL VOLUME OF
DISTRIBUTION BY 5 - 25 % AT A RATE OF 2h 1
WITH RECOVERY RATE OF 1.01V11N PATIENT NO. 13
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FIGURE 3.25 EFFECT OF CHANGING TOTAL VOLUME OF
DISTRIBUTION BY 5 - 25 % AT A RATE OF 0.1 - 2h 1
WITH RECOVERY RATE O F0.05h ‘1IN PATIENT NO. 14
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FIGURE 3.26 EFFECT OF CHANGING TOTAL VOLUME OF
DISTRIBUTION BY 5 - 25 % AT A RATE OF 0.1 - 2h 1
WITH RECOVERY RATE OF 0.05h '1IN VOLUNTEER NO. 4
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FIGURE 3.27
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described by the model, but the plasma concentrations remained lower for longer in the 
simulated profiles than were actually found. This, once again, may be a consequence of 
the volunteers being younger and their homeostatic mechanisms being quicker to 
reform pre-prandial conditions.
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3.6 DISCUSSION
In this chapter it has been suggested that food consumption is implicated in the 
perturbations in plasma piroxicam concentration/time profiles found in both healthy 
volunteers and patients with rheumatoid arthritis. It has been suggested that a 
displacement from albumin binding sites occurs as a result of fatry acid binding to the 
albumin molecule. However, this may not be relevant due to the theoretical 
considerations developed above. Clearance altera dons m a y  contrib-te to these 
perrurocuons. C-t or-* it mere is a massive increase m c.earanoe, am  mis is an —r —iie*y
parallel decreases m 5 m;* drcv.piroxicam. concentrations Lrore-ased clearance of parent
any of me p a re n ts  srudied.
distnbuuon would be with this drug. Therefore only an aiterauon m the
plasma compartment volume could explain the results found. In the model, this volume 
was fixed at 3 Litres but the consumption of food and drink wo-ld res-It in a transient 
expansion of plasma volume during absorption Trus idea helps to explain the res-Its 
obtained and a simple "dilution" of the plasma volume after food consumption may be 
all that is involved.
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CHAPTER 4
STUDY DESIGN OPTIM ISATION AND THE JACKKNIFE TECHNIQUE
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4.1 INTRODUCTION TO CHAPTER 4
In this chapter the design characteristics of an interaction study (Chapter 5) 
examining the combination of H 2  receptor antagonists and piroxicam will be closely 
scrutinised As this study will rely on AUC assessments to reveal any changes in 
clearance and/or bioavailibility, as a result of the combination, consideration has to be 
made of the limitations of the methods commonly used to calculate AUC’s (i.e. the 
trapezoidal rule). Although errors in trapezoidal AUC determinations are not normally 
calculated it does not mean that they do not exist. This is important when considering a 
study’s power to detect pre-set endpoints.
One method to calculate the error in a trapezoidal AUC estimation is to use the 
Jackknife technique. The theory of this statistical technique is illustrated. Also shown 
are some examples its use in a variety of situations involving AUC assessments.
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4.2 JA CK K N IFE THEORY
This technique has been extensively reviewed by Efron & Gong (1983). It has 
been used in the determination of the errors associated with the estimation of model 
parameters, using a two compartment pharmacokinetic model for illustration (Nimmo et 
al 1981).
The essential steps, in the Jackknife technique, are as follows and are illustrated 
in Figure 4.1.
1. Assume a data set, e.g. concentration/time points, consists of n 
observations, x ,^ tj where i= l,...,n, and that a parameter, 0 , e.g. AUC, is 
to be estimated using these data. Using all data points the AUC is 
determined by the trapezoidal method to provide the best estimate for that 
area, 0 .
2. Starting from the first data point, each point is sequentially removed
o
and replaced. With each point removed, a value for © is estimated, 0^,
o
using (n -1) points, where i= l,...,n. Thus n estimates, 0 j, i= l,...,n, are 
obtained.
3. A "pseudoparameter", 0^, is obtained from the areas calculated in 
steps 1 and 2, using the following equation:
0-= n 0  -(n -1)0^
4. The average value of the n 0 j provides an estimate of 0  and the 
standard error of the n0- provides an estimate of the standard error 
associated with 0 . This error value is an estimate of the error associated
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with the full trapezoidal measurement Once calculated, the standard error 
can be normalised by expressing it as a percentage of the "best estimate" 
of area, 0 . This is known as the "% Jackknife error". If a number of 
simulated concentration/time curves are obtained then a "mean %
Jackknife error" value can be calculated. This will provide an estimate of 
the error in the AUC assessment
The difference between each pseudo-area value and the average parameter (e.g. 
AUC) value will indicate the importance of that data point to the overall parameter 
(e.g.AUC) estimation. This may be important in determining:
(i) "design points" in the study protocol i.e. points which have a critical influence 
on the overall parameter estimate
(ii) which points are outliers.
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4 3  CALCULATION OF PHARMACOKINETIC PARAMETERS
AUC’s can be calculated by both parametric and non-paramctric methods, the 
latter usually employing the trapezoidal rule (linear and logarithmic) the formulae of 
which are detailed in the Appendix.
This chapter examines the use of the Jackknife technique in both single dose and 
steady state simulated concentration/time profiles. Data from the single dose study 
described in Chapter 3 were used to provide a priori information. The steady-state 
simulations were performed using the pharmacokinetic parameter values obtained by 
fitting the appropriate pharmacokinetic model to the single dose data. This section 
describes the fitting of these pharmacokinetic models to the individual subjects’ plasma 
piroxicam/concentration time data.
43 .1  PATIENTS AND METHODS
The demographic details of the six healthy volunteers are given in Chapter 3.
43.2  DATA ANALYSIS
The 4 pharmacokinetic models shown in Figure 4.2 were fitted to each plasma 
piroxicam concentration/time data set. The choice of "best model" was based on 
examination of the General Linear Test and the Akaike Information Criterion 
(Yamaoka et al 1978) as shown in Table 4.1 (formulae for which are given in the 
appendix).
43.3  RESULTS
A one compartment model with first order absorption (including lag time) and 
first order elimination (model 3) was found to be the "best model" using the criteria 
outlined above (Table 4.1). A summary of the pharmacokinetic parameters relevant to 
this model appears in Table 4.2.
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FIGURE 4 . 2  : PHARMACOKINETIC M O DELS : 
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TABLE- 4 ,2
1MP1Y1BUAL. -MODEL PARAMETER ESTIMATIONS
SUBJECT PARAMETER _ ESTIMATE ± S.D.
m . (L) £ L Z E ( L h - i )  I _ L A Q  (h) Kfl. (h’ 1 )
1 9 . 1 1 1 0 . 2 9  0 . 2 3 0 1 0 . 0 1 0  0 . 4 1 3 1 0 . 0 5 2  3 0 . 2 1 2 2 . 4
1 8 . 9 5 1 0 . 5 6  0 . 1 8 9 1 0 . 0 1 6  0 . 4 6 4 1 0 . 0 5 6  2 . 4 0 1 0 . 6 1
1 6 . 4 9 1 0 . 4 2  0 . 1 7 1 1 0 . 0 1 1
1 5 . 1 9 1 0 . 0 4  0 . 1 4 3 1 0 . 0 0 1
0 . 6 3 2 1 0 . 0 9 3  0 . 8 4 1 0 . 1 4
0 . 4 2 2 1 0 . 0 0 4  4 5 . 5 1 4 . 4 6
1 7 . 7 9 1 0 . 3 1  0 . 2 1 7 1 0 . 0 1 0  0 . 4 5 8 1 0 . 0 2 1  9 . 1 8 1 3 . 7 4
1 8 . 3 0 1 0 . 4 9  0 . 2 4 5 1 0 . 0 1 6  0 . 3 8 0 1 0 . 0 6 2  3 . 2 9 1 0 . 9 9
MEAN 1 7 . 6 4 0 . 1  9 9 0 . 4 6 4 1 5 . 2 4
SUBJECT NO. 1 P a ra m e te r s  for l o w e s t  p la s m a  c o n ce n tr a t io n  t ime  curv e
SU BJECT NO. 4 P a r a m e te r s  for h i g h e s t  p l a s m a  c o n c e n tr a t io n  t im e  c ur v e
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4.4 TH E EFFECT OF VARYING THE NUMBER OF POINTS USED IN THE 
CALCULATION OF EXTRAPOLATED SINGLE DOSE AUC VALUES
Under normal circumstances, the number of data points used to calculate the 
slope of the terminal (log-linear) elimination phase of a concentration time curve is 
arbitrarily made. If the extrapolated AUC~ is made up only in small part by the AUC^ 
where, t, is the last time point, the potential for enror in the overall AUC estimation is 
great.
This study examines the effect of varying the number of data points in the 
terminal elimination phase used to calculate the slope and, therefore, the eventual 
extrapolated AUC value. The individual AUC’s obtained from the six volunteers in the 
single dose study described in Chapter 3 were used. A % Jackknife error value was 
obtained for the AUC^value and comparisons were made between this error value and 
the % Jackknife error value obtained when the AUC was extrapolated to infinity using 
3, 5, and 10 data points to define the slope of the terminal elimination portion of the 
individual concentration/time profiles. The results are shown in Table 4.3. Also 
shown, in parenthesis, is the regression coefficient obtained after linear regression 
analysis of the log concentration/time data was performed.
From the results obtained it can be seen that, as expected, reduction in the error 
associated with the extrapolated AUC estimation is made by increasing the number of 
data points used to defme the slope. Reduction of the % Jackknife error is also 
associated with an increased regression coefficient value. When the number of data 
points used to define the slope was increased from 3 to 5 dramatic improvements were 
seen in subjects 2, 3, and 4. In all subjects increasing the number of data points to 10 
resulted in % Jackknife error values approaching the values obtained during the interval 
AUCq which on average contained 73% of the area once extrapolation was performed.
The potential therefore exists for errors in AUC estimation to be introduced when 
extrapolated areas are calculated using few data points. This is a consequence of one or
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TABL E - 4 J
EFFECT OF INCREASING NUMBER OF DATA POINTS 
IN EXTRAPOLATION. .ON .AUC ERROR- ESTIMATION
% JACKKNIFE ERROR IN AUC ESTIMATION
S U B J E C T £Lz±_i
(3 points) (5 BQl n t ? ) UQ-PQintgj
1 . 4 4 . 0
( r = - 0 . 9 7 2 6 )
5 . 8
( r  = - 0 . 9 9 0 7 )
2 . 1
( r = - 0 . 9 9 3 4 )
3 . 5 3 0 . 7
( r = - 0 . 5 9 0 3 )
1 2 . 1
( r = - 0 . 8 3 6 3 )
4 . 5
( r = > 0 . 9 2 4 4 )
2 . 9 1 3 4 . 5
( r = - 0 . 7 5 5 9 )
3 0 . 5
( r = - 0 . 8 3 9 2 )
7 . 3
( r r . 0 . 9 4 6 1 )
3 . 3 1 0 2 . 1
( r s - 0 . 6 5 4 6 )
3 2 . 0
( r = - 0 . 7 4 3 9 )
7 . 2
( r s * 0 . 9 2 7 2 )
2 . 2 9 . 0
( r  = - 0 . 9 0 1 1 ’
7 . 5
( r  = - 0 . 9 4 5 6 )
3 . 1
( r r - 0 . 9 7 7 3 )
2 . 6 9 . 3
( r  = - 0 . 7 8 5 7 )
1 5 . 5
( r  = - 0 . 7 7 9 0 )
5 . 0
( r = - 0 . 9 3 3 4 )
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more biased data points having a relatively greater influence on the overall extrapolated 
AUC estimation. Furthermore, if this extrapolated area is only made up in small part by 
the AUCq the error in the AUC assessment will be increased.
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4.5 EXAMINATION OF THE "LO G  JACKKNIFE" VERSUS THE "LIN EA R  
JA C K K N IFE": A SIMULATION STUDY
The requirement to logarithmically transform the pseudoparameter in some 
instances has been described by Miller (1974). Using the pharmacokinetic parameters 
in Table 4.2, the two sets of parameters corresponding to the highest and lowest plasma 
concentration/time curves and the mean of the six individual parameter estimates were 
employed in a single dose simulation study. AUC’s were obtained over the range 0-t 
and 0-oo using 5,10, or 15 data points to calculate the extrapolated area, with the 
addition of either 5, 10, or 15% random error to the simulated plasma 
concentration/time data points. This was repeated ten times in each individual and a 
mean % Jackknife error value was obtained for both linear and logarithmic 
transformations of the pseudoparameter. In total 540 simulated profiles were obtained.
Table 4.4 shows the results obtained over the interval 0-t. It can be seen that the 
results obtained were consistent across the range from high to low parameter sets. The 
mean % Jackknife error increased arithmetically as the random error increased. 
However, the log transformation of the pseudoparameters conferred no advantage to the 
mean % Jackknife error value obtained over this interval.
Table 4.5 shows the results obtained in the extrapolated AUC using 5, 10, or 15 
data points. Once extrapolation occurs there is an increase in the mean % Jackknife 
error compared to the values obtained over the interval 0-t. In all instances, however, 
as the number of points used in the extrapolation is increased the mean % Jackknife 
error decreases. In most cases greater error is obtained when the high parameter set is 
used compared to the mean or the low parameter set. When many data points were 
used in the extrapolation, no difference was obtained between the mean % Jackknife 
errors after log transformation of the pseudoparameters. At low extrapolation numbers, 
however, smaller mean % Jackknife error values were obtained after log transformation 
of the pseudoparameters. The discrepancy in the results confirms Miller’s observation
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TABLE 4.4
O N E  S . D.  MEAN % J A CK K N I F E E R R O R  F O R  A U C „  * ESTIMATION
5 %  1 0 %  1 5 %
N O R M A L  L O £  N O R M A L  N O R M A L
A v e r a g e  ± 8 . 5 9  - 8 . 7 7  ± 1 6 . 8 4  - 1 6 . 2 5  ± 2 5 . 6 3
+ 9 . 2 3  + 2 0 . 0 4
H i g h  ± 8 . 1 5  - 7 . 8 2  ±1  6 . 3 6  - 1 7 . 6 4  ± 2 4 . 4 2
+ 8 . 1 6  + 2 0 . 4 3
L o w  ± 8 . 0 5  - 8 . 6 9  ± 1 7 . 7 9  - 1 6 . 1 3  ± 2 4 . 5 9
+ 9 . 3 2  + 1 7 . 8 4
L O G
• 2 3 . 3 6
♦ 2 8 . 9 1
• 2 5 . 3 5  
+ 3 3 . 3 4
• 2 3 . 5 8  
+ 3 1 . 1 0
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35
that the use of the log transformation of the pseudoparameters can reduce bias (Miller 
1974).
As smaller mean % Jackknife error values (with less than 10 data points used to 
calculate the slope of the terminal elimination portion) were obtained after log 
transformation of the pseudoparameters, the use of this transformation realistically 
applies to most situations where AUC’s are calculated.
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4.6 PROSPECTIVE POW ER CALCULATION
As described earlier, this study was initiated to investigate the theoretical 
inhibition of piroxicam metabolism as a result of H 2  receptor antagonist 
coadministration. As the results would depend largely on an AUC comparison, 
determination of the error in the AUC estimation has to be made in order to justify the 
eventual number of subjects included in the study. The straightforward geometric use 
of the trapezoidal rule (both linear and logarithmic) ignores the fact that the computed 
area will be subject to error. This is in contrast to pharmacokinetic model fitting using 
non-linear regression analysis, for example, where estimated errors in a particular 
parameter are studied closely. An assessment of the magnitude of this error is 
important in prospective power calculations as many interaction studies that rely on 
trapezoidal AUC assessment may fail to show any significant differences as a result of 
inadequate power to detect pre-set endpoints rather than the absence of an interaction 
per se.
4.6.1 M ETHODS AND RESULTS
Using the pharmacokinetic parameters in Table 4.2, the two sets of parameters 
which gave the highest and lowest plasma concentration profiles and the mean of the 
six individual parameter estimates were selected to provide the widest range of 
simulated profiles. Using these three sets of parameters, steady state simulations 
employing the proposed blood sampling schedule for the interaction study were 
generated as shown in Figure 4.3. 5, 10, or 15% error was introduced to mimic realistic 
experimental conditions as illustrated in Figure 4.4. Here, 15% random variability 
creates the erratic curve which defines the area subsequently processed by the Jackknife 
technique. This procedure was repeated 50 times for each of the three parameter sets at 
the three levels of added error. The total number of simulations performed was 
therefore 450.
On examination of Table 4.6 it can be seen that whatever value of error was
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TABLE 4.6
ESTIMATED, ERROR IN SIMULATED STEADY STATE 
AiiC DETERMINATIONS
ERQEiLE NUMBER QE MEAN ± SD % JACKKNIFE ERROR AT
DESCRIPTION SIMULATIONS EACH LEVEL OF ADDED ERROR
AT EACH LEVEL 
QE.—ERROR
High 5 0  1 . 8 6 ± 0 . 6 6  3 . 6 6 ± 1 . 7 3  5 . 5 2 ± 2 . 5 8
Mean  5 0  1 . 8 8 ± 0 . 8 8  3 . 5 1 1 1 . 6 4  5 . 0 8 ± 2 . 2 6
Low 5 0  1 . 7 5 ± 0 . 9 2  3 . 6 0 1 1 . 8 8  4 . 8 6 ± 2 . 1 4
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introduced, the mean % Jackknife error was uniform across the range of parameters. 
Furthermore as the level of random variability increased a corresponding increase in the 
mean % Jackknife error was obtained. It was considered appropriate to add 15% 
random variability as the average residual error obtained after the fitting procedure in 
the single dose pilot study was 14.6% (Table 4.7). With the addition of 15% random 
variability, a mean % Jackknife error of approximately 5% was obtained. This value, 
then, provides an estimate of the average error at steady state. It must be borne in 
mind, however, that as an interaction study usually examines the alteration in an AUC 
value due to the coadministration of another drug, the error in the ratio of the AUC’s 
must incorporate the uncertainty generated by both AUC determinations. This can be 
estimated as follows:
R = AUC 1 /AUC2  
(8 R/R ) 2  = (SA U C^A U Cj) 2  + (SA U CyA lK ^)'
= 2. (5AUC/AUC ) 2
therefore SR/R = ■J2. 8 AUC/AUC
and since 8 AUC/AUC = 5%
8 R/R = 7%
where:
R is the ratio of the two areas, AUCj:AUC 2  
8 R/R is the average error in the ratio of the two AUCs 
8 A U Cj/AUCi is the average error in the determination of AUCj 
8 AUC2 /AUC2  is the average error in the determination of AUC2
The value of 7% represents the minimum error that is ever attainable in the ratio
142
R
ES
ID
U
A
L 
ER
R
O
R
 
C
A
L
C
U
L
A
T
IO
N
<z>Q
CO
LU
CC
a?
CO
o <o o cm
<D co o o> r- © -H
T— r-~ CO (O T“
r - T“ r- t—
14
.6
1
LU
O<
cr
LU><
U)
LU
U J
cco
LUO
OO
LU
LU
CC
•n
co
n
co
m CO in ID CMT- co *r m e'­ OTT a> CO a> en o
CO CM m CO
o o O o o o
O
LU—>
CD
3(0
LLQ
V)o
ccOw
CO
143
of AUC determinations with 15% random (experimental) error. If all subjects were 
identical this minimum value of 7% could be used in a power calculation to determine 
the number of subjects required to detect a preset difference in AUCs (e.g. a difference of 
20% or more). More realistically, the 8R/R value should be increased to account for both 
inter and intra subject variability. Table 4.8 illustrates the effect on the study power by 
increasing the 8R/R values from 10 to 30%. The type I error value (a) has been set, for 
this instance, at 0.015 and not 0.05, the conventional level. This is to account for 
multiple comparisons being made between AUC’s obtained in the same subject on three 
separate occasions i.e. the Bonferoni correction was applied. Clearly, as the variability in 
the AUC increases, the power to detect a 20% difference in AUC’s decreases.
It was considered appropriate to propose that 15 subjects would be more than 
adequate to detect a 20% difference in AUC’s in the piroxicam interaction study. Using 
15 subjects in a paired design meant that even with a 23% 8R/R value the study would 
still have an 80% power to detect a 20% difference in AUC’s.
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TA B L E 4 .9
PROSPECTIVE POWER CALCULATION
T Y P E  I E R R O R  RATE (a )
T Y P E  II E R R O R  RATE (P)
D I F F E R E N C E  T O BE DETECTED 
VARIABILITY IN P A R A M E T E R  
P O W E R  O F  S TUD Y 
N U M B E R  O F  S U B J E C T S
Subjec ts  are paired and test was  two-tailed
0 . 0 1 5  0 . 0 1 5  0 . 0 1 5
0 . 0 0 0  0 . 0 9 6  0 . 4 7 7
2 0  2 0  2 0
1 0  2 0  3 0
1 . 0 0 0  0 . 9 0 4  0 . 5 2 3
15 15 15
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4.7 EFFECT OF INCREASING INTERVAL BETWEEN DATA POINTS
In the simulated steady state profile shown in Figure 4.3 there is a 10 hour gap 
between the last two data points. This interval, in many studies, can be even longer and 
the effect of altering this time interval on the error in the AUC assessment is considered 
in this section. Using the three sets of parameters listed before (high, mean, and low) 
steady state simulations were performed using the proposed sampling schedule (16 data 
points, interval 14-24 hours). The sampling schedule was altered: 15 data points, interval 
12-24 hours; 14 data points, interval 10-24 hours; and 13 data points, interval 9-24 hours. 
5,10, or 15% random error was introduced as before. 50 simulations were performed in 
each instance, which in total amounted to 1800 simulations performed.
Again there was uniformity across the range of parameters (Table 4.9). At the 
5% level of added error, little effect was found as a result of increasing the interval 
between the two data points. However, this was not the case when 10 or 15% random 
error was added to the simulations. This is a reflection of the very flat 
concentration/time profile shown by piroxicam, which, at steady state, shows little 
fluctuation over a 24 hour period.
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TABLE 4x8
E FF E C T  Q F INCREASING TIME INTERVAL BETW EEN PENULTIMATE AND LAST DATA POINTS 
ON AUCg* ESTIMATION ERROR
% E R R O R  INTRODUCED
NO. Q F  DATA POINTS 
(PE N U L TIM A T E  TIME POINT1) lfl I S
PA R A M E T E R
££I
1 6 (1  4 h ) 1.88±0.88 
1.86±0.66 
1 . 7 5 ± 0 . 9 2
3 . 5 1  ± 1 . 6 4  
3 . 6 6 ± 1 . 7 3  
3 . 6 0 ± 1 . 8 8
5 . 0 8 ± 2 . 2 6  
5 . 5 2 ± 2 . 5 8  
4 . 8 6 ± 2 . 1  4
( A v e r a g e )
( H i g h )
(L o w )
1 5( 1  2 h ) 2 . 1 2 ± 1 . 1 3  
1 . 9 7 ± 0 . 9 2  
2 .1  6 ± 1 . 3 2
3 . 5 8 ± 1 . 7 9  
3 . 7 2 ± 1  . 9 2  
3 . 8 3 ± 2 . 2 5
5 . 5 1  ± 2 . 8 5  
5 . 7 4 ± 3 . 6 6  
5 . 6 6 ± 2 . 9 4
( A v e r a g e )
( H i g h )
(L o w )
1 4(1  Oh) 2 . 2 6 ± 1 . 2 2  
1 . 9 7 1 1 . 1 5  
2 . 2 1 ± 1 . 3 0
3 . 8 2 ± 2 . 0 7
3 . 8 7 ± 2 . 3 5
3 . 9 2 ± 2 . 2 2
6 . 9 0 ± 3 . 5 8  
6 . 2 6 ± 3 . 3 8  
5 . 9 1  ± 3 . 7 9
( A v e r a g e )
( H i g h )
( L o w )
1 3 ( 9 h ) 1 . 8 8 1 1 . 3 6  
2 . 0 2 ± 1 . 4 8  
2 . 1  9± 1  . 4 4
4 . 8 6 ± 2 . 5 7
4 . 8 6 ± 3 . 3 8
5 . 0 6 ± 3 . 6 6
6 . 5 8 ± 4 . 4 7  
6 . 7 9 ± 4 . 1  4 
7 . 1  5 ± 3 . 6 9
( A v e r a g e )
( H i g h )
(L o w )
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4.8 DISCUSSION
This chapter has explored the relationship between the Jackknife technique and 
study design, with particular emphasis on AUC calculations. The AUC is a parameter 
that is easily calculated and is therefore very popular. Little regard, however, is paid to 
its limitations in relation to particular data sets because the confidence with which 
AUC’s are calculated is never stated. It is unjustifiable to employ "model-independent" 
methods of analysis to present data that is too poor to be modelled by "model-dependent" 
methods: AUC estimation will also be compromised by poor quality data. However, the 
AUC estimation error is not obvious when the trapezoidal rule is applied. The Jackknife 
technique will, however, allow estimation of this error and will also allow certain 
protocol design features to be specified. This is of particular importance in the design of 
interaction studies (i.e. prospective analysis).
Furthermore as many interaction studies report a lack of effect as a result of 
coadministering two drugs, the Jackknife technique could also provide a retrospective 
assessment of a study’s power to detect its particular endpoints (with the number of 
subjects employed).
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CH APTER 5
A STUDY OF THE CONSEQUENCES OF H 2 RECEPTOR ANTAGONIST 
CO ADMINISTRATION W ITH CHRONIC PIROXICAM THERAPY IN 
PATIENTS W ITH  JO IN T  DISORDERS
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5.1 INTRODUCTION TO CHAPTER 5
As outlined in Chapter 1, NANSAIDs are associated with a wide range of 
gastrointestinal side effects ranging from mild dyspepsia to frank ulceration and 
perforation, with the elderly being at the greatest risk from these toxic effects. It has 
been estimated that one third of all patients receiving these drugs are likely to exhibit 
some gastrointestinal symptom with up to 10% resulting in discontinuation of therapy. 
This obviously has important implications for patients with chronic conditions such as 
rheumatoid arthritis and osteoarthritis.
H2  receptor antagonists or prostaglandin analogues can be co-prescribed with 
NANSAIDs to treat and/or prevent recurrence of drug induced gastropathy allowing 
patients to continue their NANSAID’s with a reduced incidence of gastrointestinal side 
effects. The combination of H 2  receptor antagonists and NANSAIDs, in particular, has 
become common place in selected groups e.g. those with a previous history of 
dyspepsia or peptic ulceration, and the elderly.
Cimetidine, however, is implicated in a number of pharmacokinetic drug 
interactions. It can bind to hepatic cytochrome P450 leading to an inhibition of its 
metabolic function. This is of particular importance with drugs which have low 
therapeutic indices such as phenytoin (Bartle et al 1982), warfarin (Hetzel et al 1979) 
and theophylline (Roberts et al 1981). There is a real risk of oven toxicity.
There may also be a problem with drugs such as piroxicam. Increasing the steady 
state concentration may lead to increased risk of adverse toxic side effects. Daily doses 
in excess of 30mg do not confer any extra therapeutic benefit, but toxic effects are more 
prevalent (Data Sheet Compendium 1990). As the newer H2 receptor antagonists 
(nizatidine, famotidine and ranitidine) have lower in vitro affinity for cytochrome P450 
the same concern may not exist for these agents.
The object of this study was to find out whether the steady state pharmacokinetics 
of piroxicam or 5-hydroxypinoxicam would be altered by the concomitant
150
administration of H2  receptor antagonists. On a theoretical basis, such a combination 
might lead to elevation of plasma levels of piroxicam, and an increased risk of 
piroxicam toxicity.
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52  STUDY DESIGN
A randomised crossover study comparing the effects of the coadministration of 
either cimetidine or nizatidine on the steady state pharmacokinetics of piroxicam and its 
major metabolite 5-hydroxypiroxicam was carried out in an appropriate group of 
patients, namely patients with rheumatoid arthritis or other arthropathies requiring 
treatment with an NANSAID.
Inclusion Criteria
a) Patients with a joint disorder requiring treatment with an NANSAID
b) No concurrent treatment with an NANSAID
c) Normal renal and hepatic function as assessed by standard biochemical tests
Exclusion Criteria
a) Patients with a past history of peptic ulceration or alimentary blood loss
b) Patients who were receiving treatment with a H 2  receptor antagonist
c) Women of childbearing age at risk of becoming pregnant
d) Patients who had donated blood within the previous 6 months
e) Any other significant medical history
Patients already receiving piroxicam were maintained at that maintenance dose 
throughout the study. If they were not receiving piroxicam, but were considered 
suitable candidates for inclusion in the study, piroxicam therapy was initiated with a 
loading dose of 40mg for two days, not less than eight days prior to the first study day. 
Figure 5.1 shows the study protocol in greater detail. There were three full study days 
i.e. days 8, 33 and 77. On each study day, after an overnight fast, the patients received 
piroxicam at time zero. Blood samples (5ml) were taken at 0 ,0 .5 ,1 ,1 .5 , 2, 3 ,4 ,4 .5 , 5, 
6 ,7 , 9, 10, 12, 14, 24, and 48 hours. Urine was collected for 24 hours and the total 
volume noted. Meals were provided at 4, 8 and 12 hours. Their constituents are listed 
in Table 3.1. Patients were randomised for the order in which they received either 
cimetidine 400mg b.d., or nizatidine 150mg b.d. Each co-administration phase lasted
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for 24 days because any alterations in the steady state concentrations of a drug with such 
a long elimination half life as piroxicam would be achieved slowly. Between days 35 
and 55 there was a wash out period in which no H2  receptor antagonist was taken. On 
days 53 ,54,55, trough blood samples were withdrawn allowing comparisons between 
these trough concentrations and those obtained on the first study day.
Plasma and urine were analysed for both piroxicam and 5-hydroxypiroxicam as 
described in Chapter 2.
Finally, it was considered crucial that compliance should be monitored. Success 
in this study depended on steady state levels being consistently maintained. After each 
treatment phase, the number of tablets or capsules remaining were compared with the 
expected number assuming 100% compliance. Any value outwith the range 80%£ x£ 
120% was considered as non compliance.
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5 3  PATIENT DEM OGRAPHIC DETAILS
In Chapter 4, it was shown that 15 patients were considered sufficient to detect 
any significant (>20%) alteration in either the piroxicam steady state AUC’s. One 
patient who completed the study was excluded from the eventual analysis due to poor 
compliance (see Section 5.6). All patients had an arthropathy (11 rheumatoid arthritis, 
3 osteoarthritis, 1 psoriatic arthritis) which was suitable for treatment by a single 
NANSAID, as assessed by a Consultant Rheumatologist (P.E.McGill). Twelve females 
and 2 males eventually completed the study. Table 5.1 shows the concomitant 
medications each patient received, a number of whom were also prescribed second line 
disease modifying agents. Five patients had mildly but consistently elevated alkaline 
phosphatase levels, and another two had consistently elevated gamma glutamyl 
transferase levels. These raised levels were in the older members of the group.
The mean age was 58 years (range 28-82), the mean weight was 61 kg (range 26- 
99) and the mean albumin was 40g/l (range 35-48, normal range for hospital 36-52 g/1). 
Two patients received lOmg piroxicam daily, eight 20mg, and four 30mg daily.
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5.4 DATA ANALYSIS
Area’s under the plasma concentration time curves were estimated by a 
combination of both the logarithmic and linear trapezoidal rules (linear from 0 to 14 
hours and logarithmic from 14 to 24 hours) for both piroxicam and 5- 
hydroxypiroxicam . Urinary concentrations of 5-hydroxypiroxicam were determined 
before and after incubation with glucuronidase enzyme and the percentage daily 
piroxicam dose excreted in the urine over 24 hours as 5-hydroxypiroxicam was 
estimated for both pre and post glucuronidase incubation.
Clearance estimates for piroxicam were obtained by dividing the daily dose by 
the AUC (within the dosage interval), i.e. D /A U C ^. This value was then divided by 
the patient’s weight in order to standardise the results. Total 5-hydroxypiroxicam renal 
clearance was calculated using the relationship:
renal clearance = urine flow x urine concentration 
average plasma concentration
During each treatment phase, and during the washout period, the 0, 24 and 48 
hour samples corresponded to trough steady state levels. As these trough samples were 
obtained during two "piroxicam only" phases it was possible to determine whether the 
original steady state conditions had reformed during the wash out period prior to 
commencing the second H 2  receptor antagonist.
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5.5 STATISTICAL ANALYSIS
Comparisons were made between the following parameters on the three study 
days:- piroxicam plasma A U C ^; plasma 5-hydroxypiroxicam A U C ^ ; the ratio of 
these two; the percentage daily dose excreted in the urine as 5-hydroxypiroxicam 
before and after glucuronidase incubation and the mean of the three trough steady state 
piroxicam and 5-hydroxypiroxicam concentrations on each study day and during the 
wash-out period. Logarithmic transformations were performed if considered 
appropriate to normalise data. These transformations gave rise to the asymmetry seen 
in some of the Figures. Repeated measures one way ANOVA with Bonferoni 
correction was used to detect any differences in the mean values.
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5.6 RESULTS
The degree of compliance on each treatment phase is shown in Table 5.2 for all 
patients. Patient No. 15 was outside the limits of between 80 and 120% compliance on 
two occasions and was excluded from the subsequent statistical analysis.
Table 5.3 and Figure 5.2 show the effect of coadministering nizatidine and 
cimetidine on the steady state plasma piroxicam AUC’s in the remaining 14 patients.
No significant difference was found between the mean piroxicam AUC on the three 
study days. Table 5.4 and Figure 5.3 show the influence of the H2  receptor antagonists 
on the steady state plasma 5-hydroxypiroxicam AUC’s. Again no statistically 
significant differences were found between the mean AUC’s on the three study days. 
When the ratio of these two parameters were considered, however, significant 
differences emerged between the piroxicam only study day and both the 
piroxicam/nizatidine and the piroxicam/cimetidine study days (Table 5.5, Figure 5.4). 
The ratio of metabolite to parent drug allowed detection of more subtle inhibitory 
effects than examination of the individual AUC’s. For example, on the nizatidine study 
day the mean 5-hydroxypiroxicam AUC had decreased, but not to a significant level 
compared to the piroxicam only study day, while the mean piroxicam AUC had 
increased, but again not to a significant degree. However, when the ratio of these 
AUC’s was considered, the reduced numerator value (5-hydroxypiroxicam) in addition 
to the increased denominator value (piroxicam) resulted in a ratio that was significantly 
lower than that ratio obtained on the piroxicam only study-day. When the cimetidine 
study day was considered, the decreased ratio appeared to be derived solely from an 
increased denominator value (piroxicam).
Urinary excretion of 5-hydroxypiroxicam was examined to investigate the 
influence of alterations in the renal excretion of metabolite on the plasma 
concentrations. As discussed in Chapter 1, piroxicam is extensively metabolised with 
75% of a total dose being excreted in the urine and faeces as either 5-hydroxypiroxicam
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TABLE 5.3
ELASMA PIROXICAM AUC’s ON THREE STUDY DAYS
PIROXICAM A U C 0 2 4  (mg/ L/ h)
P A T I E N T P I R O X I C A M
O N L Y
P I R O X I C A M  / 
N I Z A T I P I N E
PI ROXICAM / 
CI ME TI DI NE
1
2
3
4
5
6
7
8 
9
1 0 
1 1 
1 2 
1 3 
1 4
2 3 0 . 0 4
1 6 7 . 9 7  
1 5 9 . 4 9  
1 4 9 . 3 7  
3 1 6 . 1 2  
1 6 2 . 8 6  
2 4 0 . 8 1  
2 3 2 . 3 1
7 4 . 3 2
1 0 8 . 0 7
9 2 . 4 0
7 7 . 6 8
3 1 6 . 9 7  
1 9 3 . 8 8
2 7 9 . 6 4  
1 7 1 . 5 9  
1 4 7 . 5 4  
1 5 2 . 5 9  
3 5 0 . 2 7  
1 3 2 . 4 5  
2 4 5 . 7 9  
2 6 4 . 6 7  
6 9 . 8 9  
1 6 3 . 3 4  
9 2 . 9 1  
7 4 . 0 4  
3 0 6 . 1 6  
1 8 3 . 1 9
3 8 0 . 9 4
1 7 5 . 0 4
1 3 6 . 8 2  
1 5 3 . 0 0  
3 9 1 . 5 9
1 6 6 . 8 3
2 2 1 . 6 4  
2 8 1 . 8 6
6 6 . 9 0
1 9 4 . 6 4  
9 4 . 8 2  
6 3 . 7 0
3 4 1 . 3 8  
1 9 8 . 4 5
ME A N  
± 1 S. D.
1 6 2 . 3 9
1 0 0 . 4 8 - 2 6 2 . 4 3
1 6 7 . 3 4
1 0 0 . 4 8 - 2 7 8 . 6 6
1 7 7 . 6 8
9 9 . 4 8 - 3 1 7 . 3 5
ANOVA p = 0 . 208
PIROXICAM ¥ S  PIROXICAM / NIZATIDINE N / S
PIROXICAM PIROXICAM / CIMETIDINE N / S
PIROXICAM / NIZATIDINE YS.  PIROXICAM / CIMETIDINE N / S
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FIGURE : 5.2 PLASMA PIROXICAM AUC’S ON THREE STUDY DAYS
mean ± 1 S.D.
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TABLE 5.4
E lASMA 5-HYPRQXYPIROXICAM AUC's ON THREE STUDY DAYS
5 - HYDROXYPI ROXI CAM A U C e 2 4  ( mg / U h )
P A T I E N T P I R O X I C A M
QKLX
PIROXICAM / 
MIZATIIEIME
PIROXICAM / 
C I ME TI DI NE
1
2
3
4
5
6
7
8 
9
1 0 
1 1 
1 2 
1 3 
1 4
4 5 . 3 6
3 2 . 5 9
3 3 . 1 8  
3 7 . 8 5  
3 4 . 8 0
3 7 . 6 8
4 9 . 1 8
4 5 . 7 1  
1 2 . 1 4
3 2 . 7 1  
2 1 . 6 1  
1 3 . 4 6  
4 4 . 0 9
2 9 . 6 9
4 9 . 6 6  
2 8 . 2 6  
3 2 . 1 3  
3 0 . 4 2  
2 6 . 2 6  
2 9 . 1 0  
4 9 . 8 8  
5 0 . 2 3  
1 0 . 4 6  
4 5 . 2 7  
2 1 . 7 1  
1 1 . 0 8  
3 9 . 9 9  
2 5 . 4 1
6 0 . 1 2
2 8 . 5 2
2 3 . 7 1
3 9 . 7 8  
4 8 . 4 7  
3 0 . 9 0  
4 0 . 5 0
5 1 . 7 8  
9 . 7 0
4 8 . 4 0
2 1 . 2 6
1 0 . 3 2
4 2 . 3 4
3 1 . 0 0
ME A N
± 1 S.D.
3 1 . 1 9
2 0 . 2 9 - 4 7 . 9 4
2 9 . 0 8  
2 1 . 5 4 - 3 9 . 2 3
3 0 . 8 8
1 7 . 6 4 - 5 4 . 0 5
A N O V A p = 0 . 405
PIROXICAM PIROXICAM / NIZATIDINE N / S
PIROXICAM Y J i PIROXICAM / CIMETIDINE N / S
PIROXICAM / NIZATIDINE _ ¥ £ _  PIROXICAM / CIMETIDINE N / S
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FIGURE : 5.3 PLASMA 5 - HYDROXYPIROXICAM AUC’S ON THREE STUDY
DAYS
mean ± 1  S.D.
PIROXICAM PIROXICAM/ PIROXICAM/ 
NIZATIDINE CIMETIDINE
STUDY DAY
TABLE 5.5
RATIO QF 5-HYDROXYPIROXICAM : PIROXICAM AUC’» ON THREE STUDY DAYS
PATIENT P I R O X I C A M
O N L Y
PIROXICAM / 
NI ZATI DI NE
PIROXICAM / 
CIMETIDINE
1
2
3
4
5
6
7
8 
9
1 0 
1 1 
1 2 
1 3  
1 4
0 . 1 9 7  
0 . 1 9 4  
0 . 2 0 8  
0 . 2 5 3  
0.11 0 
0 . 2 3 1  
0 . 2 0 4  
0 . 1 9 7  
0 . 1 6 3  
0 . 3 0 3  
0 . 2 3 4  
0 . 1 7 3  
0 . 1 4 2  
0 . 1 5 3
0 . 1 7 8
0 . 1 6 5
0 . 2 1 8
0 . 1 9 9
0 . 0 7 5
0 . 2 1 9
0 . 2 0 3
0 . 1 8 9
0 . 1 4 9
0 . 2 7 7
0 . 2 3 4
0 . 1 5 0
0 . 1 3 1
0 . 1 3 9
0 . 1 5 8  
0 . 1  6 3  
0 . 1  7 3  
0 . 2 6 0  
0 . 1 2 4  
0 . 1  8 5  
0 . 1 8 3  
0 . 1 8 4  
0 . 1 4 5  
0 . 2 4 9  
0 . 2 2 4  
0 . 1 6 2  
0 . 1  2 4  
0 . 1 5 6
ME A N  
±1 S . D.
0 . 1 9 7
0 . 1 4 8 - 0 . 2 4 6
0 . 1 8 0  
0 . 1 2 9 - 0 . 2 3 1
0 . 1 7 8
0 . 1 3 6 - 0 . 2 2 0
A N O V A  p = 0 . 0 07
PIROXICAM V I  PIROXICAM / NIZATIDINE S I G N I F I C A N T
PIROXICAM V_§. PIROXICAM / CIMETIDINE S I G N I F I C A N T
PIROXICAM / NIZATIDINE PIROXICAM / CIMETIDINE N/S
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FIGURE : 5.4 RATIO OF PLASMA 5 - HYDROXYPIROXICAM : PIROXICAM
AUC'S ON THREE STUDY DAYS
J  mean ± 1 S.D.
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STUDY DAY
or 5-hydroxypiroxicam glucuronide. Since less than 5% is excreted as parent drug in the 
urine, urinary piroxicam concentrations were not quantified. Table 5.6 shows the 
results before and after the 5-hydroxypiroxicam glucuronide underwent in vitro reverse 
metabolism to reform 5-hydroxypiroxicam. No statistical differences were obtained in 
the amount of 5-hydroxypiroxicam excreted as either 5-hydroxypiroxicam or as 5- 
hydroxypiroxicam glucuronide on each study day. Alteration of glucuronide formation 
would not be expected due to H 2  antagonist coadministration (Patwardhan et al 1980). 
Glucuronidation is a type II metabolic pathway, i.e. conjugation, and is not mediated by 
microsomal enzymes such as cytochrome P450. Figure 5.5 illustrates the total 5- 
hydroxypiroxicam excreted in the urine on each study day expressed as a percentage of 
the piroxicam daily dose.
The AUC values shown in Figures 5.2 to 5.5 have not been corrected for dosage. 
Calculation of clearance will therefore show the true inter-subject variability in this 
group. Examination of the individual patient’s clearance will also allow the 
determination of any age-related effects. Some authors have described correlations 
between increasing age and decreased piroxicam clearance (Chapter 1). Table 5.7 
illustrates the piroxicam clearance on each study day and Figure 5.6 is a plot of 
clearance versus age. Figure 5.6 shows that in this group of patients, there is no 
relationship between age and clearance for this drug.
The renal clearance of 5-hydroxypiroxicam was calculated for each subject on 
each study day (Table 5.8) and this was plotted against age (Figure 5.7). Again no 
association existed between age and 5-hydroxypiroxicam renal clearance, consistent 
with the majority of studies which examined age related phenomena.
Finally when the mean of the three trough (0, 24, 48 hour) piroxicam or 5- 
hydroxypiroxicam concentrations were calculated on four separate occasions (three 
study days and the wash-out period) no statistically significant differences were 
obtained (Tables 5.9,5.10).
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FIGURE : 5.5 TOTAL 5 - HYDROXYPIROXICAM EXCRETED IN URINE 
EXPRESSED AS A % OF PIROXICAM DOSE
mean ± 1 S.D.
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TABLE .5 .7
PLASMA PIROXICAM CL/F FOR EACH STUDY DAY
PATIENT A£_E WEIGHT 
(kg)
PIROXICAM PJBQXI.QAJM
( L / h / k g x i O- 3 ) /NIZATIDINE
PIROXICAM 
/Cl MEUPINE 
( L / h / k g x 1 0 * 3 ) (L/h/ kgxIO*3 )
1
2
3
4
5
6
7
8 
9
1 0 
1 1 
1 2 
1 3 
1 4
6 3  
6 2  
5 0  
5 3  
2 8  
8 2  
5 7  
5 5  
4 5
6 4  
6 3  
68  
7 1  
5 7
6 7  
9 9
5 0
5 1  
5 4
68 
5 7  
7 5  
8 1  
7 0  
2 6  
6 7  
6 4  
6 7
1 . 3 0  
1 . 2 6  
3 . 7 6
1 . 3 1
1 . 1 7  
1 . 8 1
2 . 1 8  
1 . 7 2  
3 . 3 4  
3 . 9 7  
4 . 1 9  
3 . 8 3  
0 . 9 9  
1 . 5 4
1 . 0 7
1 . 1 7
4 . 0 5  
1 . 2 8
1 . 0 6  
2 . 2 3
2 . 1 4  
1 . 5 1  
3 . 5 3
2 . 6 3
4 . 1 4  
4 . 0 3  
1 . 0 2
1 . 6 3
0 . 7 8  
1 . 1 5  
4 . 3 8  
1 . 2 8  
0 . 9 5  
1 . 7 6  
2 . 3 7  
1 . 4 2  
3 . 6 8  
2 . 2 0  
4 . 0 5  
4 . 6 6  
0 . 9 2  
1 . 5 1
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TABLE.. ..5.9
MEANJn=3) TROUGH PIROXICAM PLASMA CONCENTRATIONS (mo/L)
P A T I E N T PIROXICAM / PIROXICAM / PIROXICAM / P J R O X I C A M  /
O N L Y NI ZATI DI NE W A S H - O U T CI ME T I DI N E
1 9 . 2 4 1 1 . 1 9 1 1 . 7 4 1 4 . 7 0
2 6 . 8 5 7 . 1 5 5 . 0 3 6 . 3 3
3 7 . 1 4 6 . 1 1 7 . 8 6 5 . 6 8
4 5 . 5 1 6 . 1 9 X 6 . 0 9
5 1 3 . 5 6 1 5 . 2 6 1 9 . 1 7 1 5 . 7 8
6 6 . 1 3 4 . 5 9 4 . 8 4 5 . 5 8
7 1 1 . 4 6 * 1 0 . 8 4 9 . 4 2 1 1 . 0 9
8 1 0 . 1 6 * 1 2 . 9 5 1 2 . 7 2 1 3 . 4 3
9 2 . 9 8 * 2 . 9 9 3 . 2 3 2 . 7 0
1 0 5 . 2 0 6 . 7 2 6 . 8 2 * 8 . 6 8
1 1 3 . 8 8 3 . 7 0 3 . 2 4 * 3 . 8 6
1 2 2 . 3 6 2 . 2 1 2 . 3 2 * 2 . 1 6 *
1 3 1 3 . 5 4 1 3 . 7 0 1 2 . 6 8 * 1 5 . 1 0
1 4 7 . 9 3 7 . 4 8 8 . 8 7 * 7 . 7 7
M E A N 6 . 6 9 6 . 8 5 6 . 9 9 7 . 1 8
± 1 S. D. 3 . 9 2 - 1 1 . 4 6 3 . 7 9 - 1 2 . 3 5 3 . 7 2 - 1 3 . 1 7 3 . 8 0 - 1 3 . 5 6
A N O V A  p r  0 . 5 4 3
PIROXICAM / ONLY 1 3 PIROXICAM / NIZATIDINE N / S
PIROXICAM / ONLY 1 3 PIROXICAM / WAS H OUT N / S
PIROXICAM / ONLY 1 3 PIROXICAM / CIMETIDINE N / S
PI ROXI CAM / NIZATIDINE 1 3 PIROXICAM / WAS H OUT N / S
PI ROXI CAM / NIZATIDINE 1 3 PIROXICAM / CIMETIDINE N / S
PIROXICAM / WASH OUT 1 3 PIROXICAM / CIMETIDINE N / S
* n = 2
x No  a s s e s s m e n t  ma d e
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TABLE 5.10
P A T I E N T P I R O X I C A M  / PIROXICAM / PIROXICAM / P I R O X I C A M  i
O N L Y NI ZATI DI NE W A S H O U T CI METI DI NE
1 1 . 9 4 2 . 3 1 2 . 0 9 2 . 4 8
2 1 . 4 5 1 . 2 3 1 . 3 8 1 . 2 9
3 1 . 3 9 1 . 4 3 1 . 91 0 . 9 3
4 1 . 5 9 1 . 3 8 X 1 . 7 7
5 1 . 5 4 1 . 0 4 1 . 8 4 2 . 0 5
6 1 . 5 6 1 . 2 7 1 . 2 9 1 . 3 1
7 2 . 1 6 * 1 . 9 2 1 . 8 1 1 . 8 9
8 1 . 8 8 * 2 . 3 9 2 . 4 6 2 . 4 7
9 0 . 4 6 * 0 . 4 0 0 . 5 4 0 . 4 0
1 0 1 . 3 6 1 . 9 1 1 . 9 6 * 2 . 1 8
1 1 0 . 9 2 0 . 8 8 0 . 6 6 * 0 . 8 4
1 2 0 . 4 9 0 . 4 4 0 . 5 1 * 0 . 4 2 *
1 3 1 . 9 4 1 . 8 2 2 . 0 8 * 1 . 9 8
1 4 1 . 1 1 1 . 1 0 1 . 1 6 * 1 . 1 7
ME A N 1 . 4 1 1 . 3 9 1 . 5 2 1 . 5 1
± 1 S. D. 0 . 8 9 - 1 . 9 3 0 . 7 7 - 2 . 0 1 0 . 8 7 - 2 . 1 6 0 . 8 1 - 2 . 2 1
A N O V A p  = 0 . 3 29
PIROXICAM / ONLY V S  PIROXICAM / NIZATIDINE N / S
PIROXICAM / ONLY V S  PIROXICAM / WASH OUT N / S
PIROXICAM / ONLY V S  PIROXICAM / CIMETIDINE N / S
PI ROXICAM / NIZATIDINE V S  PIROXICAM / WASH OUT N / S
PI ROXICAM / NIZATIDINE V S  PIROXICAM / CIMETIDINE N / S
PIROXICAM / WASH OUT V S  PIROXICAM / CIMETIDINE N / S
n = 2
x No  a s s e s s m e n t  m a d e
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5.7 RETROSPECTIVE POW ER CALCULATION
In Chapter 4 it was shown that 15 patients were considered sufficient to detect a 
difference of greater than 20% in the steady state AUC’s of piroxicam as a result of H 2  
receptor antagonist coadministration. In this section examination will be made of the 
assumptions used in determining the power calculation, and as a consequence, the 
validity of the results obtained.
The mean % difference in the piroxicam steady state AUC as a result of 
combination with cimetidine was 14% for this group of patients. This was statistically 
a non-significant difference. However, the prospective power determination (Chapter 
4) was calculated with respect to the number of subjects required to detect a greater 
than 20% difference in the steady-state AUC.
A retrospective assessment should be made, of the study’s power, using the 
number of subjects who actually met the study requirements for inclusion in the 
eventual data analysis.
As no steady state AUC’s were determined on two separate occasions an estimate 
of the variability in this parameter was obtained by examining the mean trough plasma 
concentrations (Table 5.9). There were two "piroxicam only" phases during the study 
i.e. the first study day and the wash-out period and these were used to estimate 
variability. When calculated, a value of 10% was obtained and this acted as a 
substitute for the intra-subject variability in the AUC.
Table 5.11 lists the retrospective power calculation and Figure 5.8 shows the 
power curve generated using the above data. With 14 subjects there was a 99% power 
to detect the 14% difference in piroxicam steady state AUC’s. It is therefore possible to 
be confident that the findings of this study were valid.
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TABLE 5. 11
RETROSPECTIVE POWER CALCULATION
TYPE I ERROR RATE (a) 0 . 0 1 5
TYPE II ERROR RATE (P) 0 . 0 0 5
DIFFERENCE TO BE DETECTED 1 4
ESTIMATED VARIABILITY IN PARAMETER 1 0
P OWE R OF STUDY 0 . 9  9 5
NUMBER OF S UBJ ECTS 1 4
S u b j e c t s  are  pai red a nd  t e s t  w a s  t wo- t a i l ed
171
PO
W
E
R
FIGURE 5.8 RETROSPECTIVE POWER CURVE
0 2 4 6 8 10 1214 1 6 1 8 2 0 2 2 2 4  2628 30 
NUMBER OF SU B JEC TS
5.8 DISCUSSION
If there was a significant inhibition of piroxicam metabolism by the H 2  receptor 
antagonists, less metabolite would be formed and the levels of parent drug in the 
plasma would rise. However, if this was only a mild inhibition, parent and 
metabolite AUC’s might well fail to show a statistically significant difference. The 
ratio of metabolite to parent drug would, however, will allow the detection of milder 
inhibitory effects.
It can be seen that, in terms of steady state piroxicam and 5-hydroxypiroxicam 
AUC’s, there was no significant pharmacokinetic interaction, and therefore by 
implication, no clinically significant interaction between piroxicam and these two H 2  
receptor antagonists in the patients studied. Theoretically this is an unexpected result 
Piroxicam has been shown earlier to be extensively metabolised principally to 5- 
hydroxypiroxicam with subsequent conjugation with glucuronic acid. The 
hydroxylation step is cytochrome P450 dependent, and cimetidine can inhibit this 
enzyme’s metabolic function. Inhibition by cimetidine is rapid and can occur after a 
single dose. Recovery is equally rapid, and no tolerance to inhibition is apparent on 
chronic therapy (Speed et al 1982).
Cytochrome P450 has been shown to exist in multiple molecular forms with 
different but overlapping substrate specificities (Lu 1979). Depending on the nature of 
the isoenzyme and substrate, the different forms of cytochrome P450 can catalyse the 
metabolism of a particular substrate at comparable rates but bio-transfer other 
substrates at significantly different rates (Lu 1979). This is likely to be an important 
factor when the results obtained in this study are considered.
In order to attempt an explanation, examination has to be made of the 
mechanisms by which cimetidine, and other H 2  receptor antagonists bind to 
cytochrome P450. Figure 5.9 shows the chemical structure of the four H 2  receptor 
antagonists currently available in the U.K.. Cimetidine is the only molecule which
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FIGURE: 5.9 CHEMICAL CLASSIFICATION OF H2 RECEPTOR ANTAGONISTS
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contains an imidazole ring and it appears that this moiety can form co-ordinate bonds 
with haem in the cytochrome P450 molecule resulting in an inhibition of the enzyme’s 
metabolic function (Knodell et al 1982).
Ranitidine can also bind to cytochrome P450 groups but the enzyme-substrate 
complex formed is less stable than that obtained with cimetidine (Rendich et al 1982, 
Smith & Kendall 1988). Hoensch et al (1985) showed that both cimetidine and 
ranitidine could inhibit O-deethylation in human microsomes, but in the case of 
cimetidine the inhibition was five times more potent. The authors stated that cimetidine 
was a relatively non specific inhibitor of all cytochrome P450 isoenzymes, whereas 
ranitidine was more selective. This is probably due to all isoenzymes of cytochrome 
P450 containing a haem group.
Studies by Reilly et al (1983) have shown cimetidine combined to two distinct 
and independent classes of binding sites on cytochrome P450. These represent binding 
via the imidazole ring (which will have a lower affinity) and specific substrate binding 
via both the imidazole ring and the side chain of the molecule (which will have a higher 
affinity). Reilly et al (1983) suggested that cimetidine could bind differentially to the 
various isoenzymes of cytochrome P450.
The other H 2  receptor antagonists have also been shown to bind to cytochrome 
P450 in vitro, but with greatly varied affinities. When Klotz et al (1987) examined 
cimetidine, oxmetidine, ranitidine, famotidine, and nizatidine, with respect to their 
inhibitory effects on three human microsomal enzymes, aryl hydrocarbon hydroxylase, 
7-ethoxycoumarin-O-deethylase, and 7-ethoxyresorifin-O-deethylase, oxmetidine was 
the most potent inhibitor, cimetidine was second, and nizatidine third, but ten times less 
potent than cimetidine. The other H 2  antagonists can therefore cause mild inhibition of 
cytochrome P450 metabolism due to competitive displacement. However, their binding 
affinity is much lower than that of cimetidine, and the potential for causing significant 
interactions is, therefore, reduced.
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It is unknown whether the metabolism of piroxicam is specific to one or to a 
range of isoenzymes (Pfizer UK, Medical Information). It can be assumed, however, 
that if piroxicam was metabolised via an isoenzyme to which cimetidine bound with a 
high affinity, then inhibition of the drug’s metabolism would be the result. We must 
conclude, therefore, that the isoenzyme(s) responsible for the metabolism of piroxicam 
undergo low affinity, non substrate-specific binding to cimetidine, resulting in either 
mild or no inhibition of piroxicam metabolism.
Piroxicam is not the only drug which, on theoretical grounds, is surprisingly 
unaffected by cimetidine coadministration. Selective inhibition of specific theophylline 
pathways has been shown by Grygiel et al (1984). In this study in humans, cimetidine 
inhibited the 3- and 7-demethylation pathways but not the 8-oxidation, all of which are 
cytochrome P450 dependent. No effect was seen on tolbutamide hydroxylation, (Dey 
et al 1983), ibuprofen hydroxylation (Conrad et al 1984), isoxicam hydroxylation 
(Famham 1982), naproxen hydroxylation (Holford et al 1981), misonidazole 
demethylation (Begg et al 1983), mexiletine oxidation (Klien et al 1985), steroid 
hydroxylation and epoxidation (Somogyi & Muirhead 1987) in humans. Therefore it 
cannot be assumed that cimetidine is a universal inhibitor of phase I hepatic drug 
metabolic pathways, and the results obtained in this study would appear to support this 
contention.
In conclusion, this study showed no significant alteration in the steady state 
pharmacokinetics of either piroxicam or 5-hydroxypiroxicam as a result of H 2  receptor 
antagonist coadministration in patients receiving this drug for joint disorders. It must 
be considered unlikely, therefore, that any adverse events would occur in patients as a 
result of this coadministration.
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CH A PTER 6
GENERAL DISCUSSION
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When the general population is considered, the prevalence of peptic ulcer lies 
between 5 and 10%. Despite an overall decrease in the incidence of peptic ulcer in 
recent years, rising rates are evident in some groups. Coggon et al (1981) showed ulcer 
perforation, as determined by hospital admission rates between 1958 and 1977, to be 
less common in young adults (35 and under) with perforated gastric ulcers occurring at 
20% of the previous frequency. However, in middle aged and elderly women there was 
an increase in the incidence of perforated duodenal ulcers. When Walt et al (1986) 
expanded the time scale studied (1958 to 1982), an increased duodenal perforation rate 
was again shown in elderly females. However, in the very elderly an upward trend was 
also shown in males and the question arose as to what role increased NAN SAID use in 
these groups was having on the ulcer epidemiology. It has been shown in a number of 
case controlled studies, that the over 60’s, in particular, cany an increased risk of ulcer 
complications (Langman 1989, Jick et al 1987). Collier & Pain (1985) documented a 
highly statistically significant correlation between the annual number of elderly patients 
with perforated peptic ulcer taking NANSAIDs and the annual number of prescriptions 
issued for these drugs. The true incidence rate, however, is difficult to ascertain as it is 
not known how many individual patients were contained in the total number of 
prescriptions dispensed, and also by the presence of asymptomatic gastrointestinal 
upsets which do not allow full quantitation of the extent of the problem with these 
drugs (Roth 1986).
Piroxicam was one of a whole series of NANSAIDs that came under close 
scrutiny in the 1980’s with regard to their potential to cause gastrointestinal and other 
toxic side effects. A series of reports in the scientific literature implicated piroxicam as 
an unsafe drug and one that, if not withdrawn altogether, should have its licence 
significantly limited. On closer inspection of the data citing piroxicam as a dangerous 
drug, it appeared that many of the conclusions were not valid. Many papers were 
flawed due to the reliance on spontaneous adverse reaction reports. Adverse Drug
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Reaction (A.D.R.) reporting schemes are biased by many factors, principally their 
inability to determine the number o f patients exposed to a drug, making incidence rates 
impossible to calculate. Further bias is introduced when a drug is initially marketed, as 
reporting rates tend to be greater for newer rather than for established agents. The
C.S.M. published data which showed that piroxicam could not be distinguished from 
the other NANSAIDs (apart from low dose ibuprofen) in terms of its overall toxicity 
profile.
The drug, therefore, has had a controversial history, although its undoubted 
clinical efficacy, and at the time, unique "once a day" administration, ensured its 
commercial success and continued use.
In terms of the toxicity controversy, the case against piroxicam was found "not 
proven". However, the question of whether the drug undergoes enterohepatic 
circulation, has received a lot of speculation but little experimentation. This question 
was aroused by the presence of "multiple peaks" in the plasma concentration/time 
profiles in a number of studies. Many authors felt that enterohepatic circulation would 
contribute to the drug’s long elimination half life in man, although enterohepatic 
circulation per se does not guarantee a prolonged elimination half life. Indomethacin, 
for example, undergoes well documented enterohepatic circulation, but has an 
elimination half life in man of only 2-4 hours.
In this thesis, a close inspection has been made of these "multiple peaks" in an 
attempt to characterise their appearance in terms of physiological events altering the 
individual’s pharmacokinetic disposition of the drug. It was shown that after high 
protein and fat containing meals, perturbations appeared in the plasma 
concentration/time profiles in both healthy volunteers and in patients receiving 
piroxicam. These perturbations were not consistent with the "classical" timing of 
enterohepatic circulation-related events, generated by bile release following food. The 
perturbations found in this study followed a consistent pattern, a rapid decline in the
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plasma concentration followed by a more sustained rise- certainly not a "peak". When 
the excretion of the drug and its metabolites into the bile was examined, the results 
agreed with a previous study examining piroxicam and 5-hydroxypiroxicam 
concentrations in the bile. In that study (Verbeeck et al 1986) no piroxicam or 5- 
hydroxypiroxicam was detected 15 hours after a single 20mg dose of piroxicam in a 
healthy volunteer. However, no information was given regarding the assay technique 
employed and its limits of detection. Furthermore, no attempt was made to quantify the 
presence of 5-hydroxypiroxicam glucuronide. The study was also flawed in the respect 
that only a single 20mg dose of piroxicam was given making detection of small 
amounts of metabolite difficult.
The inaccessibility of the biliary system makes studies of biliary excretion 
inherently difficult. This was certainly the case in the current studies. It was 
considered experimentally desirable to study patients who had not suffered recent 
surgical trauma (e.g. those with T-tubes inserted after cholecystectomies). It was also 
considered desirable to employ a technique which enabled total biliary output to be 
collected (which is certainly not the case with T-tubes). An alternative to T-tubes, 
naso-biliary drains, inserted to relieve blockages in the biliary system, were thought to 
be ideal investigational tools but at a practical level, only one suitable patient was 
identified. Nevertheless, interesting results were obtained. Piroxicam did not enter the 
bile to any great extent, with the concentrations obtained being only 2% of those 
achieved in the plasma. When 5-hydroxypiroxicam was considered, biliary 
concentrations were approximately 33% and 25% of those found in the plasma and in 
the urine respectively. The most significant result, however, was the finding of 5- 
hydroxypiroxicam in the form of 5-hydroxypiroxicam glucuronide in the bile, at half 
the urine concentration. This has been previously unreported, and the biliary route 
must therefore be considered as a major route of excretion of the principle piroxicam 
metabolite in man.
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When enterohepatic circulation is considered, however, it would appear that 
piroxicam is not present in the bile in large enough quantities to qualify as a candidate 
for significant enterohepatic circulation. However, the same cannot be said for 5- 
hydroxypiroxicam as it is excreted in the bile (as its glucuronide) to a significant extent. 
The consequences of any 5-hydroxypiroxicam enterohepatic circulation must be 
considered innocuous as 5-hydroxypiroxicam possesses little anti-inflammatory 
activity, and by implication, there will be little scope for gastrointestinal toxicity. Only 
if the metabolite undergoes reverse metabolism to reform parent drug, could this 
become significant.
The conclusion that the perturbations found in plasma piroxicam concentrations 
were independent of biliary involvement was substantiated by Guentert et al (1988). 
Although in this study the coadministration of cholestyramine reduced the elimination 
half life of the drug (which the authors contended was a result of increased biliary 
clearance) the "multiple peaks" were not abolished, casting doubt on the role of bile in 
their generation.
It therefore appears unlikely that bile is involved to any extent in the generation 
of these "multiple peaks". Investigation was therefore made of other events 
accompanying the consumption of a meal that may be important in their generation. 
Consideration was made, on both a physiological and a pharmacokinetic basis, of the 
alterations to various parameters that may occur after consumption of a meal, with a 
particular nutritional constituency. A possible role of fat in displacing albumin bound 
piroxicam was discussed and the consequences of such a displacement on the clearance 
and volume of distribution of the drug was investigated via simulation studies. From 
these studies it was predicted that any transient alterations in clearance or volume of 
distribution, as a result of increasing the unbound fraction of the drug in plasma, would 
have little or no effect on the total plasma piroxicam concentration, and therefore the 
consequences of a displacement reaction must be considered trivial. However,
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alteration in the plasma volume, as a result of food consumption, may explain the results 
obtained, and simulations were shown to substantiate this contention. This proposed 
increase in plasma volume would result in a "dilution" of the total (bound and unbound) 
piroxicam and metabolite circulating in the plasma, whereas an increased clearance of 
piroxicam would cause an increased metabolite production. In all cases, the food 
induced fall in piroxicam concentration was mirrored by a fall in 5-hydroxypiroxicam 
concentration, suggesting that plasma volume dilution was occurring. It was speculated 
that the mechanisms involved in this altered volume were a consequence of osmotic 
events accompanying the consumption of a meal with a high protein content.
It was therefore decided, to standardise both the content and timing of food 
administration in all future studies.
In the 14 subjects who participated in the H 2  receptor antagonist study, consistent 
falls in plasma piroxicam and 5-hydroxypiroxicam were detected when the standard 
lunch was consumed with no alteration in plasma concentrations found after 
consumption of the standard evening meal. This study examined whether the effects on 
steady state AUCs of piroxicam due to the coadministration of H 2  receptor antagonists 
would achieve clinical importance (cimetidine is an established agent known to inhibit 
cytochrome P450 to a significant extent, and nizatidine is a newer agent with lower in 
vitro affinity for this enzyme). As already described, NANS AID induced gastropathy 
is a well recognised consequence of both acute and chronic administration of these 
drugs, and as a result, prophylactic treatments have become the focus of much attention. 
Only full doses of H 2  receptor antagonists have been shown to heal or prevent ulcer 
recurrence, with duodenal lesions found to be more likely to respond to treatment. 
However, it was important to consider the theoretical effects of cimetidine (and 
nizatidine) inhibition of cytochrome P450 metabolism in patients receiving drugs that 
are metabolised by this pathway (which includes most NANSAIDs).
Prior to commencing the study, careful consideration was made of the
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experimental design. Many studies which examine theoretical interactions fail to show 
any differences as a result of inadequate power to detect the pre-set differences in the 
parameter under investigation (e.g. AUC). Furthermore AUC estimations are 
considered impervious to poor study designs, and as a result, are considered 
appropriate for any data set. It was important that these factors should be addressed in 
full prior to commencing the interaction study, so that the subsequent results could be 
obtained with a degree o f statistical confidence. The Jackknife technique was 
introduced, and examples made of its application to study design optimisation. A 
prospective power calculation, incorporating an estimated uncertainty component for 
the steady state AUC determinations, was described. This allowed a conservative 
estimation of the number of patients required to detect the pre-set endpoints of a greater 
than 20% alteration in the steady state piroxicam AUC. Investigation was also made of 
the influence of the number of points used in extrapolation on an overall AUC 
estimation error. Not suiprisingly, as the number of points used in the extrapolation 
increased, the AUC estimation error fell. Marked improvements were seen when the 
number was increased from 3 to 5 in many instances. Furthermore, the requirement to 
logarithmically transform the pseudoparameters was highlighted when few points were 
used in the extrapolation.
Once the study design requirements were addressed, the interaction study 
proceeded. Patients receiving piroxicam for a variety of arthropathies, had steady state 
piroxicam and 5-hydroxypiroxicam AUCs calculated on three separate occasions. One, 
while receiving piroxicam alone, and the other two while receiving one of the two H 2  
receptor antagonists, in a randomised cross over manner. There was no significant 
alteration in the steady state AUCs of piroxicam and 5-hydroxypiroxicam found in this 
study, although the ratio of these two (5-hydroxypiroxicam :piroxicam) was 
significantly decreased in combination with either of the H 2  receptor antagonists. This 
would indicate a mild, but clinically non-significant interaction which on theoretical
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grounds, may be a result of cimetidine and nizatidine binding to the isoenzyme 
responsible for piroxicam metabolism with low affinity. Certainly there is precedence 
in the literature to show that cimetidine cannot be considered as a universal inhibitor of 
phase I hepatic biotransformations.
This study has important implications with regard to the cost effective treatment 
of NANS AID induced gastropathy. Table 6.1 outlines the relative costs of one month’s 
maintenance treatment with the four H 2  receptor antagonists currently available in the 
U.K.. The costs are detailed in terms of both in-patients and out-patients, but, the vast 
majority of patients receiving these drugs would obtain their treatment from their 
General Practitioners. From Table 6.1, it can be seen that the cost of one month’s 
cimetidine treatment is approximately 33% less than the other H2  receptor antagonists. 
There is, therefore, a potential for saving, if prescription habits can be altered. 
Ranitidine is commonly preferred as it does not to inhibit cytochrome P450 to the same 
extent as cimetidine. Cimetidine therapy also has been associated with reversible 
gynaecomastia (2 in 1000 men treated). Certainly if the patient is not receiving a drug 
that is known to interact with cimetidine to a clinically significant effect (warfarin, 
theophylline and phenytoin) there is no reason why cimetidine cannot be regarded as 
the drug of choice in the treatment and maintenance of remission of piroxicam induced 
gastropathy.
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APPENDIX
FORM ULAE
1) Linear Trapezoidal Rule
AUC = 1 1 /2  (Yj +Y2) AX
2) Logarithmic Trapezoidal Rule
AUC = (Yr Y2)AX
LnYj -lnY2
3) General Linear Test
G.L.T. -  SSQRES(Reduced) - SSQr e s ^ ujj) 
D R (Reduced)'  D R (Full)
4) Akaike Information Criterion
A.I.C. = NLnCWSSQREs) +2.P
SSQr e s  = Residual Sum of Squares (unweighted)
WSSOr e s  = Residual Sum of Squares (weighted)
D.F. = Degree’s of Freedom
N = Number of Data Points
p  = Number of Parameters
s s QrES(Fu11)
D R ( F u11)
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PROGRAM M E FOR ACI, AV SIMULATIONS
REM get details 
REM output details
REM get clearance Jce 
REM get cone
10 DEFINTI-N 
20 CL$=CHR$(27)+"E"
50 DT = .01 
52 T = 0 
100 GOSUB 1000:
102 OPEN FSPEC$ FOR OUTPUT AS #2
103 GOSUB 4000:
105 F O R K = l TO HOURS 
110 FOR 1=1 TO 10 
120 FOR J=1 TO 10 
125 T = T + DT 
130 GOSUB 2000:
140 GOSUB 3000:
160 NEXT J
165 PRINT#2,USING 'Tim e = ###.##, Cl. = ##.##, V = ##.##, Cone = ##.###, 
(Cone = ###.###)";T,CL,V,CONC,SCONC
166 IF ISPEC = 0 THEN 170
168 PRINT USING "Time = ###.##, Cl. = ##.##, V = ##.##, Cone = ###.###, 
(Cone = ###.###)";T,CL,V,CONC,SCONC 
170 NEXT I 
180 NEXT K
998 CLOSE#2
999 END
1000 REM Study details 
1005 PRINT CL$
1010 INPUT "steady clearance 
1020 INPUT "delta clearance 
1030 INPUT "rate constant for cl recovery 
1040 INPUT "starting cone 
1050 INPUT "steady volume
1052 INPUT "delta volume
1053 INPUT "rate constant for volume change
1054 INPUT "rate constant for volume recovery 
1060 INPUT "dose
1065 INPUT "absorption rate constant 
1070 INPUT "time (post dose) for food 
1080 INPUT "time to monitor
1120 INPUT "Output device.(S=ScreenrP=PrinterJ7=File)[S]
1130 ISPEC=0:FSPEC$="scm:":
1140 IF A$=”P" OR A$="p" THEN FSPEC$="lptl:":ISPEC=l:GOTO 1200 
1150 IF A $ o "F "  AND A $ o " f ' THEN 1200
1160 INPUT "Output file name (incl. drive & ext) ";FSPEC$
1165 ISPEC=1 
1200 GUT = DOSE 
1210 SKE = CL0/V0 
1220 SCO = CONC 
1999 RETURN
0/hr)
(1/hr)
(/hr)
(mg/1)
0)
0)
T)
(/hr)
(mg)
(/hr)
(hr)
(hr)
CL0
DCL
XCL
CONC
VO
DV
XV A
XV
DOSE
XKA
TFOOD
HOURS
A$
(continued on next page)
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2000 REM ************************************* get clearance & volume 
2010 CL = CLO
2020 IF T < TFOOD THEN v = vO:vl = v : goto 2999
2030 CTIME = T - TFOOD
2040 CL = CLO + DCL * EXP( - XCL * CTIME)
2050 v l = v
2055 V = vO + DV * (EXP( - XV * CTIME) - EXP( - XVA * CTIME))
2999 RETURN
3000 REM ************************************** get cone 
3005 DGUT = XKA * GUT * DT
3010 DCONC = DGUT /  V - (CL/V) * CONC * DT 
3020 CONC = v l * CONC/ v + DCONC 
3030 GUT = G U T-D G U T
3040 SCONC=SC0*EXP(-SKE*T) + DOSE*XKA*(EXP(-XKA*T)
-EXP(-SKE*T))/(V0*(SKE-XKA))
3999 RETURN
4000 REM ************************************* output details
4010 PRINT#2,"steady clearance (1/hr) ";CL0
4020 PRINT#!,"delta clearance (1/hr) ";DCL
4030 PRINT#2,"rate constant for cl recovery (Air) ";XCL
4032 PRINT#2,"steady volume (1/hr) ";V0
4034 PRINT#2, "delta volume (1/hr) ";DV
4035 PRINT#2,"rate constant for vl change (Air) ";XVA
4036 PRINT#2,"rate constant for vl recovery (Air) ";XV
4040 PRINT#2,"starting cone (mgA) ";CONC
4060 PRINT#2,"dose (mg) ";DOSE
4065 PRINT#2,"absoiption rate constant (Air) ";XKA
4070 PRINT#2,"time (post dose) for food (hr) ";TFOOD
4080 PRINT#2,"time to monitor (hr) ";HOURS
4100 PRINT#2,"" 
4110 PRINT#2,"" 
4999 RETURN
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